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Abstract
Objective of this PhD thesis is to investigate new ways of measuring health system
performance. First, we focus on the development of an output index for healthcare. Four
key challenges are involved: (1) correct identification of healthcare output and (2) of its
quality characteristics, (3) addressing the issues relating to the existence of
technological progress, and (4) identification of a way of weighting different goods and
services into a single index. We develop an output growth measure that takes into
account and tries to address all four key challenges. We calculate cost weighted output
indices both by NHS sector and for the NHS as a whole.
Second, we investigate whether it is feasible to develop a model of output and
productivity growth for a single programme of care. Using the output index developed
in part I, we calculate output and productivity growth measures for all circulatory
diseases in England, for the time period 1998/99 - 2003/04. We explore the use of
patient reported health outcome measures for two procedures. We use average unit costs
data to account for inputs used in the production process. We find that output growth for
hospital treatment of all circulatory diseases has increased when quality characteristics
are taken into account, which also results in annual improvements in physical
productivity.
Third, we investigate the impact of devolution on income-related inequality in health
and inequity in the delivery of health care in England, Wales and Scotland by means of a
concentration index. Health is captured through three measures of self-assessed health.
The utilisation of healthcare resources is proxied by GP consultations, outpatient visits
and inpatient stays. We find that after devolution no clear pattern of change in income-
related inequality in health and inequity in healthcare utilisation.
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Introduction
The concern with measuring health system performance and health care is not recent.
As early as the 1860s, Florence Nightingale concerned herself with recording patients
leaving her care as relieved, unrelieved or dead. Since then, it has become increasingly
important to collect, analyse and disseminate information on health system outcomes
data in order to understand and improve performance (DEeD, 2002). Different stake-
holders, from national accounts, to policy-makers and all those that are usually
responsible for the provision, funding and regulating of the production and provision of
healthcare services, are usually interested in finding ways of assessing the impact of
government policies. The principal reason to measure health system performance
derives from the very goal of each public health system: to deliver equitable, efficient,
and effective healthcare services to patients that need them, in a timely manner and
with dignity (Naylor et al., 2002). It is, therefore, extremely important to be able to use
available information to assess the impact that different government policies have or
may have on any of the goals that a health system pursues.
This PhD thesis is divided into two distinct areas of research. In the first (Part I and II),
we address the measurement of health system performance in terms of how efficient and
productive a health system is, or otherwise; whether the extra financial resources spent
in the NHS, for example, have produced value for money. In the second (Part III), we
explore whether the objectives in terms of equitable treatment of patients who are in
need of care are affected by changes in the political administration of the National
Health Service.
The first area of research focuses its attention on the English NHS; firstly by developing
a new output index with which to estimate whole system output growth. Such macro
measures of productivity are important when deciding how much public money to
devote to the NHS, and in holding the NHS to account. Secondly, recognising that it is
also important to gain an understanding of the productivity of individual programmes of
care, so as to ensure that resources are allocated efficiently within the NHS, we examine
'macro' level productivity at the national level for a single programme of care -
circulatory disease - in the hospital setting.
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The second area of research deals with the impact of policy reforms that occur at an
even more 'macro' level, as they have been implemented by the national government
and have potential impacts on the National Health Services of England, Scotland and
Wales.
Hence, this thesis addresses the issue of measuring health system performance from
three different points of view: 1) the 'macro' national level of analysis of the health
system in England, Scotland and Wales, 2) the analysis of one particular health system:
the English NHS; and finally 3) the analysis of a one component of a health system: a
single programme of care.
A summary of the content of each Part of this PhD thesis is presented below.
Part I "Measuring government output: the case of Health" focuses on the development
of an output index for healthcare. Four key challenges are involved when measuring
output growth. First, it is necessary to identify and quantify healthcare output correctly.
Second, even if it is possible to count these output, it is difficult to measure their
quality. In particular, two aspects need to be resolved: 1) identifying what constitutes
the quality of healthcare, and 2) develop a way of incorporating these quality
characteristics into an output growth index. Third, technological progress changes
healthcare output continuously, with new treatments and drugs, but also with new ways
of delivering existing services. Fourth, some means of weighting different goods and
services is required in order to aggregate them into a single index. We develop an output
growth measure that takes into account and tries to address all four key challenges. As
data on quality characteristics of NHS care are currently available only for hospital
inpatient services, and for some specialties of outpatient visits, we present output
growth estimates, both quality-adjusted and unadjusted, first by NHS sector. This
allows us to investigate and understand how different quality indicators impact on the
measure of output growth. We then proceed in calculating and discussing the overall
NHS output growth measure.
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Part II - "Circulatory disease in the NHS: measuring hospital output and productivity"
investigates whether it is feasible to develop a model of output and productivity growth
for a single programme of care: circulatory diseases. As early as 1962, Scitovsky
recognised the importance of measuring costs of a whole episode of care, proposing to
develop indices that would not count the costs of items such as drugs, physicians' visits,
etc, but would aim at determining the costs of the complete treatment of individual
illnesses. Consistent with Scitovsky, the US literature on disease-specific and patient-
based healthcare output and price indices focuses on the direct measurement of medical
costs of treating an episode of illness. We use the output index developed in part I to
calculate output measures for all circulatory diseases in England, for the time period
1998/99 - 2003/04. A series of diagnosis and procedures falling under the classification
of circulatory diseases are identified and mapped to Healthcare Resource Groups
(HRGs), which constitute the unit of account of the hospital data used in this chapter.
Hospital output is adjusted for survival rates, both 'in-hospital' and 'in-hospital and 30-
days post discharge'. We explore the use of patient reported health outcome measures
for two procedures - coronary bypass graft (CABG) and percutaneous transluminal
coronary angioplasty (PTCA) - to highlight the potential of introducing more general
health outcomes into the output growth index. We use average unit costs data from
Reference Costs to account for inputs used in the production process for the treatment
of all circulatory diseases. Finally, we determine productivity growth for circulatory
diseases.
Part III "Equity in the delivery of healthcare in Great Britain: the impact of
decentralisation" investigates the impact of devolution on equity in the delivery of
healthcare in the constituent countries of Great Britain: England, Wales and Scotland.
So it is using performance measurement to explore policy impact. Decentralisation of
the health care sector has received substantial attention as a policy reform in the last
decade or so inmany countries. Even so, the effects of this reform are neither thoroughly
investigated nor completely understood. We believe that in public health systems, there
is the risk that equity will be undermined by a policy of decentralisation. In particular,
decentralisation of the health care sector can jeopardise equity if individuals who are
"equal" in every respect but the 'jurisdiction' in which they happen to live are treated
differently than they would be in a more centralised structure. In 1998 the Labour
Government passed an important reform which transferred political power and
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responsibilities from Westminster to Scotland, Wales and Northern Ireland. Health is the
most important responsibility that has been devolved to constituent countries in the UK,
representing about 70 per cent of the budget that the devolved governments have control
over. Prior to devolution, health services in the constituent countries of the United
Kingdom were administered as part of the National Health Service, which was designed
to achieve common standards across the whole of the UK. However, since devolution,
each constituent country has been granted freedom to organise aspects of their NHS
differently, subject to overarching criteria and constraints. Data are taken from the General
Household Surveys (GHS) administered in 1995/96 and 2001102. In particular, we test for
income-related inequity in health care utilisation within and across the three constituent
countries of Great Britain, by means of a concentration curve index. The level of health
is captured through different measures of self-assessed health. The utilisation of primary
and secondary care is proxied by GP consultations, outpatient visits and inpatient stays.
Self-assessed health, however measured, and the utilisation of health care resources is
standardised by age and sex for individuals reporting morbidity, following the direct
standardisation methodologies outlined in O'Donnell and Propper (1991).
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1 Measuring government output: the case of
Health
The first part of this thesis addresses the issue of the measurement of government
output, and in particular of the healthcare sector. It is of great relevance not only for the
National Accounts but also to policy-makers who are usually responsible for provision,
funding and/or regulating these public goods and services. There are a number of
challenges involved in this, which we address in this chapter. We propose a quality
adjusted index formulation for the measurement of the NHS output. In Section 1.2 we
define price and output indices. An overview of the issues relating to the measurement
of government output in general is presented in Section 1.3. The challenges in
government output measurement are then addressed for health system output in Section
1.4. In Section 1.5 we introduce the methodology used in measuring the output of the
English health system. Data sources and variables used to calculate the quality adjusted
cost weighted output index (CWOI) are briefly described in Section 1.6.We then
address the issues of how to determine healthcare output and its quality characteristics
in Section 1.7. Cost weighted output indices by sector and for the NHS as a whole are
presented in Section 1.8, followed by conclusions and implications for policy and future
research.
1.1 Introduction
The government is a major actor in every economy. Its functions span from setting
policies, to forming and maintaining social structures, to collecting taxes, and
redistributing resources. Most governments also have an extensive role in the provision
and/or financing of a wide range of goods and services. In particular, governments
provide public goods and services which are of two types: collective goods and services
and individual goods and services. The former comprise goods and services provided to
society as a whole, whereas the latter include goods and services that are consumed,
generally, on an individual basis. Government provision and expenditure on collective
services are justified by their status as public goods, which people can neither be
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excluded from nor abstain from consuming (Myles, 1995). National defence is the
classic example. For the countries shown in Table 1-1, government spending on
collective services averages about 30 per cent of total government spending and about
15 per cent of GDP. The UK spends less than the average of these countries, spending
proportionately less on general public services but more on defence.
Table 1-1 - Government expenditure in selected EU countries (2004)
Countries
United Kingdom Germany Spain France Italy
·1. of e;. of % of % of -I. of % of ·1. of % of e;. of % of
Government exe;nditure Govt exe GOP Govt ex~ GOP Govtexe GOP Govtexe GOP Govt exe GOP
Collective services
General public services 9.8 4.2 12.9 6.1 12.3 4.8 13.6 7.2 18.6 8.9
Defence 5.9 2.5 2.4 1.1 2.8 1.1 3.7 1.9 2.9 1.4
Public order and safety 5.9 2.5 3.5 1.7 4.7 1.8 2.5 1.3 4.0 1.9
Economic affairs 6.2 2.7 7.8 3.7 13.4 5.2 5.6 3 8.0 3.8
!,nyironmen_t protection ... 1.7 0.7 1.0 0.5 2.2 0.9 1.5 0.8 1.8 0.8
Individual services
- -- _"_ . - ---
Heahh 15.8 6.7 13.0 6.1 14.1 5.5 13.7 7.3 14.0 6.7
Education 13.7 5.8 9.0 4.3 11.3 4.4 11.6 6.2 9.6 4.6
Social protection 36.5 15.6 46.7 22 33.4 13 41.7 22.2 37.7 18
Housing and community amenities 2.2 0.9 2.3 1.1 2.1 0.8 3.4 1.8 1.5 0.7
Recreation, culture and religion 2.3 I 1.3 0.6 3.6 1.4 2.7 1.4 1.8 0.9
Total 100 42.7 100 47.1 100 38.9 100 53.2 100 47.7
Source: Eurostat online (2008) (http://epp.eurostat.ec.europa.eu)
Although not explicitly mentioned in the table above, it is worth noting that some health
expenditures are on collective services including amongst others public and
environmental health services.
A larger proportion of government spending is on individual goods and services such as
healthcare, education, social protection, recreation services, and cultural services, which
together account for an average of 31% of GDP for these countries. A common
justification of government provision of such services is that, left to the market, there
would be general under-provision or socially unacceptable inequalities of access. Of
these individual services, government expenditure on social protection is the largest
category, incorporating such things as sickness, disability, housing .and unemployment
benefits. The UK government spends proportionately more on health and education than
the other European countries where there may be a higher proportion of private
expenditure on these services.
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In recent years there has been considerable international interest in finding ways of
examining the efficiency and effectiveness of public services. The interest in measuring
the output and efficiency of government services is not, however, new. From the early
1960s up until the end of 1990s, the output of the public sector in all national accounts,
as well as in the UK, was valued simply by adding up expenditure on inputs, an
approach termed the "output=input" convention.
This approach had the advantage that it bypassed the measurement and the valuation of
non-market goods and services. However, three main drawbacks are associated with this
method. First, it is circular. and self-justifying. The value of output produced by the
public sector is determined by the amount of resources the government decides to spend
on producing or purchasing public goods and services. Second, any improvements in
the production process that make it less costly, say, to produce the same amount of
goods/services will necessarily appear as a reduction in the output. For example, if the
introduction of a new drug allows for patients to be treated more cost-effectively
without being admitted to hospital, the convention of equating inputs to outputs would
show a fall in the "output" of the health system because total expenditure appears to
have fallen. Thirdly, the output=input conventions necessarily implies that the
government sector is characterised by constant (zero) productivity growth.
The inadequacy of this convention led to recommendations from international bodies
such as the United Nations and Eurostat for the development of measures of
government "outputs" using methods that are independent of expenditure on inputs
(Worldbank, 1993; Eurostat, 1995). A system of accounts was introduced in Europe in
response to the UN System of National Accounts 1993 (SNA93), known as ESA95.
The standard practice started to shift gradually from measuring inputs (the number of
doctors and nurses employed in the health sector; the number of teachers in schools) to
outputs (the number of operations performed; the number of children taught) (Klein,
2000). It became more and more crucial to find ways of improving the efficiency with
which resources were used (Hood, 1991; Pollitt, 1985; Smith 1995) and most
importantly to prove whether the extra resources that were injected in the public sector
produced 'value for money' (Griffiths, 1992; Pollitt, 1995;Webster, 1998).
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In particular, the Office for National Statistics (ONS) began to update its methodology
in constructing the national accounts in line with ESA9S for health, education, and
administration of social security as early as 1998 (Office for National Statistics, 1998;
Neuberger and Caplan, 1998; Caplan, 1998). Direct indicators of government "output"
were introduced for the above areas of the public sector, which took the form of cost-
weighted activity indices. In the following years, the new methodology extended to all
other government functions (Baxter, 2000; Pritchard, 2001; Ashaye, 2001; Pritchard,
2002; Pritchard, 2003). So, for instance, instead of reporting what was spent on
education, the ONS started to measure how many pupils were taught. Similar changes
were incorporated in the 2000 and 2001 Blue Books, for administration of justice, fire
and personal social services (Office for National Statistics, 2000; Office for National
Statistics, 2001; Netten et al., 2002, 2005 and 2006).
Further, in 2000 the British Prime Minister made the decision to significantly increase
public expenditure on the National Health Service and on education. This provided the
impetus for identifying some of the benefits that derive from the increased expenditure
in order to demonstrate that the money is well spent. However, it was soon clear that I)
tools to measure whether the new investment was delivering more and better services
were inadequate; and 2) sufficient information to measure ''value for money" was not
available. In 2002 this lead the National Statistician to commission Sir Tony Atkinson
to conduct an independent review of the measurement of government output in the
National Accounts (Atkinson 2005), with the aim
'To advance methodologies for the measurement of government output, productivity
and associated price indices in the context of National Accounts, recognising: a) the full
scope of government outputs; b) differences in the nature and quality of these outputs
over time; c) the relationship between government outputs and social outcomes; d) the
need for comparability with measures of private sector services' output and costs; e) the
existing work of the Office for National Statistics (ONS); and t) the appropriate
measurement of inputs, including quality and the distinction between resource and
capital, so that, together with the measurement of output, light can be thrown on
developments in government productivity' (Atkinson, 2005).
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The interest in measuring output and productivity of non-market services is not
confined to the National Accounts. It is of great relevance also to policy-makers, who
are usually responsible for the provision, funding and/or regulating these public goods
and services.
This chapter addresses the issues relating to the measurement of the output and
productivity of one particular governmental function': Health. Healthcare output (and
productivity) can be measured in two different ways by either using patient-
based/disease specific measures or overall health system measures. The first considers
single diseases or areas of healthcare and is the object of analysis of chapter 2. In this
chapter we address issues related with overall measures. These aim at assessing and
valuing the output and productivity of an entire health system.'
1.2 Price and output indices
Measuring changes in price and volumes of consumer goods and services can be
achieved by using either a price index or an output index. There is a certain degree of
duality between the measurement of prices and volumes: as Eurostat (2001) points out
'one can either deflate a current year value with a price index, or alternatively
extrapolate a base year value with a volume index to arrive at an estimate in prices of
the base year', thus only one of the measures is required and the other can be derived as
a residual. The two approaches are not completely interchangeable, however, with a
price index generally preferred over a volume index in most contexts, with the
exception of government goods and services for which consumers do not pay at point of
use (Eurostat, 2001).
A price index usually assumes the evaluation of a constant basket of goods and services
over time. In the Laspeyres form this would imply the measurement of
(1) PI, ~iPi,xqiO
~iPioxqiO
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Where Pit is the price of good i at time t; and qiO represents the fixed basket of goods and
services as measured in time 0 (= base year). In the healthcare sector, the calculation of
a price index requires knowledge of the prices paid by private/public medical insurers as
well as out-of-pocket payments made by consumers for the healthcare goods and
services received. Real output growth in the healthcare sector is then calculated by
deflating expenditure by the price index. In the US healthcare sector where prices (of
some form or another) are available, it is feasible to measure real output using price
deflation (Christian, 2007).
Price indices are less useful as measures of productivity change in a health system like
the British NHS, as healthcare goods and services are provided free of charge to all
patients at the point of use. In the absence of prices, the UK literature has focused on
output growth measures. This allows the measurement of how output changes over
time, given a fixed set of prices or costs. The Laspeyres form of an output index can be
written as
Where qit represents the quantity of healthcare good/service i at time t; and Pio measures
its price (= cost) in the base year O.
1.3 Challenges when measuring public sector output
Internationally, the need to compile national accounts has provided a motivation for
greater standardisation in describing, measuring and valuing goods and services
provided or purchased by the government.
The first step in moving towards the measurement of government "output" is to define
what constitutes an accurate measure of it. The preferred starting point should be to
consider the full range of goods and services that are valued by society as a whole. In
the case of the provision of hospital services, for example, patients may not only expect
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to receive a certain treatment, but also that its standard is of high quality, that they did
not have to endure a long waiting time, and not least that their health is improved as a
result of contact with the health system.
However, this has posed a number of challenges to economists, policy-makers and
national accountants.
First, there are difficulties in describing and quantifying what constitutes the "output" of
the public sector. For example, the maintenance of armed forces is justified on the
grounds that it deters aggression from other countries but the extent to which defence
spending reduces the threat of war is very difficult to measure. Similarly, fire services,
for example, deal not only with the extinguishing of fires, which is an easily countable
activity; they also deal with fire prevention, which is more difficult to measure.
Moreover, if fire services become increasingly better in preventing fires, so that the
number of fires extinguished decreases, a simple count of activity in terms of fire
extinguished would not correctly reflect the level of output produced by the sector.
Secondly, even if it is possible to count government "output", it may still be difficult to
measure its quality. In the case of education, for example, a simple count of lessons
taught does not capture the quality of these lessons; a better indication of which could
be given by the number of qualifications obtained by the pupils (an output measure).
Further, there are other benefits (outcomes) associated with education that affect
individuals' utility and hence should be accounted for. Remaining with the education
example, a different way of looking at the quality of these qualifications is to consider
the higher earnings that pupils may expect to receive because of their qualifications (an
outcome measure).
Further, there are difficulties related to the measurement of governmental "output" over
time in the presence of technological progress. For example, in the case of healthcare, if
technological change makes it possible to reduce the number of treatments required to
treat a certain illness/disease, then a volume measure that simply considered a count of
activity would show a decreasing level of government output (and productivity) over
time. Technological progress may also have a positive effect on the quality of public
goods and services. In the healthcare sector, for example, technological progress
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constitutes a very important source of quality improvements. Technological changes of
this nature can be embodied in a classification system such as the Diagnostic Related
Groups (DRGs) only by a res-structuring of the system itself. This has been an
important consideration in the development of the most recent version (v. 4) of the
Healthcare Related Group (HRG) system in England, for example.
And finally, a further difficulty arises when one wants to aggregate different goods and
services into a single output index, in which case some means of weighting these
different goods and services together must be devised. In the private sector, prices exist
that reflect the marginal evaluation of the benefits and costs associated with a given
good or service to consumers. Market prices are, hence, used as weights in an output
index. In contrast, most non-market goods and services are provided free of charge or at
a nominal price, which does not reflect the value to the consumer, at the point of
delivery. Hence, some other way of aggregating these goods and services must be
devised.
1.3.1 Describing outputs
In order to facilitate the identification of the accurate measure of government "output",
a common distinction is made between activity, outputs and outcomes (Eurostat, 2001;
Dawson, 2005).
Activity refers to, for example, the number of hospital consultations, the number of
lessons taught, or the number of patrols carried out by the police. Activity data is
usually available and easy to measure; however, it might not be detailed or
comprehensive enough. Moreover, counting simple activities does not allow for the
quality characteristics of these to be taken into account.
Output is defined in terms of bundles of activities (Eurostat, 2001; Atkinson, 2005;
Dawson et al. 2005). In the case of individual goods and services, such as health and
education, outputs are easily identifiable as an 'actual delivery of that output takes place
from the producer to the consumer' (Eurostat, 2001). Thus, the output of the public
education sector would be given by the number of GSCEs obtained, for example. In the
case of the healthcare sector, the output is constituted by the amount of care received by
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a patient. Similarly to activity, using output measures has the limitation that they do not
capture all quality aspects of the goods and services delivered. Hence, it is important to
identify both objective and subjective characteristics of public goods and services that
affect individuals' utility.
The third and final distinction considers the outcomes achieved by the public sector.
These relate to the overall and/or specific benefits that derive from the provision of
public goods and services, which are valued by individuals and society as a whole. As
such, they appear to also include the quality characteristics of public goods and services.
They are identified in terms of, for example, the level of crime, the level of education in
the population, and life expectancy. Outcomes need to be used, however, with caution
as these can also be affected by factors external to the public sector. Only outcomes that
are directly attributable to the working of the public sector should be in fact accounted
for in a volume measure. This would require the isolation of the marginal contribution
that the public sector makes in a specific area. This is not always a feasible task; and
even when feasible, it may be extremely costly. It is, however, unquestionable that
outcome measures are a potential source of information of the quality of the services
provided by the public sector and should be used alongside an appropriate measure of
governmental "output" to quality-adjust it (Eurostat, 2001; Atkinson, 2005).
The use of indicators based on outputs, as defined above, is advocated by Eurostat
(2001) and Atkinson (2005) on the grounds that unlike for market goods and services
prices for governmental goods and services are usually not available as these are
provided in most cases free of charge at the point of delivery and in some at a nominal
price that is not 'economically significant' (Eurostat, 2001). In particular, Atkinson
recommends that in measuring government output, one should follow procedures
similar to those adopted for market outputs (Principle A3, Atkinson, 2005). Further, the
Eurostat Handbook (2001) outlines some criteria that should be satisfied in order to be
an 'appropriate' price and volume measure (type A method). An output indicator has to
be as comprehensive as possible, covering for any particular public sector area, all
goods and services provided; it should use cost weights for each type of output in the
base year and it should be as detailed as possible. A final requirement is that output is
quality-adjusted. On this regard, Atkinson (2005) requires explicitly that only
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"incremental contribution" attributable to the workings of the public sector should be
accounted for (Principle B).
1.3.2 Measuring quality
Considering quality aspects is particularly important, both in the private and in the
public sector. Accounting for quality and quality change is not, however, an easy task.
In general, the quality of a product is defined 'by its (physical and non-physical)
characteristics' (Eurostat, 2001). Hence, different varieties of the same product can be
considered as products of different qualities. Quality can also be related to the way a
product is prepared and to how, where and when it is delivered. Further, the conditions
of sale, circumstances and environment can all be considered as making up the quality
of a certain product (Eurostat. 2001). If a product's characteristic changes, it is to be
considered as a different quality of the product. Any change in the characteristics of a
product needs to be registered as a change in the volume and not in price (cf. ESA95,
par. 10.16).
Valuing changes in quality is not straightforward. In a situation of 'perfect competition',
the market price of a product gives an indication of an individual's preferences and the
producer's costs. Or in other terms, the market price reflects both the consumer's
marginal willingness to pay for an extra unit of that product, and the producer's
marginal cost to produce that extra unit without making a loss. Hence, differences in
prices of two products can be interpreted as reflecting differences in the value that
consumers attach to the characteristics (quality) of these two products. Higher quality
products are usually associated with higher prices. This applies only to markets
governed by perfect competition; in all other situations price differences can be due to a
variety of reasons.
In the case of goods and services provided by the public sector where prices do not exist
as these are supplied free of charge or at a nominal price at the point of delivery, other
ways of incorporating quality characteristics into an output measure need to be
developed. Three different approaches are feasible. The first approach focuses on the
direct measurement of the quality of the output itself. This could be done through the
administration of surveys to assess the quality of public services. These are believed to
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be able to '[ ... ] give (some) indications of the changes in quality over time' (Eurostat,
2001). The difficulty inherent with this type of approach is that the information can be
subjective and not consistent over time.
The second approach concentrates on the measurement of the quality of inputs
(Eurostat, 2001). This approach implies that the quality change in inputs automatically
reflects a quality change of the output. An assumption that can only be truly verified by
measuring the quality of the outputs.
The third approach focuses on the identification and measurement of the outcomes
associated with a public good or service. In this way, changes in quality are investigated
as changes in some outcome indicator. For example, in the case of the police force, a
reduction in the level of crime can be used as an indication of the improved
effectiveness of the police. In the case of healthcare, a reduction in mortality rates can
be used as an indication of improved effectiveness of the healthcare system. A number
of problems are, usually, related with using an outcome indicator. The first, which we
have mentioned earlier in the chapter, is that an outcome may be affected by factors that
are external to the working of the public sector. Hence, it is important to be able to
attribute the marginal contribution made by the public sector. Another problem
mentioned in the Handbook is that there may be a time lag between the change in the
quality of the output and the change in the quality of the outcome. Further, it states that
on a practical basis, there may be difficulties in linking an outcome indicator to an
output indicator.
1.3.3 Measuring change over time
Technological progress is one of the determinant of how outputs change over time,
especially in the case of health. It is responsible for the introduction of completely new
goods and services (e.g. new surgical treatments, drugs); for changes in the quality
characteristics of existing goods and services; for the way services are being delivered;
etc.
In the private market, improvements in quality tend to be reflected by increases in the
real value of products; if this has increased, the assumption is made that the increase in
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value is capturing an increase in quality. A second approach is to use hedonic price
techniques (Cockburn and Anis, 2001) to calculate the implicit prices of the various
characteristics of a good or service.
1.3.4 Valuing outputs and quality characteristics
The majority of governmental goods and services are provided free of charge or at a
nominal price at the point of delivery. In the absence of prices to reveal individuals'
marginal valuations of government outputs, alternative means of estimating their values
need to be found. There are three main competing approaches: extrapolating private
sector prices; using contingent valuation methods; and unit costs.
The use of private sector prices is only feasible if goods and services provided by the
former have similar characteristics to those publicly provided. This is quite problematic
as the quality characteristics of private goods and services may be different to those
publicly provided. An example is posed by private healthcare output which produces a
mix of outcomes (shorter waiting times, better quality of 'hotel services') that are
arguably more valuable. Thus, the price of private healthcare may overstate the
willingness to pay for NHS output.
Dawson et al. (2005) have also explored the use of international prices for the
healthcare sector and have rejected this option on three grounds: 1) there is no market
for healthcare and all domestic prices are distorted in some way; 2) countries use
different classification system to define and group their activity, making it impossible to
compare like with like; and 3) even for those healthcare activities that are comparable,
they find that the valuation basis is sensitive to which country the data carne from.
Another way of measuring the social value attached to different outputs or to their
characteristics is to elicit individuals' willingness to pay for them through contingent
valuation techniques. These have been used for example to elicit people's values for
various aspects of environmental protection and the premium individuals are prepared
to pay to live within the catchment area of a good primary school. A number of studies
have also used this technique to evince the relative value that people put on different
aspects of healthcare, ego Diener et al. (1998). The problem associated with this
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technique is that many research studies are necessary to determine people's willingness
to pay for all good and services provided by the government, making it a not viable
option. Moreover, the studies would need to be repeated frequently if new goods and
services are being offered or simply to measure change over time.
In the National Accounts the assumption is made that marginal social values are
measured by the unit costs of production. This requires that two assumptions hold true,
namely that 1) average unit costs are equal to marginal costs and 2) that resources are
allocated efficiently within a particular public sector. These assumptions are, however,
highly questionable. Moreover, using cost weights has the drawback that more
expensive activities have a higher weight attached. If these activities were to be
substituted by more cost-effective one, this would result, in principle, in a reduction of
the output measured.
In the following Section, a very brief summary of the literature on the measurement of
healthcare output is presented. Key journal articles, working papers and books were
identified through a systematic search on two electronic databases: Health Management
Information Consortium (HMIC)4 and EconLit. These were searched between April and
May 2004, and restricted on publications from 1989 onwards. A search strategy was
implemented after having identified a number of key words. These were: price index;
medical productivity, healthcare productivity, multifactor productivity, amongst other.
A further refinement search strategy was also implemented to ensure a closer focus on
the research area of interest. Full details on search strategies for both the HMIC and
Econlit databases can be found in Appendix I-B.
We focus in this chapter on literature concerning the measurement of output growth by
means of price/output indices, which are particularly relevant for our proposed new
methods and the methodology adopted in the National Accounts.
1.4 Measuring healthcare output
As early as 1962, Scitovsky recognised the importance of measuring the costs of a
whole episode of care, proposing ..... an [price] index which would show changes, not in
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the costs of such items of medical care such as drugs, physicians' visits, and hospital
rooms, but in the average costs of the complete treatment of individual illnesses
[emphasis added] such as, for example, pneumonia, appendicitis, or measles'",
Consistent with Scitovsky, the US literature on disease-specific and patient-based
healthcare output and prices indices focuses on direct measurements of medical costs of
treating an episode of illness. These have been developed for various illnesses such as
heart attacks (Cutler et al., 2001), mental health (depression: Berndt et al., 2002, and
Berndt et al., 2001; schizophrenia: Frank et al., 2003) and cataract surgery (Shapiro et
al., 2001). Further, Cutler and Huckman (CH) (2003) and Mai (2004) investigate the
effect of technological change in medical treatment on healthcare output growth and
productivity. Mai's analysis is carried out within an output index approach. More
recently, the Atkinson Review (AR) (2005) set out an important recommendation
encouraging the use of ''whole courses of treatment for an illness, rather than its
components (para 8.39, AR (2005»" when constructing an output measure. This type of
measure is thought to be more appropriate when considering the quality of healthcare
provided, technological change and the possible treatment substitution that is usually
associated with medical innovations. The task of incorporating changes in quality is one
of the most challenging when measuring healthcare output growth as these are likely to
be an important source of productivity change in many sectors of the economy
(European Commission, 2002).
Shapiro et al. (1999), Berndt et al. (2000) and Cutler et al. (2001) outline a number of
challenges when dealing with the pricing of healthcare goods and services, making it a
much more difficult task than that of pricing private goods and services." First of all,
there is the problem of moral hazard, which occurs in situations where most medical
care payments are paid for by private and/or public insurers, with consumers only
paying a given (and relatively small) percentage of total medical costs. Subsidisation
means that consumers are likely to consume more than their marginal value. However,
Shapiro et al. (1999) add that patients bear substantial non-pecuniary costs, such as pain
suffered and a period of recovery, which will most likely impact on their demand for
healthcare. These non-monetary costs need to be considered as well. The second
difficulty derives from the existence of asymmetric information between patients and
physicians, with the latter sometimes not acting in their patients' best interests
(principal-agent problem). These two aspects of the hea1thcare sector make it
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particularly difficult to construct and interpret consumer price indices, as the marginal
private costs and social costs do not coincide.
A third difficulty derives from technological and organisational changes that result in
new services being introduced all the time, and/or to improve the efficacy of existing
treatments. In particular, Shapiro et al. (1999) analyse two possible effects: I) it can
lead to a considerable improvement in outcomes; 2) it can reduce both monetary and
non-monetary costs to patients. They note that when technology results in an increase in
the treatment value, more treatment is likely to take place. This might be reflected in a
greater number of patients treated as well as in interventions taking place at different
stages of an illness. A change in the timing of interventions has occurred in the
treatment of many conditions, including cataracts, angioplasty and joint replacement.
Interestingly, it this has not always been beneficial, as for example, Chemew, Fendrick
and Hirth (1997) point out in the case of gall bladders, where it resulted in unnecessary
operations.
Finally, the most important problem in the measurement of healthcare goods and
services is that individuals do not value these goods directly but value the expected
effect they have on their health. Routine measures of these health effects are rarely
available, thus making it particularly challenging to allow for quality change. Shapiro et
al. (1999) argue that improvements in outcomes and reduced patient burden should be
reflected in the price index. To allow for this, the net benefit (immediate and life-time
lasting benefits) of the treatment needs to be measured, and changes in this net benefit
should then be used to adjust unit costs. One approach is to undertake patient surveys,
with scope for either contingent valuation methods to be applied to elicit patients'
valuation of hypothetical outcomes, or for quality adjusted life years or QALYs7.These
can be combined with expert opinions on the efficacy of treatment administered.
Shapiro et al. stress that both patients' assessments of the value of outcomes and expert
opinions on the effects of treatments should take into consideration the variation and
uncertainty in successful outcomes and how the illness would have progressed if not
treated.
To conclude, Shapiro et al. make a number of recommendations for the measurement of
price indices for the hea1thcare sector. They argue that a 'standard metric' for quality-
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adjusting the price of treatments is required, which should also incorporate knowledge
of medical professionals and experts. They propose the development of a "database of
values of healthcare outcomes". This database should be based on standard values for
"broad dimensions of impairments", such as blindness, deafness and mortality, followed
by an ongoing evaluation of how changes in treatments impact upon outcomes in terms
of these dimensions. In this manner, consistency across varying diagnoses could be
achieved.
1.4.1 The measurement of healthcare output in the UK National
Accounts
The measurement of healthcare "output" in the National Accounts prior to 2004
included 16 different activity series (Pritchard, 2004a). One series counted inpatient and
day case activity, which accounted for about fifty per cent of the expenditure included
in the index. Outpatient activity, community health treatments, GP prescribing and
dental treatments were counted separately". One of the limitations of this approach lies
in the fact it used very broad categories of activity, which washed out all quality and
complexity aspects of the different treatments. Further, it gave an equal weight to all
activities regardless of their complexity, cost and clinical benefit, so for example a
simple procedure such as the removal of varicose veins had the same weight as the more
complex procedure of a heart bypass surgery.
This rudimentary method was updated by ONS in collaboration with the Department of
Health in June 2004. The new methodology was extended to incorporate higher
differentiation of healthcare activity. In particular, it used hospital inpatient activity data
classified in about 1,200 Healthcare Resource Groups (HRGs), following a
recommendation set out in the Eurostat Handbook (200I) that suggested to measure
'output (= treatments) [... ] on the basis of the so-called Diagnosis Related Groups
(DRGs) type classifications. DRG systems are similar to HRGs and are used to classify
hospital stays into groups that are medically meaningful and as homogeneous as
possible with regard to resource use'.
Average unit cost information for hospital activity is derived from the National
Schedule of Reference Costs, which also constitute the source of volume and cost data
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for the remaining other NHS activity (400 groupings). General practice consultations
and prescribing is derived, respectively from the General Household Survey and the
Prescription Pricing Authority. Other activity includes NHS Direct, NHS Direct Online,
NHS Walk-in-Centres and Dentistry.
Although a more comprehensive method, the ONS/DH cost weighted activity measure
has a number of limitations that need to be addressed in order to meet the requirements
set in the Eurostat Handbook (2001) and the principles proposed in the Atkinson
Review (2005). In particular, two aspects need to be improved to comply with the
calculation of type A methods and with principle B of the Atkinson Review.
A more comprehensive measure of healthcare output needs to be introduced, where
possible, and quality characteristics of healthcare services need to be investigated and
incorporated into the output measure.
1.5 Methodology
We have developed a new methodology to measure NHS output growth and
productivity (Dawson et al., 2005, Castelli et al., 2007b), that addresses the issues
relating to the measurement of the most appropriate unit of healthcare output, and
investigates the issues regarding the quality characteristics of this output.
An ideal index - value weighted output index (VWOI) - is developed to capture the
value of what is produced by the NHS. It adjusts volumes of activity to take account of
changes in (the quality of) healthcare characteristics. Weights are attached to these
characteristics that reflect the marginal value society places on them. A feasible" version
of the ideal index by Dawson et al. (2005) has been developed taking into account
nature and availability of healthcare data. In particular, it incorporates adjustments for
health outcomes, life expectancy, and it may also take into account any possible
detrimental effect caused by having to wait for treatment (see eq. (1» (Dawson et al.,
2005)
35
(1)
Xjt is the volume of output in period t.; aft is the probability of surviving treatment j at
time t; kjt is equal to the ratio of a measure of patient-recorded health outcome before
treatment (h°jt) and after treatment (h jt) at time t; Ljt represents healthy life expectancy
after treatment, which is assumed to vary by treatment j and over time, and is
discounted using interest rate ri: and Wjt is waiting time, which is also allowed to vary
by treatment j and over time. 1Ck and 1CW are the marginal social values respectively for a
quality adjusted life year (QALY) and for a day spent waiting.
Output is defined in terms of whole courses of treatment provided to a patient. Patients
often require multiple contacts with different parts of the health system in their care
pathway. Complete treatments should comprise all healthcare activities (operative
procedures, diagnostic tests, outpatient visits, consultations etc) that are relevant for a
given treatment, that is 'medical services, paramedical services, laboratory and
radiological services and, in the case of hospitalisation, non-medical services such as the
provision of food and accommodation' (Eurostat, 2001). Ideally, we would like to be
able to link together all the different treatments that an individual receives, from GP
consultations to inpatient stays, readmissions, outpatient attendances, follow up care and
prescriptions. The main advantage of this type of measure is that it would make an
output growth index less subject to fluctuations/distortions due to changes in medical
andlor organisational practice, and technological change (Atkinson, 2005).
IT technology currently available in the UK does not allow for such a measure of
healthcare output to be implemented yet. An alternative measure is developed limitedly
to inpatient (elective and day cases, emergency) admissions, which builds on the
method 10 developed by Lakhani et al. (2005) and allows to link all episodes of care
received by a patient when transferred from one consultant to another within the same
provider; and to link these records also to other providers if a transfer is required by the
patients' course of care.
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Outcomes of healthcare output are defined in terms of those characteristics that affect an
individuals' utility and that individuals value in their contact with the healthcare sector
as patients. The primary objective of a health system is to improve the health of
patients, thus improved health outcomes are the most important characteristic of
treatment.
The focus in health economics has been on the change in health produced by a course of
treatment and measured, usually, in terms of QALYs (Williams, 1985). This is but one
of the characteristics of healthcare that affects individuals' utility. Other valued
characteristics are various measures of patient experience such as waiting time, choice
of date of treatment, certainty of date of treatment, being treated with dignity and
respect, distance and travel time to services, the interpersonal skills of healthcare staff,
the range of choice and quality of hospital food, and the degree to which patients feel
involved in decisions about their treatments (Castelli et al., 2007a; Atkinson I I ,2005).
The value weighted index incorporates only some of these quality aspects of healthcare:
survival following treatment; a measure of the change in health status; life expectancy
and waiting time.
The remaining challenge is to place a value 1t:th expressed in some unit of account, on
the characteristics of healthcare goods and services. The issue of valuing outputs and
quality characteristics has already been addressed in Section 1.3.4. The main conclusion
is that value weights for public healthcare output do not currently exist. However,
Eurostat (2001) and Atkinson (2005) recommend the use of unit cost to weight
healthcare output.
Thus, we formulate a cost weighted output index (CWOI) (see eq. (2), Dawson et al.,
2005). Similarly to the YWOI, the cost weighted output index allows to adjust NHS
output to take into account changes in survival rates (ajt), in health outcomes (kj), life
expectancy (Ljt) and in waiting times (Wjt). Its Laspeyres forml2 is:
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(2)
The main difference to the VWOI lies in that it uses cost weights to capture the relative
importance of each NHS output and adjusts these weights where outcome data are
available.
Equation 2 presents the formula of the full quality-adjusted output growth index, where
all quality dimensions are taken into account. In order to investigate the effects of
incorporating these quality characteristics into an output growth measure, we construct
four alternative output indices. These are presented in Table 1-2.
Table 1-2 - Cost weighted output indices
Quality adjustment Output growth index
None
(CWOI)
Survival
(CWOI 1)
Survival and health
(CWOI 2)
Survival, health
expectancy
(CWOI 3)
& life
Source: Dawson et al. (2005)
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The first and most simple output growth index is the cost weighted output index
(CWO I) without any quality adjustment, where Xj/ is the amount of output undertaken in
period t and Cj/ is the average unit cost of output j in time t.
The other two indices allow to determine the effects of quality adjusting NHS output by
survival rates only, and by survival rates and change in health status. In CWOI 1, the
ratio ajt+/laj/ represents the proportionate increase in surviving treatment for output j
between period t and period t+ 1. Ceteris paribus and assuming that mortality rates have
been improving over time, quality adjusting the output growth measure should yield
higher growth rate. The magnitude of the survival adjustment on the overall output
growth measure depends clearly on the initial survival rate aj/; if the majority of NHS
patients survive their treatments, then the overall effect of this quality adjustment on
output will be minimal.
Changes in pre- and post-treatment health status are incorporated in CWOI 2, alongside
survival rates. i9 is an estimate of the proportionate effect of treatment conditional on
survival. It is calculated as the ratio of average health reported outcome pre- (hOj) and
post- treatment (h~) Note that kj is time-invariant in this application as data on patients'
health status before and after treatment are currently not routinely collected on an
annual basis.
The last index (CWOI 3) in Table 1-2, incorporates life expectancy (Lj/) defined as the
average age of patients getting treatmentj at time t, discounted at the rate ri. In this way
we are able to estimate the effect on health, condition on survival, over the remaining
life years of a patient. Ceteris paribus, and assuming that life expectancy is increasing
over time; we expect that incorporating this further quality adjustment should yield
better estimates of the output growth index.
In Section 1.7, we present all data used to construct these output growth indices. In
particular, we describe how the output measure for hospital inpatient stays is
constructed. Inpatient data is currently the only data that contains the required
information to follow a patient through his/hers healthcare pathway ('whole course of
treatment). Further, we address the issue of quality-adjusting NHS output; we analyse
what should be measured and what can be measured, given current data collection.
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A brief description of the various data sources used to populate the NHS output growth
index is provided in the next Section.
1.6 Data Sources
Several data sources are used to populate NHS output over the time period 1998/99 -
2003/04. The Hospital Episode Statistics (HES) is used as the data source for inpatient
electives and non-elective (emergencies) stays; the National Schedule of Reference
Costs (hereafter, simply referred to as Reference Costs) provides data on all other NHS
activity, such as outpatient care, ambulance services and mental health services. It also
contains data on average unit costs, which are used as weights in the calculation of the
output growth index. Data on primary care are not readily available; hence, estimates of
primary care consultations are produced using the General Household Survey (GHS).
Data on pharmaceuticals prescribed are available from the Prescription Pricing
Authority (PPA). All these sources are described in further detail in the remainder of
this section.
Hospital Episode Statistics
HES database provides information on admitted patient care delivered by all NHS trusts
in England, including acute hospitals, primary care trusts and mental health trusts, from
1989 onwards. It also records care provided to NHS patients by the independent sector,
including that taking place in treatment centres, and care given to private patients in
NHS hospitals.
HES includes information on all medical and surgical specialties, comprising more than
12 million patient records (Hesonline, 2009). Patient records are collected according to
the financial year (1st April to 31st March) in which the episode of care finished.
Each patient record includes information on the demographic characteristics (e.g. age,
gender) of patient treated, clinical information such as diagnosis and procedures
performed and details of the hospital and specialty where the patient received treatment;
administrative information, such as time waited and date of admission; and
geographical information on where the patient was treated and area in which she
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resides. Each episode of care is classified in terms of Healthcare Resource Groups
(HRGs).
HRGs are designed as grouping of treatments with similar clinical characteristics and
similar resource use (NHS, 2008). They are determined from both procedural (OPCS)
and diagnostic (lCD) codes, that are intended to capture every detail of a clinical event
by simple alpha-numeric symbols. OPCS stands for Office of Population Census and
Survey and it is the standard classification system in use in England to record healthcare
procedures and interventions. The version ofOCPS used to inform HRG versions':' 3.0,
3.1 and 3.5, which are used in this chapter, is version 4.2. ICD stands for International
Classification of Disease and Related Health problems, which is the diagnosis coding
system in use worldwide. It is developed and managed by the World Health
Organization (WHO). The version used to inform HRG versions 3.0, 3.1 and 3.5 is
version 10.
Reference Costs
The HRG coding system is also used as one of the basis for reporting activity and
average unit costs in the Reference Costs database. Reference Costs were introduced in
England in 1997 and constitute the basis for setting prices under Payment by Results
(DH, 2006). Costing of NHS activity is a complicated exercise, and it requires a
methodology that takes into account the type of patients treated and the nature of
treatment administered to patients. To this end NHS providers collect and record data
based on HRGs.
Reference Costs provide detailed information (e.g. activity, average unit costs) on a
broad range of surgical procedures and medical treatments administered to NHS
patients in a number of settings. It covers services provided by NHS hospital trusts, by
Primary Care Trusts, and by a number of other settings, as well as covering paramedic
services provided by Ambulance NHS Trust (2003/04 onwards). The coverage ofNHS
activity included in the Reference Costs database has increased over time, as well as the
quality of the data submitted. We recognise that the Reference Costs may suffer from
the usual drawbacks associated with routinely collected data in terms of large variation
in the unit costs measures (Jacobs and Dawson, 2003). These variations may be due to
'differences in case-mix, resources being used, factor prices, particular hospital features,
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different priorities, differences in the quality of services and patient outcomes, the
external environment, different accounting treatments, data errors and random
fluctuations (Jacobs and Dawson, 2003)'. Nonetheless, we believe that they make for a
valuable and reliable source for both activity and average unit costs data for the
purposes outlined in this chapter.
General Household Survey
The General Household Survey (GHS) is a multi-purpose continuous survey carried out
by the Social Survey Division of the Office for National Statistics (ONS) since 1971.
The survey collects information on a range of topics from people living in private
households in Great Britain. The topics cover health and use of health services,
household and family information, education, and employment, amongst others 14. The
GHS is affected by a number of drawback that are widely recognised (Atkinson, 2005).
One of the limitations of the GHS, as outlined by the Office for National Statistics in a
recent quality review exercise (ONS, 200Sb), is posed by the nature of the clustered
sample design. It is stated that 'clustering has can lead to an increase in sampling error
if the households or individuals within the PSUs [Primary Sampling Units] are
relatively homogenous but the PSUs differ from one another (ONS, 200Sb),. Other
limitations are more generally related to the collection of information through surveys.
These are systematic error, random error and sampling error'".
However, it constituted the most comprehensive source'" of data for this particular
sector at the time this analysis was carried out. Cost weights for primary care
consultations are taken from PSSRU's annual publication reporting Unit Costs of
Health and Social Care'", which estimates the unit costs of GP and nurse consultations
using a variety of official and unofficial sources. Several of the estimates rest on self
reported GP activity from the 1992/3 GP Workload Survey", These constitute the most
recent survey of GP activity at the time the analysis was carried out. A more recent
survey was carried out in 2006/0719•
Prescription Pricing Authority
The Prescription Pricing Authority collects data on primary care prescribing in order to
remunerate pharmacists and dispensing GPs. It constitutes, therefore, a reliable and
comprehensive measure of the volume of prescriptions dispensed in England. The
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prescriptions data are disaggregated by product type (item). A system is in place to
calculate reimbursements and remuneration to all drug dispensers'? that are registered in
England.
1.7 Outputs and quality characteristics
1.7.1 Output measure for hospital inpatient stays
Each record in HES represents a Finished Consultant Episode (FCE), defined as the
time a patient spends under the care of a single consultant. We convert FCEs into
continuous inpatient spells of NHS care, a measure developed by Lakhani et al. (2005)
and used in Dawson et al. (2005). This measure enables one to capture in a more precise
manner patients' journeys across NHS hospital providers.
Lakhani's method, in fact, enables one 1) to link all episodes of care received by a
patient when transferred from one consultant to another within the same provider; and
2) to link records of patients transferred to other providers to receive, for example, more
specialist procedures" that are required by the patients' course of care.
In particular, to identify the episodes of care associated with each continuous inpatient
spell, all episodes are sorted by a number of patients' admission details and patient's
identifiers (HESID, EPISTART, EPIORDER AND EPIEND fields in this order)
(Lakhani et al., 2005). In this way, it is possible to identify all episodes of care
associated with the same patient and that may belong to the same Continuous Inpatient
Spell (CIPS). Transfers to other providers (hospital) can also be considered by imposing
certain checks. We follow the methodology set out in Dawson et al. (2005) to identify
CIPS ofNHS care.
Table 1-3 reports the number of episodes available in HES and the number of provider
spells and NHS spells that can be obtained by linking FCEs by provider (for provider
spells) and by provider and across providers (for CIPS ofNHS care).
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Table 1-3 - Number of finished consultant episodes, provider spells and CIPS ofNHS care by HES
data year
HES data FCE Episodes (millions) Provider spells (millions) CIP speDs (millions)
year
1997/98 11,404 10,893 10,799
1998/99 12,001 11,350 11,211
1999/00 12,203 11,285 11,106
2000/01 12,273 11,257 11,075
2001/02 12,316 11,183 10,994
2002/03 12,719 11,739 11,542
2003/04 13,332 12,148
The numbers are very similar, an indication that the majority of CIPS of NHS care is
made up of single episodes of care. However, there is a number of CIPS with multiple
finished consultant episodes. As HRGs are usually assigned at episode level and having
linked episodes into spells, there is the need to assign an HRG code to each CIPS. This
is done on the basis of the HRG code of the first finished consultant episode within a
CIPS of NHS care. This can be justified on the basis that it identifies the underlying
health condition that brought up the initial contact with the healthcare system. It is
worth noting, however, that the HRG thus assigned may not be the dominant or most
costly procedure (HRG) within a patient's CIPS22•
Two limitations are identified with the way CIPS are constructed. First, important co-
morbidities may be present, which this particular linkage method may "wash out".
Secondly, the case-mix of a CIPS HRG may well change over time. However, we
accommodate for this by applying in-year cost weights to hospital output.
Cost weights are derived from the Reference Costs. These are, however, assigned to
FCEs. Hence, a method was developed to determine average unit costs of CIPS HRGs.
First, we allocate every patient i to the HRG recorded in the first FCE, designated by
HRG j. For each patient, we then calculate the cost of their CIPS (cF1PS_HRGj) by
summing the HRG costs across all the FCEs that are assigned to the same patient.
II
(12) CIPS_HRGj _ FCE-HRGj +~ FCE-HRGjc; -c; ~cla
k~j
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Where C{CE-HRGJ represents the unit costs of the first finished consultant episode, which
also determines the HRG code to be assigned to patient i CIPS of NHS care. The second
component in equation (12) allows us to attribute to each patient all subsequent associated
with his/her treatment pathway, ie until the end of his/her continuous inpatient spell of
NHS care.
So, once we have calculated total costs for each patient treated, we calculate the total
cost of all CIPS allocated to HRG j, indicated by the left-hand side of equation (13).
This is obtained by summing all patients' costs whose first episode of care is grouped
under HRGj, and of which we have an amount x:
x
(13) C~JPS-HRGJ = LC{CE_HRGj
;
Total volume of CIPS activity (ie the number of patients treated whose first HRG is the
same) assigned to HRGj is designated with XjCIPS_HRGJ. The average CIPS cost for HRG
j is hence calculated by dividing the total CIPS cost for this HRG by the number of
CIPS assigned to HRGj.
CCIPS-HRGj
(14) ~JPS-HRGj = jCJ -'::"CI=PS~-=HR""'G-j
Xj
1.7.2 All other NHS activity
For all remaining NHS activity (outpatient visits, A&E, community services, etc),
Reference Costs are used to provide data on both volume of activity and average unit
costs. It is not possible to summarise these data into an output unit, as we have done for
hospital inpatient records.
As explained in Section 1.6, the coverage of NHS activity included in the Reference
Costs has increased substantially over time. This is due to 1) the inclusion of activity
that was previously unmeasured, and 2) the re-categorisation of previously quantified
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activity. In both cases, we are presented with data for any two adjacent years that is not
exactly the same and hence cannot be directly compared.
The traditional approach (EurostatiCommission of the European Communities et al.,
1993) so far used requires output categories to be consistent across adjacent years. Thus,
allowing for the inclusion of activity categories if and only if information is available in
two successive years. This is not a good approach as it leads to the loss of potentially a
great volume of activity.
We propose an alternative method, which involves the mapping of new and retiring
activities. The mapping requires that new and retiring categories are somehow related
and judgements need to be made about the nature of their relationship. This method
represents an improvement on the traditional approach, as the mapping allows for some
activity that would have previously been lost to be included. However, it has the
limitation that it is not always possible to map all activity, especially previously
uncounted one.
1.7.3 Quality adjustments
The quality ofNHS activity is defined in terms of the characteristics valued by patients.
These include the impact that treatment has on health outcomes, the length of time
waited for treatment, the uncertainty attached to having to wait for a treatment, patient
experience, etc. We consider two different dimensions of quality: health outcomes and
waiting times.
1.7.3.1 Health outcomes
The most important characteristic of healthcare is the contribution it makes to improve
individuals' health state. As recommended in Eurostat (2001) and Atkinson (2005), it is
only the marginal contribution of healthcare or "value added" to a patient's health that
should be taken into account and included in a measure of output growth. This means
measuring the health gain that patients derive from healthcare treatment. The most
commonly used measure is Quality Adjusted Life Year (QAL Y), which measures the
change in the quantity and quality of life, with health gains discounted to the present
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time. Theoretically, the gain in health outcome should be measured as the difference
between the number of QALYs that accrue to an individual from being treated with
those that an individual faces without treatment.
Consider Figure 1-1, h°(t) and h *(1) denote respectively the health profile of an individual
that does not receive any treatment and that of one who receives treatment. As can be
seen, the health profile of an individual left without treatment deteriorates over time
until she dies at time t2. If the person is treated at time to, her health status is slightly
reduced, a non unlikely event after some treatments, before an increase is registered.
Moreover, in the example presented here, the treatment has also lengthens the life of the
patient from t2 to t3.
So, if we want to measure the QALY gains associated with being treated as opposed to
not being treated, and in terms of Figure 1-1, we should measure the difference between
the area under the 'with treatment' curve less the area below the 'without treatment'
curve.
This is, however, not feasible for two reasons. The first is ethical, in the sense that it is
very unlikely to leave a person untreated. The second is a practical one, as the routine
collection of data would feasibly allow only for snapshots measurements to be taken at
certain points in time. In conclusion, this means that we can only observe pre- and post-
treatment health status, and that these are snapshots taken at particular points in time.
Figurel-l - QALY gain from treatment
Health
status
h=I
Without treatment: h°(t)1------------.I -_. ...
to
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It is also apparent from Figure 1-1 that the timing of the pre- and post-treatment
snapshots of health status is crucial. It is not unlikely for patients to report a reduced
health status immediately after being treated, before recovering health and registering a
substantial health gain. In some other cases, such as terminal care, the aim of the
treatment is not to improve health status but to reduce the deterioration of it, whilst
extending the length of an individual's life. This would result in an unchanged post-
treatment snapshot measure of health status. A similar scenario occurs also in case of
palliative care, whereby patients' quality of life is improved without any effect on their
length of life.
Hence, some concern exists on whether the rate of growth of M = h· - h0 is an
appropriate approximation to the rate of growth of the effect of treatment on the
discounted sum of QALYs; that is, whether the rate of change in the snapshot measures
approximates the rate of change in the area under the 'without treatment' and the 'with
treatment' health profiles.
Dawson et al. (2004) and Castelli et al. (2007b) conclude that given the lack of data on
without treatment health states, the use of pre- and post-treatment health status
measures, although imperfect, represents an improvement in current practice. This
accords with the ONS recommendation that 'it is better to measure the right thing
approximately than the wrong thing precisely' (Caplan, 1998), implying that any new
indicator would constitute an improvement in existing practicer'.
As health outcomes associated with each treatment are not observed directly, Dawson et
al. (2005) have devised a formulation which involves combining together (i) short-term
survival rates, (ii) pre- and post-treatment health status measures and (iii) healthy life
expectancy.
Patient reported health status
There are three potential ways of estimating the change in health status before and after
receiving healthcare treatment: (i) clinical trial data, (ii) expert opinions and (iii)
observational data.
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The use of clinical trials data is advocated in a number of papers (Berndt et al., 200I;
Mai, 2004), and it is suggested that these are combined with or validated by expert
opinions (Berndt et al., 2002). This route was also investigated by Dawson et al.
(2004a, 2004b) and a number of drawbacks associated with it were outlined. Examples
of the limitations24 were that the study population is not representative of patients
receiving the same treatments in routine practice, because of the existence of
inclusion/exclusion criteria; clinical trials address very specific conditions, whilst fairly
aggregated classifications (such as HROs) are needed in the construction of productivity
indices; and the measurement of productivity change necessitates continuous
information of the effect of interventions over time. There are only a few studies
published that have attempted to investigate whether the time of intervention has any
impact on the effectiveness of the intervention itself.
Dawson et al. (2004b) surveyed users of the EQ-5D instrument" in clinical trials and
reviewed thirty published studies that have employed this instrument. The EQ-5D data
extracted from this source and which we were used to infer pre- and post-treatment
health measures to use within this chapter are given in Table I-C.I in Appendix I-C. It
was necessary to map EQ-5D scores obtained from clinical trials, which are carried out
on very specific conditions, to fairly aggregated HROs groupings.
The second option available to estimate the change in health status is to use expert
opinions. Clinicians would be asked to provide estimates of the health outcomes
associated with certain ailments. Inorder for these estimates to be used within an output
growth measure, clinical experts should provide a description of changes in health state
for given conditions and for the corresponding interventions. These effects should be
summarised in terms of a standard metric. Further, clinical experts should provide
information on how health outcomes are likely to change over time for every condition
and how this would affect a patient's life expectancy. These judgements could be
provided in isolation by single clinicians or through the creation of panels of experts
deliberating together or a combination of both (Berndt et al., 2002).
Williams (1985) used clinicians in isolation for the derivation of profiles of patient
health status in the evaluation of Coronary Artery Bypass Grafting (CABO), with the
aim of converting the opinions of cardiologists into a standard generic classification of
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health status. Cardiologists were also asked to predict patients' health state conditional
on alternative forms of treatment. Another study was conducted in the Netherlands
(Stouthard et al., 1997) to establish disability weights for diseases to be used to build a
burden of disease model.
Three limitations can be associated with this approach: 1) potential danger of clinicians'
judgements being influenced by their vested interests; 2) the existence of uncertainty
around the effectiveness of specific treatments and/or the future health pathway may
comprise the forming of a generalised and accepted consensus; 3) the organisation of
expert groups for all areas of NHS care would be quite costly. However, a clear
advantage of using expert groups is that it makes the process of collecting new data
redundant and that health outcomes are dependent on the experience of professionals
who have an understanding not only of the conditions, but also of the available
treatments.
The third option, which is also the one explored in this chapter, is to use observational
data. It relies on the collection of data through a questionnaire administered to all NHS
patients before and after receiving a treatment. This type of data was not routinely
collected in the NHS at the time this research was carried out26.Notwithstanding that,
we were able to gain access to data collected by a NHS hospital trust and a private
health insurance provider (Vallance-Owen et al., 2004). These two healthcare providers
administered surveys to patients before and after an intervention on a number of health
conditions and treatments. The instruments used were SF_362728and VF_1429(for
cataract procedures since 2001).
The Orthopaedics and Trauma unit at York District Hospital has been collecting SF36
since March 2001 for patients undergoing both knee and hip replacements. Patients
completed the SF-36 instrument up to December 2002, after which the shorter SF-12
instrument was administered to patients. The first questionnaire was administered to
patients during their first recorded outpatient appointment before the operation took
place. This enabled one to determine patient's health status before receiving surgery. A
second questionnaire was administered pre-operatively upon admission. Post-operative
health outcomes were obtained predominantly through postal questionnaires (some were
collected during follow-up appointments) sent to patients between three to six months
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following their operation, and then again after 12 months. The overall dataset obtained
is very small, as it included: 253 patients at the pre-operative stage, whilst the follow-up
questionnaires administered after three months was completed by 203. The private
health insurance provider has been collecting outcomes data (before and after health
status) since 1998. The dataset contained 90,000 patient treatment episodes covering the
period 1998 - 2003. Patients filled in a questionnaire before receiving treatment and
three or four month post treatment depending on whether the instrument is SF-36 or
VF-14 (for cataract procedure since 2001). The collection exercise by the private health
insurance provider was intended originally to be comprehensive, but as from 2002
efforts have been concentrated on a number of high volume procedures, such as cataract
surgery, Percuteneous Transluminal Coronary Angioplasty (PTCA) and Coronary
Bypass (CABG), Primary Hip Replacement. Data obtained from these two sources,
along with some EQ-5D values from clinical trials, were used to infer the values for pre-
and post-treatment health status for a number of diagnosis and procedures, which were
then linked to their relevant HRGs. (Dawson et al., 2005). A full list of the identified
thirty HRGs can be found in Appendix B, along with the their respective pre- and post
treatment measures of health status.
Short-term survival rates: in-hospital and 30-days from discharge and healthy life
expectancy
Two measures of short-term survival rate" can be extracted from the HES database: 'in-
hospital' and 'in-hospital and 30-days post discharge'. HES data records for each
patient the method of discharge, identifying the circumstance under which a patient left
hospital, which enables one to capture the number of patients that were discharged as
dead. 'In-hospital' mortality rates are determined by the number of patients that are
discharged as dead. Further, ONS date of death data can be linked to the HES dataset so
that deaths following discharge can be identified. Our second mortality indicator is
given by the sum of in-hospital deaths and deaths that occur within 30 days of discharge
from hospital.
The first type of mortality indicator is justified by the fact that these deaths are more
capable of being influenced by the NHS. The second needs some more clarification.
There a number of patients who are likely to die within a short period of being
discharged. Should reductions in these deaths be attributed to the working of the NHS;
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for example to reflect changes in medical (good) practice? And which should be the
correct cut-off point for the attribution of deaths to the operating of the NHS? The
second indicator is commonly used in a variety of studies (Kosecoff et al., 1990; Rogers
et al., 1990; Lunn et al., 1987) and it is also based on US evidence that shows how
reported in-hospital mortality for some conditions has decreased over time, whilst the
30 day death figures show a substantial increase (Baker et al., 2002). Moreover, 30-day
post discharge mortality rate is less susceptible to manipulations.
'In-hospital' and '30-days post discharge' survival rates for all hospital activity
recorded in the HES dataset are highly correlated. In 2003/04 this was equal to 0.994 for
elective inpatient stays and 0.987 for non-elective inpatient stays.
Although incorporating survival rates into a healthcare service output growth index can
be considered as a way forward to quality-adjust the measure of healthcare services, it is
not free of problems. The most important is the issue of attribution, as increased
survival rates (or any other health outcome) may be associated with a number of factors
(epidemiology, demographics, technological advances in the pharmaceutical industry,
etc) other than improvements in NHS practice.
Dawson et al. (2005) explore the use of both short-term survival rates, and indicate a
preference towards the '30-day post discharge' measure. In this chapter, we will use
only the latter measure when quality-adjusting NHS output (see Section 5).
Healthy life expectancy is derived from combining information on patient's gender and
average age in each HRG (available in HES) with life tables and the 1996 Health
Survey for England (Prescott-Clarke and Primatesta, 1998). Estimates of life
expectancy are taken from the Interim Life Tables 2000-2002 for the United Kingdom
(Annual Abstract, 2002, p. 71) and from these the difference between total life
expectancy and quality-adjusted life expectancy shown in the 1996 data (Dawson et al.,
2004b) are deducted. The underlying assumption made is that of constant morbidity,
although there is no clear indication on whether healthy life expectancy is rising faster
or slower than life expectancy as a whole, that is whether expected period of poor health
is getting longer or shorter.
52
Both life expectancy and quality-adjusted life expectancy tables suffer from the problem
that they provide data only for specific ages in the case of the first, or age bands in the
case of the second. Hence, it is necessary to interpolate and extrapolate in order to
obtain the year-specific figures which we require. The interpolation allows to
interpolate/extrapolate up to the age of 95. Life tables provides clearly the reference
years around which the spline interpolates, while for the data on quality-adjusted life the
assumption is made that they relate to the mid-point of the range shown. For people
over 90 the figure is assumed to relate to 94. The method is subject to inaccuracy
particularly outside the range of data and thus for the very elderly.
A table showing (i) life expectancy interpolated/extrapolated from the Annual Abstract
table, (ii) the interpolated/extrapolated difference between total life expectancy and
quality-adjusted life expectancy from the 1996 table and iii) the resulting estimate of
quality-adjusted life expectancy calculated by subtraction is presented in the Appendix
I-D. Only the figures in column (i) for each sex were updated for the purpose of the
research carried out in this chapter, as it became known only at a much later stage that
the Government Actuary's website provides life expectancy figures for each year,
making the interpolation exercise unnecessary.
The interpolation/extrapolation was carried out by a member of the research group and
quality-adjusted life expectancy data were provided to be incorporated in the quality-
adjusted output growth index.
1.7.3.2 Waiting times
There are two ways that having to wait for a diagnostic test and/or treatment can affect
patients. First, patient can dislike waiting per se irrespective of the effect that deferring
treatment may have on their health and ultimately on their discounted sum of quality-
adjusted life-years. In this case, waiting time is considered as a characteristic of the
healthcare service.
Second, patients' health may be negatively affected by having to wait long periods of
time before receiving a treatment, which potentially can have a detrimental effect on
patients' health because (a) the condition of a patient can deteriorate whilst waiting for
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the treatment, (b) the health gain post treatment may be reduced, and (c) the overall time
period over which improved health can be enjoyed is reduced. In this circumstance,
waiting time is introduced as a scaling factor of the more general health effect. Hurst
and Siciliani (2003) found some evidence on deterioration of health and premature
death associated with waiting for cardiology treatment.
We will consider in this chapter only the second effect of waiting times. Dawson et al.
(2005) and Castelli et al. (2007a) explore also the introduction of waiting times as a
characteristic in the construction of an output growth index.
Two possible ways" are identified in Dawson et al. (2005) and Castelli et al. (2007b) to
model waiting as a scaling factor. The first values treatment at the time a person is
placed on the waiting list, with health effects being discounted to this date. The second
possibility is to value treatment at the time a patient receives treatment, with health
effects discounted to the date of treatment. As the aim of an output index is to capture
the value of a certain good or service as it is consumed, it is more consistent to measure
the benefit of treatment at the time it takes place. Further, this approach implies that
longer waits are charged more, so that reducing long waiting times will have a greater
impact than reducing short waiting times in the output growth index. In other terms, the
charge for waiting can be thought of as the welfare loss associated with not being
treated immediately. This is then compared to the benefits of the treatment for the
residual lifetime.
We will use waiting time as a scaling factor with discounting to date of treatment with
charge for waiting in this chapter.
Two alternative summary statistics are explored. Mean wait and so" percentile waiting
time. The second enables one to capture long waits, which affect not only the
individuals that experience these waits but also other patients that are waiting for
treatment.
Each patient record in HES contains two fields that allow to calculate the waiting time
as the difference between the date a patient is placed on the inpatient waiting list
(ELECDATE) and the date the person is admitted to hospital (ADMIDATE).
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These fields are used to calculate both mean and 80th percentile. Year-on-year changes
in waiting times will be presented in Section 1.8.1 for inpatient elective and day cases
only, as emergencies admissions do not experience any waiting time.
Waiting times are also available for a limited number of outpatient specialty areas.
Summary figures are presented in Section 1.8.2.
1.8 Results
1.8.1 Hospital output
The total volume of hospital output, for both elective and day cases and emergencies,
has increased over the time period considered, as shown in Table 1-4. Year-on-year
changes in elective and day case output are volatile. Hence, some volatility in the cost
weighted output index, both un-adjusted and quality-adjusted, should be expected. The
magnitude of this volatility depends on the crucial interactions between volumes of
output, cost weights, and the quality adjustors.
Total volume of hospital emergencies declined up to 2000-01, before registering a
steady increase. The sharp increases in the last two years of the time period under
investigation are also expected to be reflected in the CWOI; the magnitude of the effect,
however, will once more depend on whether the increase is recorded in high cost
procedures, and also on the interaction with the quality adjustors.
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Table 1-4 - Hosl!ital elective and emergencies outl!ut
Year Volume of Hospital output
Elective and day
%change Emergencies % change Total % change
cases
1998/99 5,380,183 5,609,801
1999/00 5,443,010 1.17% 5,457,681 -2.71% -0.81%
2000/01 5,435,477 -0.14% 5,441,082 -0.30% -0.22%
2001102 5,343,658 -1.69% 5,458,431 0.32% -0.68%
2002/03 5,533,727 3.56% 5,804,449 6.34% 4.96%
2003/04 5,692,896 2.88% 6,246,937 7.62% 5.31%
Table 1-5 shows average unit costs for hospital output, respectively for elective and day
case inpatient stays and emergencies admissions. In both cases, average unit costs have
steadily increased over the time period considered.
Tablel-S - Cost ofhosl!ital output
Year Output weighted average unit costs
Elective and day Emergencies
cases
1998/99 733 1,111
1999/00 732 1,170
2000/01 779 1,254
2001102 858 1,358
2002/03 927 1,454
2003/04 937 1,444
Summary statistics for average short-term survival rates, separately for elective and day
case and emergencies, are shown in Table 1-6. As expected mean in-hospital survival
rates for patients treated as an elective or day case are similar to their respective 3D-post
discharge figures. Greater differences exist when comparing emergencies in-hospital
survival rates to the 3D-day post discharge one. Overall, the statistics show a consistent
improvement in average survival throughout the time period.
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Tablel-6 - In-hospital and 30-day post discharge survival rates
Year Mean in-hospital survival rate Mean 30-day survival rate
Elective and day Elective andEmergencies Emergenciesday casescases
1998/99 0.9964
1999/00 0.9967
2000/01 0.9969
2001/02 0.9970
2002/03 0.9970
2003/04 0.9973
0.9566
0.9558
0.9574
0.9564
0.9585
0.9602
0.9931
0.9935
0.9939
0.9942
0.9944
0.9949
0.9464
0.9455
0.9476
0.9467
0.9497
0.9521
Average remaining life-expectancy is decreasing over the time period considered. A
reflection, perhaps, that more elderly patients have been treated in NHS hospitals. This
is expected to have a negative impact on the quality-adjusted CWO!.
Tablel-7 - Average remaining life expectancy for elective and emergency patients
Year Output weighted average life expectancy
Elective and day
cases
1998/99 25.28
1999/00 24.80
2000/01 24.35
2001102 24.12
2002/03 23.92
2003/04 23.61
Emergencies
33.72
34.14
33.89
33.88
33.05
32.68
Year-on-year changes in waiting times for hospital admissions, both mean and 80th
percentile, show also some volatility over the period, as shown in Table 1-8.
Year Waiting time
Tablel-8 - Waiting times for hospital admission
Mean 80th percentile waiting time
1998/99
1999/00
2000/01
2001102
2002/03
2003/04
89.2
81.2
82.8
85.7
89.0
86.1
134.1
118.5
119.7
125.2
129.7
127.2
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1.8.1.1 Hospital output growth index
Hospital output is the only NHS output for which all quality indicators, as described in
Section 1.7.3, are available. Therefore we present here the cost weighted output growth
indices without any quality adjustment and with all quality adjustments. Quality
adjustments will be introduced one at a time to elicit their differential effects on output
growth. All tables report the Laspeyres formulations of the output index. The preferred
measures of survival and waiting time, respectively 30-day post discharge and 80th
percentile waiting time, are used to quality adjust hospital output along side pre- and
post-treatment health status and life expectancy.
Table 1-9 shows output growth without any form of quality adjustment; thus, capturing
the effect of the increase in volume of hospital output, weighted by average unit costs.
As expected the CWOI is positive throughout the period. However, the growth rate in
each period does not match the percentage changes in volume (see Table 1-4). A
possible explanation can be that changes in output mix have occurred between adjacent
years. The effect that we capture with the unadjusted CWOI is then the shift of hospital
output towards more complex (Le. costly) procedures.
Tablel-9 - Output growth in the hospital sector
Hospital- unadjusted CWOI
Laspeyres
1998/99 _ 1999/00 1.85%
1999/00 _2000/01 0.90%
2000/01 '_2001102 0.96%
2001102 _2002/03 4.45%
2002/03 _2003/04 5.79%
Average growth 2.79%
Table 1-10 shows cost weighted output growth indices adjusted by short-term survival
only (column (ij); short-term survival with health effect (column (ii» and short-term
survival, with health effect and life expectancy (column (iii».
Introducing 30-day post discharge survival rates only has a varied effect on output
growth compared to the unadjusted CWOI. The smaller growth in 1998/99 - 1999/00,
for example, is due to a considerable decrease in emergency admissions (see Table 1-4),
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which are also associated with a decrease in survival rates. The latter has the effect of
reducing even further the output growth. In 2000/01 - 2001/02 the slight decrease
(about 0.06 percentage points) in the output growth index with survival compared to the
unadjusted one is also due to a decrease in survival rates in emergencies admissions.
Further, it is worth noting that the impact of survival adjustment depends on the rate of
change of survival across HRGs and their cost shares. Our data show that the variations
in survival rates are concentrated in relatively few procedures with very high unit costs,
with the majority concentrated in procedure with low unit costs.
The impact of allowing for 30-day post discharge survival rates on the output growth
indices of the remaining adjacent years is positive, a reflection of improved survival
rates. Overall, adjusting hospital output with patients' survival rates has a positive
impact on output growth, which increases on average by 3.01 per cent per annum.
Compared to the unadjusted CWOI, quality-adjusting output to take into account of
improved survival rates adds 0.26 percentage points per annum.
Tablel-tO - Output growth in the hospital sector with survival, healtbeffect
and Ufe expectancy adjustment
Years
Hospital - survival adjust.
Hospital- simple survival Hospital - survival adjust. with health effect & life
adjustment with health etJect expectancy
(i) (ii) (iii)
1998/99 - 1999/00 l.25% 0.74% l.1O%
1999/00 - 2000/01 1.14% 1.48% 1.27%
2000/01 - 2001102 0.90% 0.84% 0.69%
200 1102- 2002/03 5.38% 6.45% 6.17%
2002/03 - 2003/04 6.35% 7.11% 7.11%
Average growth 3.01% 3.32% 3.27%
Cut-off set equal to 0.10 in columns (ii) and (iii)
The second column (ii) allows for the positive health effects enjoyed by those surviving
hospital treatments. The estimate of the proportionate effect of treatment (kj = h//h/",
see Section 1.7.3.1) for all treatments for which we do not have pre- and post-operative
health status is derived from the sample of procedures for which data are available
(Castelli et al., 2007a) and is set equal to 0.8 for elective and day case inpatient stays
and equal to 0.4 for emergency stays. A cut-off point is introduced for treatments with
high mortality rates, to ensure that aj - k is never negative. For these procedures we
adjust only by survival rates and not by survival rates and the assumed health effect.
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Dawson et al. (2005) carried out a sensitivity analysis of the effect of choosing different
cut-off points on the output growth rates, leading to the choice of a cut-off equal to 0.10,
which corresponds to a survival rate below 90 per cent.
In all years, except for 1998/99 - 1999/00 and 2000/01 - 2001/02, the health benefits
contribute positively to growth over and above the simple survival adjustment. Overall,
taking into account improvements in survival after treatment and health effects adds on
average 0.21 percentage points per annum and 0.52 percentage points per annum,
respectively to the CWOI with survival adjustment only and to the unadjusted CWOI.
Thus, it is possible to conclude that survival adjustment which incorporates crude but
not implausible adjustments for health effects is capable of significantly adding to the
growth in hospital output.
The third column shows the effect of incorporating change in remaining life expectancy
into our output growth measure. Life expectancy is estimated at the average age of
patients receiving treatment j, and a discount rate is applied to remaining life equal to
1.5 per cent. As average remaining life expectancy is decreasing (see Table 1-7), we
expect the growth rates to reflect this. On average hospital output now grows at 3.27 per
cent per annum. Output growth rates for most pairs of adjacent years are also smaller.
Table 1-11 shows the hospital output growth rates allowing for waiting times, along
side the previous quality adjustments. Waiting times are measured as the 'certainty
equivalent wait' at the 80th percentile of the waiting time distribution for each elective
HRG. Waiting times are introduced as a scaling factor, with a charge for waiting (set at
1.5 per cent) representing the welfare loss associated with having to wait for a
treatment.32 The same cut-off point for the proportionate change in health effects,
conditional on surviving treatment, is introduced as explained above.
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Tablet-H- QuaUty-adjusted output growth
Hospital- quaUty adjusted CWOI
Laspeyres
1998/99 - 1999/00 1.16%
1999/00 - 2000/01 1.24%
2000/01 - 2001/02 0.67%
2001102 - 2002/03 6.21%
2002/03 - 2003/04 7.22%
Average growth 3.30%
Changes in waiting times add on average 0.51 percentage points per annum to the
unadjusted CWOI and 0.03 percentage points per annum to the CWOI with survival,
health and life expectancy adjustments. In some pairs of adjacent years, the full quality-
adjusted CWOI is smaller than the other two. This is due to the fact that the impact of
changes in waiting time is dependent on the cost weights associated to each HRG. Our
data suggest that most reductions in waiting times are concentrated amongst HRGs with
low average unit costs.
In conclusion, our proposed quality-adjusted output _index yields higher rates compared
to the unadjusted one. This suggests that failing to take into account the quality
characteristics of hospital output would result, on average, in an under-estimate of NHS
hospital output.
1.8.2 Outpatient activity
A large volume of NHS patients are seen in outpatient settings. These can be organised
by GPs who refer their patients to a consultant to obtain a more in depth assessment of
their conditions before deciding for the most appropriate course of treatment. These
visits are registered as first appointments. A large proportion of patients visit the
outpatient department on a number of subsequent occasions, either as part of their
healthcare pathway to monitor recovery after a hospitalisation, for example, or to obtain
results of diagnostic tests undertaken.
Data on outpatient visits can be found in the Reference Cost database. Changes have
occurred with time in the way outpatient attendances have been recorded, with a general
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increase in the number of categories over time. Table 1-12 shows how data collection
for outpatient activity by type of categories has evolved over time in NHS Trusts where
the majority of outpatient activity is carried out. Outpatient first and follow-up
appointments are recorded by specialty. The outpatient category 'Pseudo-HRG' refers
to outpatient activity that is recorded using a coding system similar to the HRG coding
system used for inpatient activity (both elective and emergencies), although the actual
codes do not correspond with the one used to group inpatient activity.
Tablel-12 - Outpatient categories in NHS Trusts, 1999/00 - 2003104
1999/00 2000101 2001102 2002/03 2003104
Outpatient
First appointments 52 55 57 58 79
Follow-up appointments 52 55 57 61 80
Pseudo - HRG 28 191 191 191 10
Oupatient Maternity
First appointments 4 4 8 8
Follow-up appointments 4 4 8 8
Other 4 4
It is possible from the quarterly returns submitted by NHS hospitals (QM0833) to attach
waiting times to some of the specialties. These quarterly returns gather data for over 60
specialties. The waiting times are reported in weeks for each quarter. The mean
outpatient waiting time for those seen during the quarter was calculated as a weighted
average of the mid-points of each time band with the number of patients seen employed
as the weight for each band (for the over 26 weeks wait we employed 32.5 weeks as the
'mid-point' for this band). To convert this quarterly data into annual waits, a weighted
average of the quarterly waits was calculated with weights reflecting the number of
outpatients seen in each quarter. Activity weighted average waiting times are reported in
Table 1-14.
As explained in Section 1.7.2, our method for calculating the cost weighted output
index involves the mapping of new and retiring activities; this may result in total
volumes of activity for the same year to be different when compared to two adjacent
years in the time series. A summary of the volume of activity by type of outpatient
activity is shown in Table 1-13; years in the middle of the time series will have two
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figures, the first of which reports volume of activity mapped to the previous year and
the second shows volume of activity mapped to the following year.
Tablel-13 - Outpatient activity
1999~0 2000/01 2000101 2001~2 2001102 2002103 2002/03 2003/04
Outpatient
First appointments
Follow-up appointments
Pseudo - HRG
5,626.749 4.881,695
14,002,032 12,998,209
5,350.427 8.651,305
5,847,683 6,216,523
14,549,859 14,979,873
20,262,255 20,760,092
6,234,138 6,501,658
15,104,153 15,390,721
20,596,752 21,810,858
5,395,934 5,877,881
13,632,101 14,034,584
25,302,800 26,711,255
Oupatient Maternity
First appointments
Follow-up appointments
633,267 616,455
1,724,299 1,638,909
18,788 89,716 689,002 729,867
80,685 135,084 1,730,165 2,012,874
Aggregated total volumes of activity are shown in Table 1-14, along with activity
weighted average unit costs and waiting times.
Table1-14 - Outpatient, activity, average unit costs and waiting times
Years Volume of Activity weighted
Activity weighted
average waiting times
(weeks)
activity average unit costs
1999/00 24,979,208 75.94 6.66
2000/01 26,531,209 76.93 5.58
2000/01 43,017,363 78.29 3.59
2001102 44,211,852 85.65 3.57
2001102 42,034,516 84.07 3.78
2002/03 43,928,037 90.89 3.31
2002/03 46,750,002 91.45 2.39
2003/04 49,366,461 98.30 2.15
There can be quite remarkable differences in the total volumes of activity included in
the calculations of the output growth index for the same year; as can be seen for
2000/01, for example. For this particular year, in fact, the calculation of the output
growth index between 2000/01 and 2001/02 uses a volume of activity which is more
than double to that compared to the previous year. This is the cause of the huge
variability in the average unit costs and waiting times reported for the same years
(attached to two 1999/00 and to 2001102, respectively). It is, hence, very difficult to
predict any effect that these will exercise on the cost weighted output growth index.
However, activity weighted average unit costs and waiting times appear to be improving
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over time, this is likely to be reflected in the quality adjusted CWOI compared to the
unadjusted one.
1.8.2.1 Outpatient output growth index
Estimates of output growth are shown in Table 1-15. Overall, the unadjusted and quality
adjusted CWOls reveal an average growth rate of respectively 4.49 and 4.50 per cent
per annum. This is an indication that incorporating waiting times has a positive, albeit
very small, effect on the average output growth rates; an exception is given for the
quality adjusted CWOI between 2000/01 and 2001102, which is smaller than the
unadjusted estimate.
Tablel-IS - Growth in outpatient activity
Outpatient - unadjusted CWOI Outpatient - quality adjusted CWOI
Laspeyres Laspeyres
1999/00 - 2000/01 4.435% 1999/00 - 2000/01 4.440%
2000/01 - 2001102 3.349% 2000/01 - 2001102 3.345%
2001102 - 2002/03 4.678% 2001102 - 2002/03 4.713%
2002/03 - 2003/04 5.483% 2002/03 - 2003/04 5.500%
Average growth 4.49% 4.S0%
1.8.3 Mental Health care services
Data on services provided to patients affected by mental health conditions is available
from two sources. The HES database records services provided to patients with mental
health problems by HRGs. The HES database includes also data on a patient's waiting
times and survival rates. Further, using information on patient's gender and average age
in each HRG and combining this with life tables and the 1996 Health Survey for
England (Prescott-Clarke and Primatesta, 1998), it is possible to calculate average life
expectancy for each HRG in mental health. The HES data on mental health are
described in section 1.8.3.1. The Reference Costs database also contains information on
services provided to patients with mental health conditions; these are described in
section 1.8.3.2.
64
1.8.3.1 Inpatient data from HES
HES data on services provided to patients with mental health conditions is grouped to
form CIPS of mental health HRGs (T codes). Volumes of mental health inpatient output
are reported in Table 1-16. These have fallen over time for activity undertaken both in
an elective setting and as emergencies up to 2001102; after this year volumes of activity
first increase and then decrease for elective and day case patients, whilst emergencies
show an upward trend. The sustained decrease in activity undertaken as elective and day
cases might be an indication of efforts made to treat patients in other settings rather than
to hospitalising them.
Tablel-16 - Mental Health output recorded in HES
Year Volume of output
Elective and day
cases
1998/99 46,883
1999/00 44,569
2000/01 44,156
2001/02 42,917
2002/03 44,366
2003/04 43,435
Emergencies
173,949
160,485
154,524
149,053
159,293
164,840
Reference cost data do not report the average unit costs of treating mental health
conditions by HRGs; hence, we have assigned the average cost of other mental activity
reported in the Reference Costs database to mental health HRGs (group T) recorded in
HES. These have resulted in the following average unit costs assigned to CIPS HRGs
for mental health (Table 1-17).
Tablel-I? - Costs applied to mental health inpatient output
Year Output weighted average unit costs
Elective and day
cases
1998/99 163 210
1999/00 172 250
2000/01 186 273
2001/02 174 281
2002/03 204 291
2003/04 213 313
Emergencies
Survival rates for mental health patients are reported in Table 1-18. Survival rates are
improving over the time period considered, although no particular trend is emerging.
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This will have an effect on the quality-adjusted CWOI, with some variability to be
expected.
Tablel-18 - Survival rates for mental health patients
Year Mean in-hospital survival rate Mean 30-day survival rate
Elective and day
Em ergencies
Elective and day
Emergencies
cases cases
1998/99 0.9853 0.9728 0.9783 0.9611
1999/00 0.9862 0.9707 0.9802 0.9598
2000/01 0.9860 0.9717 0.9798 0.9608
2001/02 0.9889 0.9683 0.9833 0.9566
2002/03 0.9858 0.9682 0.9808 0.9582
2003/04 0.9860 0.9695 0.9812 0.9597
A similar pattern emerges also for life expectancy, which are driven partly by the
survival rates and partly by the age/gender mix of mental health patients in each given
year (see Table 1-19).
Tablel-19 - Life expectancy for mental health patients
Year Output weighted average life expectancy
Elective and day
cases
1998/99 28.72
1999/00 29.25
2000/01 29.52
2001/02 29.31
2002/03 28.74
2003/04 28.99
Emergencies
25.10
25.18
25.01
24.64
24.18
23.65
Waiting times are reported in Table 1-20, these do not show any particular trend,
although up to 2000/01 there appears to be an improvement for both mean and 80th
percentile waiting time. After that waiting times have a variable trend.
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Tablel-20 - Waiting times for mental health patients
Year Output weighted average waiting time
Mean 80th Percentile
1998/99 30.76 30.91
1999/00 26.62 26.75
2000/01 23.21 23.21
2001/02 28.50 28.71
2002/03 27.16 27.29
2003/04 63.20 34.60
1.8.3.2 Activity in Reference Costs
Mental health activity in the Reference Cost is reported in different categories (see
Table 1-21). These have evolved over time, with more categories being added every
year.
Tablel-21 - Mental Health activities inReference Costs
Unit of measurement 2000101 2001102 2002/03 2003104
5 5
4 4
4 4
2 2
10 9
3 4
4 4
4 4
Inpatient Data Occupied bed days 5 5
Booked Appointments Dam First Appointment 4
Outpatient Data First Attendance 4
Booked Appointments Dam Follow up Appointment 4
Outpatient Data Follow up Attendances 4
Domiciliary Visit Data Visits 2 2
Secure Unit Data Occupied bed days 4
Specialist Services Inpatient Data Occupied bed days 4
Specialist Services Booked Appointments Data First Appointment 4
Specialist Services Booked Appointments Data Follow up Appointment 4
Specialist Teams Clients seen
Day Care Facilities Patient days
Inpatient data in the Reference Costs is recorded on the basis of occupied bed days, total
number of which is reported in Table 1-22. As explained earlier (see Section 1.7.2),
only activity that was recorded in any two consecutive years is included; hence, it is not
possible to draw any defining conclusions in existing trends.
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Year
Tablel-22 - Inpatient occupied bed days, Reference Costs
Occupied bed day
Inpatients Specialist Services
2000/01
2001/02
2001/02
2002/03
2002/03
2003/04
9,827,178
10,466,514
10,470,063
10,455,038
10,455,038
9,456,791
65,045
69,093
73,925
75,795
Table 1-23 reports volume of activity and average unit costs for all mental health
services recorded in the Reference Costs with the exclusion of inpatient activity. The
figures show an increasing trend for volumes of activity included in the calculation of
the output growth index. No clear trend emerges for average unit costs.
Year
Tablel-23 - Mental Health activity in Reference Costs, excluding inpatient activity
Volume of Activity weighted
activity average unit costs
2000/01 5,922,305 107.35
2001/02 8,178,005 111.70
2001102 10,219,416 141.67
2002/03 10,693,796 139.75
2002/03 14,311,174 134.95
2003/04 14,967,284 148.43
1.8.3.3 Growth in Mental Health Activity
The growth rates for mental healthcare activity are reported in Table 1-24. These were
calculated using inpatient data from HES and all remaining mental healthcare data from
the Reference Costs. Due to the fact that Reference Costs data are only available from
2000/01, output growth rates are first presented separately for the inpatient mental
activity as reported in HES and all other mental health activity as reported in the
Reference Costs. A column that combines all data into one single output growth index is
also provided. The quality-adjusted output growth estimates are presented only for HES
inpatient mental health activity, as no quality adjustors are available for activity
reported in the Reference Costs; hence, in the second part of Table 1-24 only HES and
'AU' quality-adjusted output growth estimates are given.
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Tablel-24 - Growth in mental health care activity
Mental Health - unadjusted CWOI
HES Reference Costs All
1998/99 - 1999/00
1999/00 - 2000/01
2000101 - 2001/02
2001102 - 2002/03
2002/03 - 2003/04
8.30% 8.30%
3.32% 3.32%
-4.10% 36.19% 33.23%
15.59% 6.64% 6.84%
10.12% 3.16% 3.35%
6.65% 9.20% 11.01%Average growth
Mental Health - quality adjusted CWOI
HES All
1998/99 - 1999/00 7.42% 7.42%
1999/00 - 2000/01 4.00% 4.00%
2000101 - 2001102 -4.86% 33.17%
2001102 - 2002/03 15.05% 6.83%
2002/03 - 2003/04 10.38% 3.36%
Average growth 6.40% 10.96%
Looking at the unadjusted CWOI first, the estimates for HES inpatient activity (first
column in Table 1-24) show some variability in the growth trend. In particular, a
positive growth in mental health inpatient activity is interrupted in the period 2000/01 -
2001/02. This is part due to a decrease in the volume of activity in 2001102 compared
to the previous year for both elective and emergencies (see Table 1-16). The decrease in
volume of activity is also emphasised by a decrease in average unit costs (see Table 1-
17). The second column in Table 1-24 reports unadjusted cost weighted output growth
estimates for mental health activity as reported in the Reference Costs. These results
need to be interpreted very carefully as the major increase between 2000/01 and
2001102,is due to improved recording of mental health activity, rather than to a genuine
increase in the number of mental health services offered.
A similar pattern emerges also for the quality-adjusted CWOI for HES inpatient
activity. The impact of quality adjusting inpatient mental health activity varied over the
time period considered. In three cases the quality adjustment has produced a smaller
output growth estimate: between 1998/99 and 1999/00, 2000/01 and 2001102, and
2001/02. The first is mainly driven by the decrease of inpatient activity, although more
costly types, as reflected in the positive unadjusted CWOI for these two years. The
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second and third are driven by a combination of reduced life expectancy and increased
waiting times associated with both elective and emergency output.
The overall quality-adjusted CWOI from 2000101 onwards will reflect the effects of
combining in one output growth estimate both the quality adjusted activity and the
unadjusted activity. No further conclusions can be drawn.
1.8.4 Primary care consultations and prescribing
In this section we assess the output growth in the primary care sector. General practice
activity is captured in our measure ofNHS output in terms of primary care consultations
and prescriptions. Primary care consultations are not measured directly so we have to
rely on survey information; on the other hand detailed data are collected about every
prescription dispensed in England.
1.8.4.1 Primary care consultations
Estimates of consultation activity are derived from the consultations reported by
respondents in the General Household Survey. Respondents are asked about
consultations in the previous 14 days. The estimate of the number of consultations per
year is made by multiplying the number of reported consultations in the 14 days prior to
interview by 26.
Information is available on the location of the consultation (surgery, home, phone) and,
after 2000, by provider (GP, practice nurse). From 1988 the GHS has collected data
over a financial year (April to March). No allowance has been made for seasonal factors
- the date of the consultation varies across respondents and has also varied between
rounds of the GHS. There have been large changes in the numbers of consultations
reported in the GHS for some age-gender groups from one year to the next. Further, in
1999/2000 no GHS was held, so that estimates for this particular year had to be
interpolated from values from previous years.
Table 1-25 reports estimates of activity by type of consultation. The same unit costs
were used for each year, except for 2003/0434• These are reported in the table below.
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Tablel-25 - Activity {OOOcontacts} and costs in 2rima!l care
Activity Cost
1998199 1999/00 2000/01 2001/02 2002/03 2003/04 AB ~ears 2003/04
GP Home Visit 11,067 11,144 8,580 9,982 12,050 12,309 47 50
GP Telephone 19,964 20,102 17,600 22,568 21,690 22,144 17 19
GP Surgery 154,504 155,572 157,740 169,477 192,800 203,774 15 16
GP Other 31,465 31,683 36,080 14,973 14,460 11,906 20 22
Practice Nurse
.
84,000 96,995 8 881,000
Total 217,000 218,500 220,000 217,000 241,000 250,133
* Practice Nurse consultations are not included in the output growth measure for 2000/01 and 2001/02.
Estimates of primary care consultations show some variability across years and by type
of consultation. Overall, and except for 2001/02, these appear to increase over time. As
unit costs are the same for the first 6 years, fluctuations in the output growth measure
will be driven by changes in volumes of activity, whilst for the years 2002/03 and
2003/04 the output growth measure will also be affected by the increase in
consultations' unit costs as reported.
1.8.4.2 Primary care prescribing
Current DH practice is to consider prescriptions dispensed by GPs as activity and hence,
these will be included as health care outputs in our measure of NHS output.
Technically, however, prescriptions should be treated as an input in the production of
health. In the hospital sector, for example, drugs administered enter the output index as
an element of the cost weight (Reference Cost) attached to each treatment and are not
counted separately as activities.
Nonetheless, one can justify the inclusion of prescription drugs in the primary care
sector as an activity on the following grounds: (i) they constitute GPs value added
through prescribing and (ii) the value GPs add to healthcare output is not reflected in the
assumption that the wage rate approximates the marginal product of GPs.
The volume of primary care prescriptions is derived from Prescription Pricing Authority
(PPA) data. Table 1-26 shows the volume of dispensed prescriptions in the primary care
sector, which has increased in the time period under investigation.
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Tablel-26 - Volume of ~riman:: care I!rescril!tionsz PPA data
Year Categories Volume of activity
1998/99 178 509,261
1999/00 178 526,630
2000/01 178 553,207
2001102 184 583,150
2002/03 186· 614,902
2003/04 186 649,155
• In the calculation of the output growth measure for 200 1/02 and 2002/03 only 184 categories for 2002/03 are used that match up
with the same categories collected for 2001/02.
Costs data are also available, which are used to weight prescribing activity.
1.8.4.3 Growth in primary care activity
Growth rates in the primary care sector are calculated as an unadjusted cost-weighted
output index, these are reported in Table 1-27 for the Laspeyres measure. The first
column of figures shows growth rates for primary care consultations only, whilst the
last column includes also growth in prescriptions dispensed.
Tablet-27 - Growth in I!rimary care and prescribing activity
Year Primary Care Primary Care & Prescribing
1998/99 - 1999/00 0.69% 3.11%
1999/00 - 2000/01 -1.11% 3.09%
2000/01 - 2001102 -2.53% 3.35%
2001102 - 2002/03 10.27% 8.89%
2002/03 - 2003/04 4.96% 6.55%
Average growth 2.46% 5.00%
Figures for primary care consultations show a decreasing trend in the early years,
followed by a rapid increase for the years 2001/02 and 2002/03 and a further slowdown
in the last two years of the time series.
The growth rates for the primary care sector show some variability throughout the entire
period; overall, the figures show an average 5 per cent per annum.
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1.8.5 Other health care services
This section considers all other categories of NHS activity reported mainly in the
Reference Costs and activity for NHS Direct, NHS Direct Online and Walk-in-Centres.
The unit in which these activities are reported differs substantially; therefore, we
describe them under several broad headings.
As the starting year of Reference Cost data collection varies for different activities,
great variability across categories is to be expected. For most NHS activity, data
collection has become more extensive with always greater number of categories being
included every year. It is not, however, unlikely to find cases where data collection has
been either discontinued or for which re-groupings'" have taken place. As explained
elsewhere, other NHS activities were mapped in any two adjacent years, where
necessary; this may result in volumes of activity for the same year to be different when
compared to the adjacent years in the time series.
1.S.S.1 Other NHS activity in Reference Costs
Activity for Accident & Emergency was first reported in the Reference Costa database
in 2000/01, with type of activity recorded increasing over the time period considered.
Ambulance services were first reported in the Reference Cost in 2002/03, prior to that
year only the total number of emergency journeys was recorded. This data was made
available to us by the Department of Health. See Table 1-28.
Tablel-28 - A&E and ambulance services
Categories
Year A&E Ambulance
1998/99
1999/00 1
2000/01 9 1
2001/02 9 1
2002/03 12 69·
2003/04 12 69
Table 1-29 shows the volumes of activity both for A&E and Ambulance services, which
have been increasing throughout the time period considered. Please note that in the last
two years of the time series under investigation, a substantial increase of the number of
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categories has occurred, going from one category only to 69. The greater detail with
which Ambulance services are now collected could explain some of the increase in the
volume of activity recorded, which therefore cannot be considered as genuine increases
in volumes.
Tablel-29 - A&E and ambulancez volume of activi~
A&E Ambulance
Year
Emergency
Attendances journeys/Incidents/
Responses
1998/99 2,720,000
1999/00 2,850,000
1999/00 2,850,000
2000/01 2,910,000
2000/01 11,016,935 2,910,000
2001/02 11,013,425 3,090,000
2001/02 11,013,425 3,090,000
2002/03 13,956,924 3,178,000
2002/03 13,956,924 5,193,302
2003/04 14,706,365 5,464,831
Clinical measurement, pathology and radiology tests categories are shown in Table 1-
30, and volume of activity in Table 1-31. The total number of clinical measurement and
pathology tests have been increasing throughout the time period, whilst radiology have
registered more volatile changes. Part of the volatility in the total numbers can be
explained by the extension of the categories in which activity is recorded, which made it
sometimes impossible to map old and new categories.
Table1-30 - Clinical measurementz l!atholoG~ and radiolo~ testsz cat!!Bories
Categories
Year Clinical Pathology tests Radiology
measurement tests
1998/99
1999/00
2000/01 10 18
2001102 11 18
2002/03 7 11 23
2003/04 7 11 23
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Table 1-31 - Clinical measurementz l!atholoBl and radiologl:z volume of activity
Clinical measurement tests Pathology tests Radiology
Year
Number of Tests Number of Tests
Number of
Tests
1998/99
1999/00
1999/00
2000/01
2000/01 78,164,296 5,506,811
2001/02 95,487,658 5,108,087
2001102 95,982,120 5,048,073
2002/03 112,943,034 5,117,269
2002/03 177,211 112,947,762 5,064,983
2003/04 279,570 153,275,528 5,293,747
The types of audiological services offered by the NHS include hearing aids, and hearing
aid repairs, neonatal screening, etc. Table 1-32 shows that the total number of categories
reported is decreasing, although the total volumes of activity for this healthcare services
is substantially increasing in 2003/04 compared to the first year of the time series (see
Table 1-33). Some volatility in recorded volumes is due to our mapping procedure.
Tablel-32 - Audiological and critical care services
Categories
Year Audiological Critical care
services services
1998/99 7
1999/00 9
2000/01 6 10
2001102 6 11
2002/03 3 11
2003/04 3 11
Critical care services, also shown in Tables 1.32 and 1.33, regard intensive care services
offered to both babies and adult for a number of high risk ailments (e.g. special care
baby unit, coronary care unit, and burns intensive care). These appear to have increased
substantially throughout the time period, along with an increase in the number of
categories reported in the Reference Costs.
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Tablel-33 - Audiological and critical care services, volume of activity
Audiological services Critical care services
Year
Bed daysActivity
1998/99 1,587,599
1999/00 1,671,545
1999/00 1,696,962
2000/01 1,721,974
2000/01 412,073 1,768,761
2001/02 357,702 2,008,297
2001/02 638,123 2,020,411
2002/03 357,718 2,014,846
2002/03 1,456,087 2,014,846
2003/04 1,968,143 2,090,733
The number of sessions of renal dialysis and the number of kidney transplantation
recorded in the Reference Cost data do not show any clear pattern in the volume of
activity over time (see Tables 1.34 and 1.35). Spinal injuries (measured as bed days)
and Community services (measured in terms of attendances, first contacts, etc) have all
increased over time.
Tablel-34 - Renal dialysis & kidney transplantation, spinal injuries and community services
Categories
Renal dialysis & kidney Community
Spinal injuriesYear
transplantation Services
1998/99
1999/00
2000/01
2001/02
2002/03
2003/04
4
4
7
7
13
47
47
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Tablel-35 - Renal dialysis, kidney transplantation and community services
Year
Renal dialysis & kidney Spinal injuries Community Servicestransplantation
Sessions! episodes Bed days Various
2000101 6,005,375 10,720,595
2001102 7,069,042 14,216,401
2001102 7,069,042 99,018 14,216,401
2002/03 6,179,293 110,266 13907717
2002/03 6,712,142 110,266 28,546,059
2003/04 7,650,658 110,859 27,922,818
Day Care, hospital at home, regular admission and ward attenders activities were first
recorded in the Reference Cost data in 2002/03. Day care activity captures regular
attendance mainly for stroke and elderly patients. Volumes of activity are increasing for
all, except for hospital at home, which decreased by almost 35 percent.
Tablel-36 - Day care and hospital at home
Day Care Hospital at home
Year Categories Attendances Categories Contacts
2002/03
2003/04
3
3
784,362
798,197
70,369
46,072
Table 1-37 - Regular admission and ward attenders
Regular Admissions Ward Attenders
Year Categories Admissions Categories Attendances
2002103
2003/04
260
260
70,383 49
96,286 49
646,981
854,640
The last two NHS activities included recorded in the Reference Cost data are
chemotherapy and radiotherapy. Activity data for the former was introduced in 2001102
and was discontinued in 2003/04. Activity on radiotherapy was first reported in
2002/03.
Volume of activity for sight tests and courses of dental treatment are shown in Table 1-
38. Information on both was made available by the Department of Health. Sight tests
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are increasing throughout the period (except for 2002/03), whilst dental treatments are
more or less stable.
Tablel-38 - Ophthalmology and Dentistry
Ophthalmology Dentistry
Year
Categories Tests Categories Courses of treatments
1998/99
1999/00
2000101
2001/02
2002/03
2003/04
1
1
6,993,000
9,399,000
9,567,000
9,808,000
9,662,000
9,846,000
32,133,360
31,819,636
32,326,618
32,269,602
32,071,232
32,347,793
1.8.5.2 Output growth index for all other NHS activity
Table 1-39 reports growth in all these activities, weighted by their average unit costs.
The growth rate is positive. However, no clear pattern emerges. This is probably due to
the fact that new activity is added every year, new categories are added within existing
activity, and also that coverage of existing activity has improved over time.
Tablel-39 - Output growth in other NHS acdvity
Year Other NHS activity - unadjusted
1998/99 -1999/00 3.76%
1999/00-2000/01 1.93%
2000/01 - 2001102 6.80%
2001102- 2002/03 0.58%
2002/03 - 2003/04 2.45%
Average growth 3.11%
1.8.6 NHS Direct, NHS Direct Online and Walk-In Centres
NHS Direct, NHS Direct Online and Walk-In Centres are recent innovations in the
provision of first contact advice and information to NHS patients. These initiatives are
designed to fulfil a role not previously offered by the NHS and to act as a substitute
provider of advice and health information (e.g. diverting activity from general practice).
Further, they are expected to reduce the costs of first contacts in the NHS.
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NHS Direct is a 24 hour telephone service providing nurse advice and health
information on (i) the steps to take if a person is feeling unwell; (ii) particular health
conditions; (iii) local healthcare services, such as doctors, dentists or late night opening
pharmacies; and (iv) self help and support organisations. Their Online service provides
similar health information and advice; it is also supported by a 24 hour nurse advice and
information helpline.
NHS Walk-In Centres offer a range of NHS services, including health information,
advice and treatment for a range of minor illnesses and minor injuries. They are run by
experienced NHS nurses, and are accessible every day of the week without an
appointment.
Aggregate data on use of NHS Direct and NHS Direct Online were provided by the
Economic and Operational Research (EOR) Division within the DH. Figures of volume
of activity and their relative unit costs are reported in Table 1-40. These are available
only from 2001/02 onwards.
Tablel-40 - NHS Directz NHS Direct Online and Walk-in-Centresz activi!l and cost data
2001/of 2002/03 2003/04
Activity Cost Activity Cost Activity Cost
NHSDirect 5,356 20.35 5,938 20.04 6,427 18.98
NHS Direct Online 2,028 0.79 3,972 0.40 6,368 0.13
Walk-in-Centres 1,154 21.82 1,375 14.25 1,625 14.15
·Volumes of activity for 2001102 will enter the calculations of the overall output growth index (see Section 7.2) only for
the years 200 1102and 2002/03.
The figures show a gradual increase in the volumes of activity reported by all three
organisations. Unit costs, on the other hand, show a decreasing trend which will depress
the impact of the increasing volumes of activity on the output growth measures.
1.8.6.1 Growth in NHS Direct, NHS Direct Online and Walk-in-Centres
Output growth figures are shown in Table 1-41. These show on average an increase in
output of just less than 12 per cent per annum of the three year period for which activity
data is available. The decrease in the last period reflects the decreasing unit costs, as
shown in Table 1-40.
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Tablel-41 - Growth in NUS Direct, NUS Direct Online and Walk-in-Centres
Year NUS Direct, NUS Direct Online &Walk-in-Centres
2001102 - 2002/03
2002/03 - 2003/04
13.40%
10.23%
Average growth 11.82%
1.8.7 Overall Output growth
Table 1-42 reports output growth indices for the entire NHS. Output indices are
reported in the Laspeyres form, which is also commonly used in the UK national
accounts.
As has been reported in great detail in the previous sections, the reporting of Reference
Cost data has increased substantially over time, with new categories being added to
existing data and with improvements in the quality of reporting by NHS providers.
Hence, care should be taken when interpreting output growth data, especially in the first
years from the introduction of the Reference Costs in 1998/99.
Tablel-42 - Output growth for the NUS
CWOI, CWOI, ~O-daysurvival CWOI ualit adjusted
unadjusted adjustment ' q y
1998/99 - 1999/00 2.61% 2.33% 2.22%
1999/00 - 2000/01 2.11% 2.22% 2.26%
2000/01 - 2001102 3.85% 3.83% 3.74%
2001/02 - 2002103 5.07% 5.39% 5.78%
2002/03 - 2003/04 4.43% 4.62% 4.93%
Average growth 3.62% 3.68% 3.79%
The first column shows the simple cost weighted output growth measure. NHS output
has increased on average by 3.62 per cent per annum. Adjusting NHS hospital output by
30-day post discharge survival, adds on average 0.03 per cent per annum to the output
growth measure. Some volatility in the estimated figures exists in the earlier years,
which results in smaller survival-adjusted output growth figures. The reduction is
particularly important in 1998/99 - 1999/00. As the survival adjustment interest only
hospital output data, one has to look at these data to find the main drivers of the reduced
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figures. These can, in fact, be explained with a considerable decrease in emergency
admissions, which are also associated with a decrease in survival rates.
The introduction of all remaining quality characteristics reduces the estimates of output
growth in the first years. This negative adjustment is primarily due to the decrease in
survival rates for a number of high activity high cost HRGs. Overall, incorporating all
quality adjustments, that is survival with changes in health status and in life expectancy
as well as improvements in waiting times, adds about 0.2 per cent per annum to the
overall output growth measure compared to the unadjusted index and about 0.1 per cent
per annum to the output index with 30-day post discharge survival adjustment. Thus, we
conclude that failing to take into account improvements in survival rates would result in
an underestimate in the true growth ofNHS output.
1.9 Conclusions and implications for policy and future
research
This chapter has considered the development of a measure of output growth for the
healthcare sector. Three major challenges are involved in measuring output growth of
the healthcare system:
It is necessary to identify and quantify healthcare output correctly. We distinguish
between activity, output and outcome. We define output as courses of treatment that
may require a bundle of activities (tests, surgery, drugs, etc.) and outcome as the quality
characteristics of healthcare output that individuals value (health improvement, waiting
time, being treated with dignity, etc.). We identified as the unit of output the patients
treated. This requires the knowledge of all the services that were delivered to patients
with particular conditions. The IT system in the NHS does not currently allow tracking
patients across all of the settings in which they receive care (primary and secondary
sectors, for example). However, and limited to hospital activity, the HES database
includes information that enables us to at least track patients across consultants within
providers and also across providers. We label this unit of NHS hospital output
'Continuous Inpatient Spell (CIPS) of NHS care'. All remaining NHS services are
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included in the output growth in the units of activity that they are collected and reported
in our various sources. These vary from number of tests performed to bed days, to
attendances, etc.
It is important when aggregating all NHS services into a single index, to determine
some way of assessing their relative value. In principle, marginal social values of
different NHS outputs should be used. The standard assumption in the national
accounting literature is that marginal social values are measured by the unit costs of
production. This requires two assumptions: 1) average unit costs are equal to marginal
costs and 2) that resources are allocated efficiently within the NHS. These two
assumptions, if they hold, imply that marginal costs of different outputs are proportional
to their marginal social values. These assumptions are highly questionable. However, in
the absence of marginal social values, and until these data will become available some
other measure is needed, and we decided to use unit costs derived from the National
Schedule of Reference Costs.
Quality of healthcare goods and services is likely to be an important source of output
growth. Two challenges are involved: I) identifying and defining what constitutes the
quality of healthcare and 2) develop a way of incorporating these quality characteristics
into an output growth index. We have identified the following quality adjustors:
survival rates, pre- and post-treatment health status for a limited number of hospital
outputs, life expectancy and waiting times. These data are currently available only for
patients admitted to hospitals as inpatients; hence, the quality adjustments will be
carried out only for output delivered in the hospital sector. Further, waiting times data is
available for a limited to number of outpatient specialties. All remaining NHS activity is
included without being quality adjusted, weighted according to their average unit costs.
We have demonstrated how quality change can be accounted for in an output growth
index, given current data availability. Further, we have analysed the effects on a cost
weighted output index of introducing these quality adjustments. Given current data
availability, it was possible to fully quality-adjust hospital output only, and to some
extent outpatient activity; we recommend to extend the quality adjustments to other
areas of healthcare; in particular, the primary care sector.
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Quality-adjusting output adds on average about 0.2 per cent per annum to the simple
cost weight output growth measure. In 2001/02 - 2002/03 and 2002/03 - 2003/04 alone,
it adds between 0.50 and 0.73 percentage points.
Further, we strongly recommend that the NHS makes it a priority to start the routine
collection of health outcomes data. These are important not only to be used in improved
measure of healthcare output growth, but could also successfully be used in surveillance
of clinical performance, resource allocation, and informing patient choice.
Although we maintain that health outcomes and waiting times are the most important
elements of quality to incorporate in an output growth measure, we realise that other
quality aspects of healthcare should be explored and included in the model, such as
measures of patient experience.
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1 The 'Classification of the functions of government' or COFOG as provided in the System of National
Accounts 1993 (UN, OECD, IMF, CEC and World Bank) identifies ten broad functions: General Public
Services; Defence; Public Order and Safety; Economic Affairs; Environmental Protection; Housing and
Community Amenities; Health, Recreation, Culture and Religion; Education and Social Protection.
2 It is worth noting that the analysis carried out for the measurement of health care output and productivity
is strictly related to that for social care, particularly because of the existence of so-called 'joint products'
(Atkinson, 2005), especially in the area of community mental health services. Although we do not address
the issue of 'joint products' and the effects that changes in the provision on goods and services in one area
can have in another, it is important to be aware of these links and the potential effects that these may
have.
3 A methodological framework is presented in the Atkinson review (2005) to direct the National
Statistician in the measurement of the goods and services produced by the public sector, the inputs used in
the production process, and upon which to base a productivity measure. This is summarised in nine
feneral principles, reproduced in Appendix I-A.
HMIC is made up of three different databases: Department of Health-Data, the King's Fund Database
and HELMIS. OH-Data and the King's Fund database include all the major health related academic
journals. EconLit is a comprehensive, indexed bibliography with selected abstracts of the world's
economic literature, produced by the American Economic Association. It includes coverage of over 400
major journals as well as articles in collective volumes (essays, proceedings, etc.), books, book reviews,
dissertations, and working papers licensed from the Cambridge University Press Abstracts of Working
Papers in Economics.
S Scitovsky (1964) cited in Berndt et al. (2000).
6 The difficulty in measuring and pricing healthcare goods and services is one that more generally relates
to the output of the government sector.
7 A QAL Y is "a generic measure of health-related quality of life that takes into account both the quantity
and the quality generated by interventions" (Culyer, 2005).
8 The categories of treatments and activity included in the healthcare output measure up to 2004 were:
Inpatient and day case episodes; Outpatients, Accident & Emergency and Ward Attenders; Regular day
patients; Chiropody; Family Planning; Screening; Health Visiting; District Nursing; Community
psychiatric nursing; Community learning disability nursing; Dental (part); Ambulances; GP consultations;
GP prescribing; Dental (part); Ophthalmic services (pritchard, 2004b).
9 The term 'feasible' attributed to this specific version of Dawson et al. value weighted output index is
due to Castelli et al. (2007).
10 The method is described in Section 6.2.
11 The full recommendation to ONS on all four quality dimensions (recommendation 8.5) can be found in
Appendix I-A.
12 A number of index formulations are usually employed in the National Accounts: Laspeyres index,
Paasche index, Fisher index. In the Laspeyres formulation, activities are valued at unit costs in the base
period (time t), whilst in the Paasche formulation, unit costs/weights of the current period (t+ 1) are used.
The Fisher index is calculated as the geometric mean of the Laspeyres and the Paasche indices. The latter
two can be seen as measuring similar entities but at the two extremes, with the Laspeyres index placing
emphasis on the base period and the Paasche index on the current period. We choose to present our
indices and results using the Laspeyres formulation as it is the most commonly used in the National
Accounts.
13 HRGs were first introduced in 1992. Since then they have had a number of revisions. The latest version
- HRG4 -was introduced in 2006/07.
14 For further information see http://www.statistics.gov.uklssd/surveys/general household survey. asp
(last accessed 18/11108).
IS Further details on the GHS sample design and sampling errors can be found in Appendix B and
Appendix C of the GHS Report for different years. The most recent (2007) is available at
http://www.statistics.gov.uklStatBase/Product.asp'?vlnk=5756 (last accessed 21105/2009).
16 Other sources of data for primary care consultations are the QRESEARCH database and the Health
Survey for England. The QRESEARCH database was explored in Dawson et al. (2005), and is currently
used in the latest NHS output growth measures. For further details see Castelli et al. (2008).
17 http://www.pssru.ac.uklpdf/uc2003/uc2003.pdf(last accessed 19/11108).
18 http://www.ic.nhs.uklpubs/gpworkload(lastaccessedI9/11108).This is a link to the 2006/07 UK GP
Workload Survey,
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19 See above.
20 The reimbursements and remunerations do not apply to private prescriptions and to non-prescription
drugs, Further details are available at http://www.ppa.org.ukippa/processanddrugcharging.htm (last
accessed 2S/11l08).
21 Dawson et al. (200S0 estimated that only about 1 per cent of all patients admitted to hospital are
transferred to a different provider at the end of an episode and within the same spell of healthcare.
22 The most recent version ofHRG (v 4.0) HRG version 4, is also spell based and assigns the HRG code
on the basis of the dominant/most costly procedure within the spell (NHS, 2008).
23 This statement is made in reference to the dismissal of the "output=input approach" in measuring non-
market output growth.
24 For the full list of identified drawbacks of using pre- and post-treatment health measures from clinical
trails see Dawson et al. (200S)
25 EQ-SD is a standardised instrument to be used as a measure of health outcome. Applicable to a wide
range of health conditions and treatments, it provides a simple descriptive profile and a single index value
for health status. EQ-SD was originally designed to complement other instruments but is now increasingly
used as a 'stand alone measure' - from the EuroQol Group website (http://www.eurogol.org/, (last
accessed 1112/2008).
26 We are aware that the Department of Health appointed the London School of Hygiene and Tropical
Medicine to carry out pilot studies to elicit pre- and post-treatment health outcomes for the following
procedures: cataract surgery, hip and knee replacement, varicose veins procedures and hernia repairs. The
pilot uses several patient reported outcome measures with the aim of identifying those that could be best
used for the purpose of measuring changes in health before and after an intervention.
27 'The SF36 (Short Form 36) is a multi-purpose, short-form health survey of thirty-six questions, which
yields an eight-scale generic profile of health status and psychometrically base physical and mental health
summary measures and a preference-based health utility index (quality-adjusted life-years)'. (Culyer,
200S)
28 The Hospital Trust collected data using both SF36 and SFl2 instruments. However, the Hospital Trust
changed the instrument administered to patients part way through the data collection exercise. As a
consequence some patients completed the SF36 questionnaire during their pre-operative appointment and
the SFl2 questionnaire post-operation. In order to identify time trends, which is part of the objective of
this chapter, we have considered it important to retain in our analysis only those patients, who had
completed the same questionnaire (SF36) before and after receiving the intervention were retained.
29 Vfl4 (Visual Functioning) is a condition-specific index of functional impairment for patient that are
affected by cataracts (Steinberg et al., 1994). The instrument assesses a patient's ability to perform
fourteen different activities that are vision-dependent, such as reading or watching television.
30 These are both calculated from mortality rates, as 1 - mortality rate.
31 Atkinson suggests that this quality indicator should be measured as the time period between when the
first symptoms of ill-health were addressed through to the completion of the treatment. This is currently
infeasible.
32 The term 'charging' is used to reflect the monetary costs associated with having to wait. The higher the
wait, the higher the premium paid by the NHS and the lower the weight attached to hospital output. The
choice of an interest rate of 1.5 % is taken from Dawson et al. (2005). A sensitivity analysis carried out in
Dawson et al. (200S, p.91 ) comparing the effects of including waiting time adjustment in the output
index with an interest rate equal to I.S% and 10%. The results show that no significant differences
emerge.
33 http://www.periOrmance.doh.gov.uk/waitingtimes/index.htm.last accessed 21111108.
34 Unit cost data for GP consultations and Practice Nurse consultations were provided by the Department
of Health. These can be found in the publication 'Unit Costs of Health and Social Care' by the PSSRU at
the University of Kent. We have used the same unit costs for the years between 1998/99 and 2002/03.
Subsequently, we have become aware that unit costs data for each year were available and we have since
been using them in more recent work in this area.
3S Re-groupings ofNHS activities take mainly two forms: aggregation of existing data and disaggregation
into more detailed categories.
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2 Circulatory disease in the NHS:
hospital output and productivity
•measuring
2.1 Introduction
There is increased interest in measuring the productivity of health systems, defined as
the ratio of healthcare outputs to the associated levels of inputs. In the English National
Health Service (NHS) this has been manifest at the micro-level in the work of the
National Institute for Health and Clinical Excellence (NICE), at the meso-level in the
increased attention to programme budgeting in primary care trusts (PCTs) and at the
macro-level in the work of the Office for National Statistics (ONS) in the development
of whole system productivity measures.
This chapter examines macro-level national productivity for a single programme of care
- circulatory disease - in the hospital setting. Circulatory disease is defined as problems
relating to the heart and the circulation of blood in central and peripheral vessels. It
includes both coronary heart disease (CHD) (problems relating to atheroma of the
coronary arteries) and cerebrovascular disease (problems due to interruptions to the
blood supply to the brain).
We use the output growth index developed in Dawson et al. (2005) to calculate output
measures for all circulatory diseases in England, for the time period 1998/99 to 2003/04.
Hospital output is adjusted for survival rates, both in-hospital and within thirty days of
discharge. Patient-reported outcome measures are used for two procedures - coronary
artery bypass graft (CABO) and percutaneous transluminal coronary angioplasty
(PTCA) - to highlight the potential of introducing more general health outcomes into
the output growth index. Using average unit costs data from the Reference Costs, we are
able to account for inputs used in the production process for the treatment of all
circulatory diseases. Finally, we determine productivity growth for circulatory diseases.
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2.2 Background and literature review
According to the World Health Organisation (WHO, 1997, p.7), diseases of the heart
and circulation account for about 30 per cent of overall deaths in the world, every year.
In the UK, coronary heart disease (CHD) and cerebrovascular disease are responsible
for 29.2 per cent of total deaths (Office of Health Economics, 2003).
There has been substantial attention from the Department of Health (DH) towards the
reduction of deaths from circulatory diseases. In the White Paper "Saving Lives: our
healthier nation" (DH, 1999) the DH sets out an action plan for tackling poor health in a
number of priority areas and for improving the health of everyone in England.
Regarding the area of circulatory diseases the aim is to reduce the "death rate from
coronary heart disease and stroke and related diseases in people under 75 years by at
least two fifths by 201036".
It is, therefore, important to be able to track and measure whether substantial
improvements in the area of circulatory diseases have occurred as a consequence of the
introduction of new policy strategies. The measurement of NHS output growth in this
particular area of healthcare constitutes a useful instrument for researchers and policy-
makers alike as it can 1) help in tracking and measuring the amount of (extra) resources
dedicated to a specific programme of healthcare; 2) show whether health outcomes
(mainly in terms of survival rates) have improved over time; and ultimately and most
importantly 3) show whether the extra money spent in tackling diseases related to
circulatory diseases has produced value for money.
The measurement of healthcare output (and productivity) can be achieved by either
considering overall health system measures or disease specific measures. As set out in
the previous chapter, overall measures aim at assessing and valuing the output and
productivity of an entire health system. Disease-specific or patient-based measures
focus on single diseases or areas of healthcare.
In this section, we review the literature on disease-specific and patient-based measures
of healthcare output and price indices. Price indices have been developed mainly in the
US, where the focus is on how to obtain disease specific measures of value for money.
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These measures are usually developed in the context of price indices for healthcare, but
the literature is closely related to the problem of calculating output indices.
As discussed in chapter 1, Sections 1.3 and 1.4, there are a number of challenges
involved when dealing with the pricing of healthcare goods and services, making it a
more difficult task that that of pricing private goods and services. The review below
considers how these challenges have been met and recommendations implemented for
the following diseases: heart attack and more generally chronic heart conditions, mental
health and cataract surgery.
2.2.1 US literature on disease-specific and patient-based price indices
2.2.1.1 Heart attack
The 'cost of living' (COL) approach was developed in Berndt et al. (2000) for the
medical sector as a whole and is used in Cutler et al. (2001) in pricing heart attack
treatments. The COL index is suggested as an alternative to the so-called 'service price
index37" which prices the physical outputs of the healthcare sector. Examples of
'service price indices' are the Consumer Price Index (CPI) and the Producer Price Index
(PPI), which are constructed and published annually by the US Bureau of Labor
Statistics (BLS) for a variety of healthcare goods and services or components of them.
As Cutler et al. (2001) point out one of the limitations of the CPIIPPI is that it is not
based on a welfare concept, but simply calculates the amount of money required in
every time period to purchase the same bundle of goods and services. Applied to the
healthcare sector, this requires identifying a representative bundle of healthcare goods
and services and observing it through time. However, if the quality of the bundle of
goods and services changes over time or, as Cutler et al. (2001) put it in their paper, "if
the same number of units of good produces greater utility", the SPI will not be able to
capture it38• Therefore, there is a need to develop an index that allows one to measure
not only the volume of healthcare goods and services at a given point in time, but also
changes in the quality of these goods over time.
The cost ofliving index applied by Berndt et al. (2000) and Cutler et al. (2001) is based
on patients' welfare where consumers purchase goods and services to maximise a
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certain utility function. Utility is affected directly by some goods and services that are
directly beneficial to them, such as cars, computers, and clothes. Healthcare goods and
services also yield utility to consumers, but indirectly as consumers value the indirect
(beneficial) effects that these goods and services have on their health. Healthcare goods
and services are only one of a number of elements that enter the production function for
health. Other factors include knowledge'" of how to use medical treatments, time spent
in seeking and receiving treatments and in recovery, lifestyles (e.g. eating and drinking
habits, smoking, exercise) and the environment (e.g. pollution). Hence, an individual's
utility function will include health, the other factors affecting health and non-health
related consumption goods. Many of the elements affecting health also appear in the
health production function, so that these have both direct and indirect impacts on an
individual's utility.
Consider a representative consumer choosing between the consumption of goods and
services (different from healthcare goods) and health, and where for simplicity there is
only one disease'", To cure this disease an individual receives medical care treatment, a
set of constant-quality treatments. Any change in the quality of a treatment or any new
development in the medical field is registered as an addition to the available set of
treatments. The utility function can, thus, be written as:
(3)
where Y denotes an individual's exogenous income; M indicates medical treatment with
price PM; I represents the quantity of a constant-quality insurance policy with price PI. L
is leisure time and T denotes time devoted to medical treatments. H represents the
individual's health state, which is a function of medical treatment M, medical
knowledge K and the environment E.
The first term of the utility function represents non-medical care consumption, the
second represents health and the third is non-medical care time. It is also worth noting
that the equation does not make any assumption about the way medical treatment
decisions are taken or medical prices are set.
89
As medical care and its price, medical knowledge, the environment and the time
dedicated to medical care all change over time, Cutler et al. (2001) pose the question:
what is the correct price index for changes between periods 0 and 1, assuming that the
consumer optimises in each period of time? Hence, they introduce an amount of money
C that the consumer needs in period 1 so as to make her indifferent between living in
period 1 and o. In the Laspeyres form, C will be the solution of the following
expression:
(4) u[r-PMIMI-~JI +C,H(MpKpEI),L-TMI]=
= u[r - PMoMo- ~oIo +C,H(Mo,Ko,Eo),L - TMO]
C can be considered as the change in the cost of living. A positive C indicates an
increase in the cost of living. Scaling C by income to produce utility in period 0 attains
the price index
(5) cost of living = I +CIY
Using a first order difference approximation, we can differentiate (4) and after
rearranging we get:
(6)
where UH is the marginal utility of health, Ux is the marginal utility of non-medical
consumption, UL is the marginal utility of leisure, assuming dCldt = Ux. The change in
the cost of living is made up of three parts: the additional spending on medical care and
insurance; the dollar value change in health over time; and the change in the time cost of
receiving medical care.
The first term on the right-hand side of equation (6) is additional spending on medical
care and insurance services over time. Medical care spending may change over time
because of either an increase in quantities or prices. However, it is only an increase in
the cost of healthcare goods and services, ceteris paribus, that will increase the cost of
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living. If the medical environment changes because a new disease appears, medical care
expenditure will likely increase, but in Cutler et al. (2001) this is not considered as a
change in the cost of living, because this assumes an unchanged environment. Similarly,
and because outcomes are being held fixed, if a treatment becomes obsolete, in curing a
disease having been replaced by a treatment (e.g. drug) that is more effective and also
more expensive, the price index should increase as it now reflects 'the reduced efficacy
(quality deterioration) of the older drug' (Cutler et al., 2001).
The second term of equation (6) captures the monetary value of the change in health
over time. As one can see, a change can occur through any of the following channels:
(a) changes in the quantity of medical care, (b) changes in knowledge or (c) changes in
the environment. Any improvement in health will lower the cost of living, ceteris
paribus. The monetary value of the change in health can be calculated by using the
marginal rate of substitution between health and other goods (UH/UX) and multiplying
the health change by this amount.
The last term in equation (6) captures the change in the time cost of receiving medical
care. Ifpatients' travel time and waiting time are reduced because of the introduction of
more efficient delivery, or if less invasive surgery reduces substantially the recovery
time of a patient, then ceteris paribus the cost of living decreases.
Estimating the values of the variables in the cost of living equation is problematic, but
not impossible. Four alternative methods are presented in Berndt et al. (2001): 1)
hedonic price analysis used to separate prices changes over time into changes in the
value of services to patients from pure price effects (as in studies for mental health
below); 2) hedonic regression on insurance plans alongside willingness to pay
techniques (Pauly, 1999); 3) making specific assumptions on how medical treatment
decisions are taken (e.g. Cockburn and Anis (2001) for prescription drugs) and 4) using
a direct measurement method of a single disease and using empirical estimates of
changes in treatment costs and medical outcomes associated with that disease. This
latter method is used in Cutler et al. (2001) for pricing heart attacks.
Cutler et al. (2001) use an outcome adjusted index that takes account of changes in
treatment and medical practice and incorporates improvements in the length of life after
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a heart attack and the extension of life expectancy due to new treatments. Quality
changes are introduced via changes in mortality rates". A monetary value42 is attached
to additional years of life gained. Further, they estimate the expected number of quality-
adjusted life years for a person after heart attack. All these different elements are used in
the construction of the cost of living index. They use two sources of medical care and
medical costs data for all heart attack patients treated between 1984 and 1994. The first
data source comes from a major teaching hospital and provides them with a complete
set of services offered, list prices (charges), demographic information and discharge
data. The second data source covers mostly the elderly population treated under the
Medicare programme. These two datasets are very rich in information and allow them to
produce both a disaggregated and an aggregate service price index, which they compare
with their new price measure.
Table 2-1 - Service price indices and the cost of living indices for heart attacks
Real Annual 0/0
change
Disaggregated price index"
Fixed basket index
Five-year chain index
Annual chain index
Aggregated price index
Fixed basket index
Annual chain index
Cost of living index
Years of Life [**]
Quality of Life [**]
2.8
2.1
0.7
2.3
1.7
-1.5 [-0.2, -13.7]
-1.7 [-0.3, -16.8]
Source: Cutler et al. (2001) Table 8.4, p.321
* includes data from both the major teaching hospital as well as Medicare;
** based on higher and lower estimates of the net value of a life year and a quality-adjusted life year
Their results presented in Table 2-1 show 'substantial reductions in the cost of living for
people with a heart attack'. It falls by 1.5 percent per annum under the benchmark
assumption that the value of an additional life year is $25,000, with a range of -0.2 in
the conservative estimate ($10,000) of the value of an added year oflife to -13.7 in the
higher value $ 100,000. The cost of living index with the quality-adjusted life years
measure falls even further by 1.7 percent per annum in the benchmark case where an
additional QALY is valued at $23,431 (in 1994). Their results contrast markedly with
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those obtained using the CPI approach, which show increases in the price index from
about 0.7 percent to 2.8 percent.
The authors interpret the contrasting results as being driven by the shortcoming of the
service price indices to take into account of changes in health outcomes. Even if there is
huge variability in the estimates of the cost of living index due to the sensitivity of the
index to the value placed on additional year of life and quality-adjusted year of life, the
authors claim that these are less misleading than the upward bias inherent in the
traditional price indices.
2.2.1.2 Mental Health
There have been substantial increases in expenditure on mental care in recent years.
This type of healthcare is also one that poses significant challenges due to the
difficulties in defining outcomes and outputs. Most studies suggest the use of a direct
measure of the medical costs of treating an episode of illness, rather than measuring the
changes in the prices of input used. This is due to the fact that although input costs are
rising in this area of healthcare, the composition of treatments is constantly changing
making it possible for the cost of treatment episodes to fall. (Berndt, 2003). For
example, a number of studies conducted by Berndt, Busch and Frank found that the
composition of treatment of depression has dramatically changed in recent years, with
depression being treated more and more frequently with the use of serotonin-reuptake
inhibitors (SSRI) drugs43, rather than with psychotherapy and tricylic antidepressants
(TCAs). Further, it is also clear that some adjustment needs to be made for quality of
care and outcomes.
Three areas of mental health care, in particular, have been investigated: major
depression, schizophrenia and bipolar disorder. For all three disorders, the analysis
suggests that the price of treating an episode or individual has declined in recent years,
despite the rising healthcare expenditure reported. Berndt (2003) maintains that the
reason behind the discrepancies with official statistics is that the latter do not allow for
changes in the composition of treatment over time. It still remains to be established how
quality of care ought to be incorporated in prices indices for mental health; this is
especially so because of the lack of data on quality and patient outcomes.
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Depression
Depression accounts for approximately half of mental health expenditure in the US
(Berndt, Busch and Frank, 2000/01). There have been a number of studies investigating
the pricing of its treatment. Although they do not use identical methods, there is a
considerable degree of similarity in both the methods employed and the conclusions
reached. The studies have focused on the episode of illness, which involves developing
a set of what Frank, Busch and Berndt (1998) term 'treatment bundles'. These group
together therapies that are ex ante expected to lead to similar mental health outcomes.
Frank et al. use results from a range of clinical trials and medical literature to form these
'bundles'. They focus on acute-phase treatment only.
Demand and supply price indices for the treatment of major depression based on the
cost of an episode of illness are formed using the identified 'treatment bundles' for the
period 1991-1995. Retrospective medical claims data from four large self-insured
employers are used to identify nine major classes of treatment which have shown to be
"efficacious" (Frank et al., 1998) in the treatment of acute-phase major depression.
Subsequently, closely related treatment bundles were aggregated, resulting in the use of
five bundles. As some of the treatment bundles may be considered substitutes, the
authors examine 4 index formulations, which incorporate differing assumptions on the
extent of substitutability across treatment bundles. Hence, the authors use 1) a base-
period Laspeyres index and an 2) end-period Paasche index, which both assume that
there is no possibility of substitution among treatments; 3) the Cobb-Douglas index,
which assumes that the elasticity of substitution is unity (perfect substitution) and 4) a
Tornqvist index, which makes no a priori assumption about the substitutability of any
of the treatment bundles, as it employs average shares across adjacent time periods.
All four indices showed that both the demand and supply price of treating depression
had fallen between 28 and 32 per cent between 1991 and 1995. These results are
opposite to the estimates published by the BLS, whose price indices over the same
period increased by 20 per cent. The average annual differential in price changes is
approximately 15 per cent - three times the differential found by Cutler, McClellan and
Newhouse (1999) for heart attack treatment. Frank et al. conclude that employing
standard price indices - which do not allow for changes observed in treatment
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composition - may lead to changes in quantity being misinterpreted as changes in price,
which is a cause for concern.
Several extensions to this work have since been carried out by Berndt, Busch and Frank
and other authors (for example, Berndt et al., 2002; Berndt et al., 2001). Berndt et al.
(2001) included a greater number of episodes and increased the number of treatment
bundles to seven. Using a Laspeyres price index, this resulted in a decline of only 0.6
per cent per annum, compared to the 9.1 per cent per annum decline reported by Frank
et al. (1998). Berndt et al. (2001) suggest that the primary difference of their results
compared to those obtained in Frank et al. (1998) derives from the fact that the new
dataset includs a greater number of patients. Moreover, their dataset includes a more
varied type of patients with an increasing share of them with '(1) more complicated
conditions, (2) greater severity of illness, and (3) elements of longer term treatments'
(Berndt et al. (2001»
Berndt et al. (2002) add to the previous research by using a method that combines
clinical evidence and expert opinion. The advantages of this method are twofold. First,
it enables the calculation of treatment price indices that include variations over time in
the proportion of 'off-frontier' production, which increases the number of observed
episodes. Second, it allows for different expected outcomes to be incorporated, as well
as considering patients that are on waiting lists or receive no treatment, who often
experience remission even without treatment. By doing so, Berndt et al. (2002) are able
to assess the incremental outcome" gains as a result of treatment compared to no
treatment outcomes.
Using retrospective medical claims data (for 1991-6), the authors identified and
classified episodes of acute phase depression according to treatment and patient type.
Information on expected treatment outcomes was gathered using a two-stage modified
Delphi procedure. Ten panellists were asked to provide opinions on expected treatment
outcomes, using the Hamilton Depression Rating Scale (HDRS) score (a standard
clinical measure for this illness). For each of the 120 patient-treatment cells, a literature
review of clinical research was provided. The experts were asked to consider a group of
100 patients and provide an estimate of how many patients would fall into four given
categories: 'no depression', 'mildly depressed', 'moderately depressed' or 'no change'.
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However, for 39 per cent of the cells, substantial disagreement among the experts was
noted. Each expert was then shown the group's rating for those cases where there was
disagreement, and after meetings they were given the option to revise their own rating.
After this process, no substantial disagreement remained.
The framework under which expected outcomes data were obtained allowed Berndt et
al. (2002) to consider results for both full and partial remission. The probability of a full
remission varies from 0.15 to 0.35, whilst the probability of partial remission is higher.
One particularly interesting finding is that approximately 40 per cent of the treatment
episodes make use of medical treatment with no or little effectiveness over the no
treatment option, accounting for 20 per cent of total spending on treatments.
Average expenditure indices for full or partial remission varies according to the
treatment of those cases where there is no expected outcome rating. Berndt et al. (2002)
calculate alternative expenditure indices for full or partial expected remission, using
observed prices and quantities of the treatment/patient cells for the period 1991-6. Their
estimation show that the average spending for both full and partial expected remission
remains unchanged in 1996 compared to 1991 when only rated cases are included. If
unrated cases are assigned the worst possible outcome, the average expenditure index
falls from 100 in 1991 to 84 for full remission and 86 for partial remission in 1996. The
explanation offered for this decline is that the proportion of rated cases increases from
62 per cent in 1991 to 73 per cent in 1996, thus reducing the proportion of cases being
assigned the worst outcome. If the median outcome is assigned to unrated cases, then
the average expenditure index for full remission remains unchanged in 1996 compared
to 1991, whilst the one for partial remission falls from 100 in 1991 to 90 in 1996.
However, expenditure per incremental expected full or partial remission is preferred.
Generally, the expenditure indices per incremental remission fall more rapidly than
average expenditure.
A base-period Laspeyres, an end-period Paasche and a Fisher Ideal price index were
constructed. The treatment price index falls for all three. However, when incremental
remission (both full and partial) is taken into account all three price indices show a
slight increase. The authors conclude that the slight sensitivity of the price indices to
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expected outcomes may be due to a changing patient mix (along with changes in the
treatment bundles), thus affecting both expected outcome and costs.
Hedonic equations were estimated to account for this potential change in patient
population. Eight patient categories were identified, depending on the presence of
medical comorbidity, gender, age if female and comorbid substance abuse. Three
alternative hedonic equations for the price per expected full remission were estimated
by OLS. The results suggest that patient categories have significant and sizeable effects
on treatment costs; comorbid substance abuse and comorbid medical conditions are
particularly likely to increase treatment costs. Also, treatments having higher
probability of full remission have higher costs ceteris paribus. All three equations
estimate reductions in price. Estimates for partial remissions lead to similar findings.
Overall, the results obtained from estimating hedonic equations are different from those
shown by the price indices, a reflection of the changing mix of patients over time. In
particular, the cost of treating episodes of depression, conditional on expected outcome,
has generally declined between 1991 and 1996, a fall between -1.66 per cent and -2.13
per cent per annum over the time period considered.
The use of expected outcomes data has been demonstrated by Berndt et al. (2002) to be
helpful in constructing price indices for medical treatments that allow for variation in
expected outcomes and patient populations. However, it is acknowledged that the
reliability of the outcome measures is a key determinant of the usefulness of this
method, and validity checks are carried out to assess this. The main conclusion that can
be drawn from this research on acute-phase depression is that the principal source of the
recorded increased level of expenditures over the period studied are due to increases in
the volume of treatments managed, given that the cost of treating an episode of
depression seems to have fallen.
Schizophrenia
The method of pricing an episode of care has also been implemented for other mental
health disorders. Frank et al. (2003) investigate the changing costs of treating
schizophrenia. Data from two counties in Florida over the period 1994/5 to 1999/00 are
used to determine 1) the annual cost of treating an individual affected by schizophrenia;
2) the composition and quality of healthcare and how these varied over time; and 3)
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changes in treatment costs if quality of care is controlled for. As the 1990s saw the
introduction of significant new treatments, Frank et al. suggest that considerable
changes in treatment patterns were likely to have taken place, impacting on both the
price and quality of care.
Producer price indices are constructed based on annual episodes of care. Quality of
healthcare is incorporated in Frank et al. 's study using the recommendations made by
the Patient Outcomes Research Team (PORT). Five of the PORT quality indicators
referred to types of treatment that are observable in the claims data. Frank et al. use
these to construct bundles of treatment that are considered to have a positive impact on
patients affected by schizophrenia. Four of these treatment bundles were 'single
treatment' bundles, such as the use of any type of antipsychotic medication. Other
treatment bundles consisted of more than one form of treatment, e.g. combined use of
one type of medication and one type of therapy. The authors also created another
category which comprised 'all other treatments'. Each person-year observation was then
categorised to one or more of the treatment bundles as appropriate. A shortcoming of
this type of quality measure - acknowledged by the authors - is that it only reveals
whether a patient has received treatment, whilst failing to indicate whether the amount
of treatment received was sufficient. Further, the authors state that their quality measure
reflects only minimum standards of care, as it is "reasonable to expect that a high
proportion of patients with [ ] schizophrenia should receive at least one of these
services" (Frank et al., 2003).
Multivariate regression equations were estimated, using the natural log of annual mental
health direct medical costs as the dependent variable. Regressors included patient
characteristics, enrolment and medical histories and indicator variables for the treatment
bundles. As the period under investigation saw significant changes in treatment, the
authors applied Chow tests for parameter stability. The results show that treatments
administered are indeed different, and hence it was decided not to pool the data across
years. In order to compare predicted spending, quality and patient characteristics were
held constant at a point in time. The results show that fixed weight and chained
Laspeyres price indices fall more rapidly than the comparative Paasche indices, which is
contrary to what one would normally expect. The authors interpret this unconventional
finding as reflecting doctors' learning about the efficacy of new and more costly
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treatments over time, which leads them to prescribe these more costly pharmaceuticals
and hence, to positive correlations between price and quantity. This would be consistent
with patients not being price sensitive, because of subsidisation of drugs.
Frank et al. reveal that there have been significant changes in treatments given to
patients with schizophrenia, with a significant increase in atypical antipsychotics. These
findings are in line with PORT guidance. At the same time, there has been a substantial
decline in the use of therapy and psychosocial rehabilitation, which raises the authors'
concern over the fact that a substantive part of current clinical practice is actually not
supported by any form of clinical evidence.
This study also demonstrates the importance of controlling for quality. As in previous
studies, not adjusting for quality would result in mean mental health-related treatment
costs increasing by 2.4 per cent over the time period under investigation or about 0.5 per
cent per annum. When treatment quality is held constant, both the fixed weight and
chained Fisher Ideal indices showed cumulative price falls of more than 22 per cent
over the period, equivalent to an average treatment cost fall of 5.5 per cent per annum
between 1994/95 and 1999/2000. Overall, Frank: et al. conclude that as the cost of
treating an individual per annum has declined, the observed increase in overall
expenditure is an indication that there has been an increase in the number of individuals
being treated.
Bipolar disorder
Research by Ling et al. (2002), discussed in Berndt (2003) investigates the changing
costs of treating bipolar I disorder. Like schizophrenia, there is at present no known cure
for bipolar I disorder, so the focus of medical care in this case is to try and improve
symptoms, including the prevention of recurrences. In contrast however, there has not
been such a dramatic change in the composition of treatment.
Ling et al. (2002) estimate a multivariate regression model, similar to that used by
Frank:et al. (2003), based on five mutually exclusive and exhaustive treatment bundles.
The results suggest a fall of31 % in the cost index between 1991 and 1995, compared to
a decline of 12% if no allowance is made for changes in patient mix and treatment
composition.
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2.2.1.3 Cataract Surgery
Important innovations have characterised cataract surgery in recent years. This has
resulted in a significant increase in the overall number of operations performed, and in
cataract patients now receiving surgery at an earlier stage of the disease. Shapiro et al.
(2001) address the issue of correctly evaluating a price index for this type of surgery.
Significant quality improvements are identified by the authors as a result of improved
and earlier interventions. Thus, they focus on the visual improvements as the "good" to
be valued and on the net benefits associated with the treatment. The net benefits are
equal to the difference between the visual function following surgery and the visual
function without surgery. The authors allow this to vary with differing stages of the
disease (serious, progressive or mild cases). Shapiro et al. maintain that the benefits
accruing from treatment and early treatment of cataract disease have a long-lasting
impact45 on well-being and this should be taken into account. In other words, the future
value of not having to endure a period of deteriorating quality of life needs to be
incorporated in a price index. As the current technology allows for patients with early
cataract conditions to be treated, the authors allow for a (endogenous) change in the
patient mix. The value that patients place on a treatment for receiving it sooner or
receiving it when they previously would not have is very important. However, these
benefits are also very difficult to estimate as different patients place different valuations
on them. Nonetheless, benefits derived from cataract surgery need to be valued and
quality adjusted life years (QALYs) may be used, although this will call for a specific
value to be placed upon the QALY. Willingness to pay (WTP) methods could also be
used to value either a QALY or the cataract surgery directly.
As seen for other conditions, Shapiro et al. recommend measuring the cost of healthcare
in terms of the unit values for treating cataract disease (or any other condition) and then
measuring cost in terms of the current inputs required for the treatment". They
construct two price indices for measuring the monetary cost of cataract surgery: a
hypothetical CPI and a prototypical cost index. Inputs are physician and hospital
services. In the CPI, weights are applied to the price indices for individual inputs
reflecting their relative importance. 1969 and 1979 are chosen as benchmark years. The
component indices are then weighted by the shares in these years. A major disadvantage
of the CPI method is that technical progress is reflected only in the rate of growth of the
index. In the specific case of cataract surgery, therefore, where there has been a
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significant fall in the hospital services required for treating a patient, this will not be
reflected in the level of the hypothetical CPI.
The prototypical cost index was calculated by "'iJq it Pit / q iO P iD ), where q refers to the
quantity of each input i, p refers to the CPI for input i, and 0 indicates the base year. An
advantage of this index over the hypothetical CPI is that it is able to incorporate changes
in the level of inputs, and therefore reflect the decline in the quantity of hospital services
used.
The results show that the hypothetical CPI index grows more rapidly than the
prototypical index. Over the period 1969 to 1994, the prototypical index increased by
4.1 per cent per annum, compared to growth of 9.6 per cent per annum in the
hypothetical CPI. If one compares overall growth over the time period considered, it
emerges that the prototypical index has actually declined. In conclusion, it appears that
the monetary cost of treating cataracts has been increasing at a slower rate than the
general price level over this period even without taking improvements in quality into
account and the value of undergoing surgery at an earlier stage of the disease.
2.2.2 Technological change in medical care: how does it affect output
growth?
2.2.2.1 Chronic Heart (Artery) Disease
As highlighted in Shapiro et al. (1999), technological progress is endemic in healthcare
and should be taken into account when constructing a price index. Cutler and Huckman
(2003) are particularly interested in investigating the effects that technological
development in angioplasty has on cost growth and how medical innovation impacts on
improving the quality of care. Ultimately, the authors would like to find out whether the
technological innovation in the medical field has produced 'value for money' "in terms
of increasing the level of quality-adjusted output per-unit of cost". Cutler et al. (2003)
observe that many medical innovations appear to reduce unit costs whilst at the same
time increasing total costs. They find that increasing medical costs are usually
associated with the introduction of new or improved medical technologies, be they
surgical procedures or pharmaceuticals. This seems to be the case also when
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innovations have lower unit-costs than the existing technologies that they are meant to
substitute. Treatment substitution by which patients are shifted from more- to less-
intensive interventions is usually associated with cost savings. These seem, however, to
be offset by a very common phenomenon known as treatment expansion; that is the
extension of more intensive treatment to patients with milder symptoms and who would
have undergone a different type of treatment (usually simple medical management)
prior to the medical innovation.
The authors suggest that these two phenomena occurred with the introduction of
percutaneous transluminal coronary angioplasty (PTCA, now known also as PCA) - a
less intensive and less costly surgical treatment of coronary artery disease - in the late
1970s/early 1980s. Prior to the introduction of PTCA, patients affected by coronary
(heart) artery disease (CAD or CHD) and with mild symptoms would be treated with
medical management only, whilst patients with severe CAD would have received
coronary artery bypass graft (CABO) surgery. This was precisely the situation described
by Williams (1985) in his classic article about QALYs. PTCA made it possible to treat
patients that would have previously undergone CABO (treatment substitution); but, it
was also administered to patients who would have otherwise received only medical
management (treatment expansion). Although a less costly procedure when compared
to CABG, PCTA is more costly than simple medical management. Hence, the combined
effect on costs and outcomes of both treatment expansion and treatment substitution
effects is hard to predict.
Cutler et al. use patient-level data from New York's Statewide Planning and resource
Cooperative System (SPARCS), which provide patient demographic (e.g. age, sex,
payer type) and medical (e.g. diagnosis, procedures performed, and total charges)
information for all inpatient hospital discharges for the period 1982 to 200047• They
supplemented this dataset with 3 years of clinical data from the cardiac surgery
reporting system (CSRS) and coronary angioplasty reporting system (CARS), which
both provide detailed clinical data for every patient that receives either a CABO or a
PTCA procedure in the State of New York.
Crude data show that annual rates of CABO and PTCA procedures for all New York
residents increased between 1982 and 2000, with PTCA procedures increasing at a
102
much faster rate than CABG, although from a lower level, up to 1997. After this year,
CABG and PCTA rates move in opposite directions, which the authors suggest is an
early indication of a substitution effect between the two procedures. An alternative
explanation is also provided, whereby the increasing rate of PCTA procedures is for
patients which would have otherwise previously received only medical management. In
order to register a substitution between CABG and PCTA, Cutler et al. require that the
marginal patient, that is one with medium-severity CAD, would become more likely to
receive PTCA relative to CABGS over time. To test this, they divide patients into three
severity categories: low, medium and high using an index developed by Mark et al.
(1994).
The authors focus their analysis on county-level data to estimate changes in the degree
of substitution between CABG and PTCA over time. They use a fixed effect model,
with the CABG rate per person age 45 years and older as the dependent variable. The
key regressors are the interactions of PTCA rate per 1000 population age 45 and older
with year. The coefficient vector on this interaction reflects the degree of substitution,
with a negative (positive) value indicating that the two procedures are substitutes
(complements). Further, a vector of controls is introduced consisting of the
demographic characteristics of a given county, such as total hospital discharges per
100,000 population of all ages and the percentage of hospital discharges for county
residents that are covered by Medicare, Medicaid and HMO. It also includes county
fixed effects and year fixed effects, to control for time-invariant factors that may affect
the use of CABG in any given area and to control for state-wide changes in the average
CABG rate over time. Estimates of the variables are shown both in their natural units
(levels) and in logarithmic form (changes).
The results show that there is indeed a substitution effect between CABG and PTCA,
with substitution accounting for about 25 per cent of the increase in PCTA volumes in
1998-2000 compared to 1986-1988 in the levels model. The results for the changes
model are similar to that for the levels model, with about 32 per cent of the increase in
PTCA volume in 1998-2000 compared to 1989-1991 being attributed to substitution
between the two surgical procedures.
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Cutler et al. then proceed to determine the effect that this has on costs. In particular,
they are interested in estimating the "net costs" associated with an additional PTCA,
where these are defined as the cost of an additional PTCA minus the savings due to the
fact that some PCTA are substituting for CABG procedures. As SPARCS does not
include cost data, Cutler et al. utilise costs found in Hlatky et al. (1997), which show
that the average 5 year cost of a CABG procedure is nearly $2700 greater than that for a
PTCA procedure administered to patients with multi-vessel CAD. Combing cost data by
Hlatky et al. with their findings on the degree of substitution, Cutler et al. conclude that
as a result of substitution the increase in total costs associated with additional PTCA fell
by 11 per cent (in the levels model) and by 16 per cent (in the changes model) between
1989-1991 and 1998-2000.
In order to determine whether the introduction of PCTA has produced 'value for
money', Cutler et al. first consider outcomes in terms of mortality rates. These are
calculated separately for the case of treatment substitution and treatment expansion as
the clinical profiles of patients receiving PTCA over CABG (substitution) are different
from those receiving PTCA instead of medical treatment (expansion). Their estimates
show no significant differences in long-term mortality for patients receiving CABG
versus patients receiving PTCA in the treatment substitution cases.
Outcomes related to treatment expansion cases are more difficult to evaluate. The main
outcome in these cases cannot be measured in terms of decreased mortality rates but
rather should be measured in terms of increased quality of life associated with being
relieved from angina. Cutler et al. make assumptions about the utility value, in terms of
QALYs, of being relieved from angina and the monetary value to be attached to a
QALY. Using clinical studies, they set a value of 0.2 QALYs per patient-year on being
relieved from angina. Using further studies, Cutler et al. set the value of a QALY at
$100,000. Thus, the average value of being relieved from angina for one year amounts
to $20,000 per patient at 1997 prices.
As CABG and PTCA have similar outcomes in long-term mortality, Cutler et al. focus
only on the net benefits that derive from treating with PTCA patients that would have
previously received only medical management. They found that the net benefit
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associated with an additional PTCA is positive and between $19,000 and $22,000. So,
essentially PTCA offers 1 year of angina relief over medical management.
The authors note two shortcomings with their analysis. First, the net benefit calculations
do not include the fixed cost of developing PTCA. Second, the increase in the level of
angina relief is assumed to be linear up to 1992 and to remain constant afterwards (a
conservative assumption on the incremental effects of PTCA procedures on angina).
Sensitivity tests confirm the productivity benefits associated with the PTCA treatment
expansion.
Following Cutler and other US researchers, Mai (2004) proposes a diagnosis-based
approach to measure healthcare output growth for coronary heart disease (CHD) in the
UK. In particular, he proposes two alternative index measures of healthcare output
which are aggregated by patient and diagnosis respectively. The two indices take into
account technological change and the introduction of innovations in existing treatments,
and use cost shares to weight together volumes of output. These are compared to the
practice of measuring healthcare output growth by means of a cost weighted activity
index (CWAI).
The construction of the proposed two new measures requires more complex data than
simple counts of activity, which constitute the basis for the cost weighted activity index.
The cost weighted patient index (CWPI) uses as the volume measure the number of
patients that receive a given treatment. In fact, patients may be administered a number
of "activities", when undergoing a particular course of treatment. Hence, in the CWPI
the weights will reflect the average cost share of not just a single activity, but the total
average cost of the range of activities involved in delivering the course of treatment.
The cost weighted disease index (CWDI) allows for the possibility that a disease may
be treated with different types of treatments. Hence, simple counts of patient numbers
undergoing a particular treatment cannot be used as the volume measure as it would fail
to adjust for the substitution of treatments that may occur over time. In the long term,
the substitution of treatments may likely shift patients from a particular treatment course
to another and a simple count of patients would not allow for this substitution effect.
Further, as different treatments may have different outcomes on patients' health, these
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should be added using 'quality adjustment weights' (Mai, 2004). These could
incorporate aspects such as health outcomes (such as mortality rates), patient experience
factors and waiting times.
Mai uses data from the Hospital Episode Statistics (HES) and the Reference Cost
datasets for the period from 1995/96 to 2002/03. Health outcomes associated with the
treatment of coronary heart disease are taken from existing literature. This shows that
both CABO and PTCA are associated with similar mortality rates and re-occurrence of
non-fatal myocardial infarction in the long term; CABO has lower re-admission rates
and lower recurrent angina; and that PTCA, being a less invasive procedure, is
associated with lower risks of death in the operating theatre. Overall, the two procedures
appear to be similar in terms of their health outcomes; thus leading Mai to set the
quality adjustment weights equal to one in his analysis.
His results show that the output of treating AMI/angina grows over time in all measures
(see Figure 2-1). However, it grows much faster when using the disease based index.
According to Mai, this shows that, over the time period considered, there has been
substitution from CABO to PTCA, that is, from a more expensive treatment to a
cheaper one. In the CWAI, a substitution between CABO and PTCA would translate
into a negative growth, as the cost weight attached to CABO is higher than the one
attached to the cheaper PTCA, although they are the same in terms of outcome. CWOI
overcomes this drawback by assigning a common weight to both alternative
interventions; hence, it implicitly increases the weight given to PTCA which had also
seen the highest increase in its volume measure.
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Figure 2-1 - Trends in output indices for AMI/angina
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Mai studied the sensitivity of the growth rates of both CWAI and CWDI to various
assumptions about the substitutability of PTCA and CABO and in the quality
adjustment weights. Results show that the indices are sensitive to different assumptions
but that failing to take account of the possibility of substitution between treatments
would result in lower growth rates of the output index for AMI/angina. Further,
allowing the quality adjustment weights to be different from one - that is moving away
from the assumption that the two treatments are perfect substitutes in terms of their
health outcomes - make the cost-weighted disease index very sensitive to the value
chosen, although the growth in the CWDI over the time period considered remains
higher than the one measured with the CWAI.
2.2.3 Conclusions
The price index literature has shown the importance of focussing on the direct medical
costs of treating an episode of an illness, rather than changes in the prices of the inputs
used in treatment, and that there needs to be some allowance for quality improvements.
Rising input costs do not necessarily imply that the costs of treatment episode are
increasing, if changes in the composition of treatment have occurred over time. Inmost
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cases improvements in the composition of treatments are related with observed
endogenous changes in the patient mix. Quality aspects can be incorporated in a price
index in various ways, and do not necessarily require the construction of complicated
algorithms. However, it is not straightforward to allow for improvements in outcome to
be fully captured in the index. Triplett (1999) maintains that health outcomes data
derived from cost-effectiveness research can be and should be used to identify medical
care outputs that adjust for quality change. His suggestion is to combine information on
prices and quantities and outcome measures such as QALYs to derive price indices that
take account of new treatments with different QALY implications. Changes in QALYs
for existing treatments can readily be incorporated into this general framework.
2.3 Methodology
We use the output growth index developed in Dawson et al. (2005) and Castelli et al.
(2007b) and described in chapter 1 to calculate NHS hospital output measures for all
circulatory diseases in England, for the time period 1998/99 to 2003/04. Activity is
adjusted for survival rates and patient-reported outcome measures are used for two
procedures - coronary artery bypass graft (CABO) and percutaneous transluminal
coronary angioplasty (PTCA) - to highlight the potential of introducing health outcome
measures into the output growth index.
The first type of index that we calculate is the simple unadjusted cost weighted output
growth index. The index aggregates activity by weighting it by average CIPS based unit
costs, which is equivalent to multiplying the ratio of outputs by their cost shares. The
base-year Laspeyres formulation (Dawson et al., 2005) is given by equation (9).
Where Xjt is the amount of output undertaken in period t and Cjl is the average unit cost
of output j in time t.
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We then introduce survival rates so that the Laspeyres formulation (Dawson et al.,
2005)of the index becomes
The ratio ajt+l/ajt represents the proportionate increase in surviving treatment for output
j between period t and period t+1. Ceteris paribus and assuming that mortality rates
have been improving over time, quality adjusting the output growth measure should
yield higher growth rates over the time period under investigation. The magnitude of the
survival adjustment on the overall output growth measure depends clearly on the initial
survival rate ajt; if the majority of NHS patients survive their treatments, then the
overall effect of this quality adjustment on output will be minimal. Even so, as we have
seen in the US literature, failing to incorporate this quality adjustor would mis-represent
the true output growth index, particularly if survival rates change over time.
The final adjustment involves incorporating patient reported health outcomes. In
principle, health outcome refers to the value added to each individual's health as a result
of contact with the health system. To construct this type of measure, ideally one should
observe with and without treatment measures of health. However, health status is rarely
observed in the absence of an intervention, as nobody is denied medical care in this
country. Pre- and post-intervention measures of health status are a potential substitute.
The formula of the cost weighted output index incorporating both survival and health
adjustments is (Dawson et al., 2005):
Where ~ represents the ratio of average health reported outcome before (hOj) and after
treatment (h), that is kj = h~jh; . Note that kj is time-invariant in this application as
data on patients' health status before and after treatment are currently not routinely
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collected on an annual basis. The before and after health status measures used in the
cost weighted output index are snapshot measures; thus, activities that have a low
survival rate or small post-treatment health level can then produce large changes in the
cost weighted output index. Indeed there may be circumstances when the survival rate is
so low that aj - kj is negative. For example, the survival rate for acute myocardial
infarction (E12) is 0.79 in 2002/03, but the ratio of the average health outcomes is 0.8.
This means that the survival with health outcome adjustment would be negative (-
0.00334). Procedures like this one create a problem in the health effect adjusted cost
weighted output index. So, if either ajl+! - kj or ajt - kj are small or negative for a
healthcare output, we will use the pure survival adjustment ajt+/ajt for that specific
procedure. A cut-off point to ajt+! - kj and ajt - kj equal to 0.1 is introduced'". In our
application, we conduct a sensitivity analysis to look at the effects on the cost weighted
output index of different values for the cut-off point.
Ceteris paribus and assuming that the patient reported health outcome after treatment is
higher than the before treatment one - a realistic assumption for the type of conditions
considered here (though not when treating terminal care) - then the introduction of this
further quality adjustment should have the effect of increasing the output growth
estimates over and above the simple survival adjustment.
2.4 Data
2.4.1 Data sources
The Hospital Episode Statistics (HES) database and the National Schedule of Reference
Costs database, as described in chapter 1 (Section 1.6), are our primary source for data.
We present data on elective and day cases inpatient stays and non-elective (emergency)
inpatient stays.
Output data and one of the quality characteristics (survival rate) are derived from the
Hospital Episode Statistics database, whilst total expenditure of inputs used in the
production process is derived using the Reference costs database. Measures of health
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outcome for circulatory diseases are provided by a private health insurer, an
independent healthcare provider (Vallance-Owen et al., 2004).
For the purpose of this study, a series of diagnoses and procedures that are commonly
known to belong to the broad category of circulatory diseases are identified using the
the DH Programme Budget'" classification for the area of 'circulation'. The DH
Programme Budget categorisation presents three separate lists of diagnosis codes under
the area of 'circulation':
• coronary heart disease (PB-I OA)
• cerebrovascular disease (PB-I OB)
• other problems of circulation (PB-l OX).
Diagnosis codes are based on the International Classification of Disease codes version
10. However, hospital activity and average unit costs data are organised by healthcare
resource groups or HRG; thus, all those identified ICD-10 needed to be mapped to the
relevant HRGs. An online HRG explorer'? was used to map diagnosis to up to five
alternative base HRGs. The mapping procedure allowed us to produce a first list of
HRGs, to which a further list of HRGs that are believed to fall under the broad
definition of circulatory diseases was added. The total number of identified HRGs
related to circulatory diseases is 5751•
2.4.2 Continuous Inpatient Spell (CIPS)
Atkinson (2005) and Cutler and Huckman (2003) advocate that disease-based or
patient-based output measures are used as the appropriate way to improve the
measurement of output and productivity growth of a health system. Currently, however,
routine administrative data do not directly track patients, and hence the resources used
by them, in their journey within the NHS. An interim measure is suggested by Lakhani
et al. (2005) and used in Dawson et al. (2005): continuous inpatient spells ofNHS care.
These, in fact, more clearly correspond to the journey that patients undergo across NHS
hospital settings, and are also "[ ... ] less vulnerable to being miscounted if transfers
among providers vary over time or if there are changes in 'how being under the care of
a consultant' is defined (Dawson et al., 2005, Lakhani et al., 2005).
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A summary of how to identify CIPS of NHS care and how to attribute average unit
costs, based on Reference Costs, to CIPS can be found in chapter 1, Section 1.7.1.
2.4.3 Quality adjustments
Quality characteristics of NHS care are captured in this chapter through survival rates
and health outcomes. In particular, we use two measures of survival rate52: 'in-hospital'
survival rate and 'in-hospital and 30-days post discharge' survival rate. A description of
these two measures can be found in chapter 1, Section 1.7.3.1.
Patient-reported outcome measures are rarely applied outside clinical trial settings. We
describe and discuss the various sources available to obtain patient pre- and post-
treatment health outcomes in chapter 1, Section1.7.3.1. We are able to identify pre- and
post- intervention measures of health status for only two of the 57 HRGs attributed to
circulatory diseases, namely coronary artery bypass graft (CABG) surgery and
percutaneous transluminal coronary angioplasty (PTCA). We recognise that this
constitutes an un-representative sample; however, we use this information as an
example to illustrate the potential advantages and better estimation of NHS output
growth measures that could be obtained were more data on patient-recorded outcome
measures to be collected on a routine basis.
2.4.4 Inputs
Inputs in the NHS constitute the resources used in the production of NHS activities and
outputs. Together these contribute to the production of health outcomes. Inputs can be
disaggregated into three different categories: labour, intermediate consumption (also
called procurement) and capital consumption. Each of these contributes to the
production of healthcare.
We use the Reference Costs as the source of data to account for total expenditure on
inputs used by NHS hospitals to treat patients affected by problems of the circulatory
system. The costing methodology of all NHS activity is standard across all NHS
hospitals and is calculated on a full absorption basis (NHS Costing Manual, 2007).
Costs are matched to services delivered and these should reflect the full and true costs
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of services provided, they should be allocated and apportioned by maximising direct
charges and where this is not possible they should be attributed and apportioned using a
standard method and matched to the services that generated them to avoid cross-
subsidisation. The methodology followed is a step-down one where hospitals should
first determine overall aggregate costs and then apportion them to the different costing
pools (a group of different hospital facilities). Costs are divided into direct, indirect and
overhead costs. Direct costs are those for which the cost centre of patient is directly
identifiable and hence should be directly allocated to the services that generated them.
Indirect costs represent all those costs that cannot be allocated to one particular cost
centre but which are shared over a number of them, e.g. Pharmacy, laundry. In this case,
costs should be allocated to specific cost centres in proportion to the use made of that
particular activity. The last type of costs is the costs of support services, which are
incurred in the effective running of the hospital provider. These may include cost of
business planning, general maintenance of ground and buildings, etc. The step-down
process continues until all costs are allocated and apportioned to all clinical services by
point of delivery such as inpatient, day cases, outpatient, etc.
For inpatient and day case activity the costs are disaggregated into HRG, which is the
chosen 'unit of currency'. NHS providers need to select the HRGs that cover at least 80
per cent of cost and activity at each point of delivery (either elective, non-elective or
day case) in order to identify what are called 'key HRGs' within each "treatment
function", Le. patient group. Within each HRG the main conditions and/or procedures
are identified for each individual patient.A resource profile is then created by the nurse
managers/ward managers which should include relevant and main cost drivers for each
diagnosis/procedure within an HRG. These cost drivers include time spent on ward,
time spent in theatre and therapies administered. An illustrative example for a resource
profile is given in Table 2-2, where we look at a condition/procedure administered for a
non elective (emergency) case of stroke or cerebrovascular accident.
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Table 2-2 - IUustrative example of a resource profile for non-transient stroke or cerebrovascular
accident <70 w/o cc (HRG Al2) (treatment function: general medicine/point of delivery: inpatient
non electivelICD code: 1634 Cerebral Infarction due to embolism of cerebral arteries
Costing Pool Pool Type Measure Units Cost per measure (£) Total cost
£
Ward Time Bed days 9 100 900
Nursing Event Admission 1 20 20
Ward Time Bed days 9 70 630
Diagnostics:
-MRI Event Event 1 170 170
- Other radiology tests Event Banded tests 2 20 40
- Pathology tests Event Banded tests 10 6 60
Therapies:
- Occupational therapy Event Session 2 25 50
- Speech Therapy Event Session 2 25 50
- Physiotherapy Event Session 5 27 135
Total Cost £2,055
Source: NHS Costing Manual 2007
The (activity) weighted average cost for an HRG is then calculated by 1) multiplying
the cost of each procedure/condition that falls under the relevant HRG by the total
number of episodes for each procedure/condition; 2) adding up all the total costs of the
procedure/condition and 3) dividing this total cost by the number of episodes in that
HRG. This average cost is then applied to all episodes for the HRG within the hospital.
Table 2-3 provides an illustrative example of the estimation of a weighted average unit
cost for a hypothetical NHS hospital.
Table 2-3 - IUustrative example of estimation of unit cost for non-transient stroke or
cerebrovascular accident < 70 w/o cc (treatment: general medicine/point of delivery: inpatient non-
electivelHRG
Number ICD code Description Cost (£) Episodes Total cost
(£)
1634 Cerebral infarction due to 2,055 40 82,200
embolism of cerebral artery
2 1650 Occlusion and stenosis of 1,748 20 34,960
vertebral artery
3 1661 Occlusion and stenosis of 2,147 10 21,470
anterior cerebral artery
4 1672 Cerebral atherosclerosis 2,239 10 22,390
Total 80 £161020
Weighted average cost for
HRG12: Non-transient stroke or cerebrovascular accident < 70 w/o cc £2,013
Source: NHS Costing Manual 2007
114
This costing methodology allows for all three types of relevant inputs to be accounted
for. Although we acknowledge that Reference Costs may suffer from shortcomings
associated with most routine costing data (Jacobs and Dawson, 2003), we believe that
they still remain a valuable and reliable source of information to calculate total NHS
hospital expenditures for all circulatory disease. These figures are used to determine
productivity growth of this programme ofNHS hospital care (See section 2.6.3).
2.5 Descriptive Statistics
This section presents some descriptive statistics on volume of output (CIPS), unit costs
and survival rates. We focus here on stroke and coronary heart disease (CHD) only. We
selected the HRGs that correspond to these diagnoses and their related procedures. To
populate the lists of HRGs for stroke and CHD, we used a list of all HRGs related to
stroke available on line at http://hcna.radc1iffe-oxford.com/stroke.htmand the National
Service Framework on coronary heart disease (Department of Health, 2005). The full
list of all relevant HRGs is shown in Table 2-4.
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Table 2-4 - List of HRGs related to stroke and coronary heart disease
HRG HRG description
code
Stroke AOI
A02
A03
A04
A19
A20
A21
Intracranial Procedures Except Trauma - Category 1
Intracranial Procedures Except Trauma - Category 2
Intracranial Procedures Except Trauma - Category 3
Intracranial Procedures Except Trauma - Category 4
Haemorrhagic Cerebrovascular Disorders
Transient Ischaemic Attack >69 or w cc
Transient Ischaemic Attack <70 wlo cc
A22 Non-Transient Stroke or Cerebrovascular Accident >69 or w
cc
A23 Non-Transient Stroke or Cerebrovascular Accident <70 wlo cc
Coronary Heart Disease
E04 Coronary Bypass
E07 Pacemaker Implant for AMI, Heart Failure or Shock
Ell Acute Myocardial Infarction w cc
E 12 Acute Myocardial Infarction wlo cc
E 13 Cardiac Catheterisation with Complications
E 14 Cardiac Catheterisation without Complications
EIS Percutaneous Transluminal Coronary Angioplasty (PTCA)
E 16 Other Percutaneous Cardiac Procedures
E 18 Heart Failure or Shock >69 or w cc
E 19 Heart Failure or Shock <70 wlo cc
E22 Coronary Atherosclerosis >69 or w cc
E23 Coronary Atherosclerosis <70 wlo cc
E28 Cardiac Arrest
E29 Arrhythmia or Conduction Disorders >69 or w cc
E30 Arrhythmia or Conduction Disorders <70 wlo cc
E33 Angina> 69 or w cc
E34 Angina < 70 or wlo cc
E35 Chest pain> 69 or w cc
E36 Chest pain < 70 or wlo cc
2.5.1 Stroke
The World Health Organisation defines stroke as 'a focal (or at times global)
neurological impairment of sudden onset, and lasting more than 24 hours (or leading to
death), and of presumed vascular origin,S3.Three major sub-categories are identifiable
and they are: ischaemic stroke, intracerebral haemorrhage and subarachnoid
haemorrhage.
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Table 2-5 - Elective and Emergencies outl!ut for Stroke
Year Volume of output Volume of output
Elective and day
% change Emergencies %change
cases
1998-99 11,908 97,728
1999-00 11,384 -4.40% 86,227 -11.77%
2000-01 11,073 -2.73% 83,479 -3.19%
2001-02 10,584 -4.42% 83,749 0.32%
2002-03 11,755 11.06% 99,582 18.91%
2003-04 12,546 6.73% 105,225 5.67%
Overall, elective and non-elective (emergencies) output for stroke has increased over the
time period considered. However, as appears from Table 2-5, there is year on year
variation in the volumes of output recorded. Elective output registers a decrease in the
first three years of the time series, before recovering in the later two years. Emergency
output also sees a decrease in the first two years, followed by an increase in the later
years. We expect this volatility to be reflected in the output growth indices.
Output weighted average unit costs show a progressive increase over the time period
considered for elective and day cases (see Table 2-6). Emergency output also shows
growing costs up to 2001-02 before the trend is reversed in the last two years.
Table 2-6 - Costs of hosl!ital output for Stroke
Year Output weighted average unit costs
Elective and day
cases
Emergencies
1998-99
1999-00
2000-01
2001-02
2002-03
2003-04
3,045
3,099
3,550
3,868
4,245
4,352
2,380
2,705
2,893
3,201
3,044
2,983
Output weighted average in-hospital survival rates have improved for both elective and
day cases and emergencies throughout the period (with the exception of 2002-03 where
a slight decease is recorded compared to the previous year for both types of hospital
output) (see Table 2-7).
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Table 2-7 - In-hosJ!italand 30-da~ J!ostdischarGesurvival rates for Stroke
Year Mean in-hospital survival rate Mean 30-day survival rate
Elective and day
Emergencies
Elective and
Emergenciescases day cases
1998-99 0.9612 0.7934 0.9525 0.8243
1999-00 0.9680 0.7814 0.9610 0.7606
2000-01 0.9704 0.7859 0.9619 0.7667
2001-02 0.9773 0.7888 0.9699 0.7716
2002-03 0.9709 0.8196 0.9649 0.8057
2003-04 0.9766 0.8365 0.9707 0.8243
Mean 30-day survival rate has also improved for both elective and emergencies in the
time period considered, with the exception of2002-2003 (see Table 2-7).
2.5.2 Coronary Heart Disease (CHD)
Coronary Heart Disease (CHD) is the condition that occurs when the constant supply of
oxygen to the heart muscle is blocked partially or completely. Oxygen is carried to the
heart muscle in the blood and flows to it through the coronary arteries (heart's blood
vessels). Coronary arteries are placed both to the left and to the right side of the aorta
and supply the tissues of the heart itself. The reduced supply of oxygen can be caused
either by the presence of a blood clot - thrombosis - or by the arteries becoming thick
and hard - sclerosis. Different types and severity of CHD may occur according to the
degree of blockage of the coronary arteries. If they are completely blocked then the
patient may experience a heart attack (myocardial infarction) and if the block is only
partial, then this can cause chest pains otherwise known as angina. Acute Myocardial
Infarction (AMI) refers to the complete cessation of the heart muscle, whilst heart
failure or shock refers to a condition in which the pumping action of the heart is
inadequate. Coronary Artery Bypass Grafting (CABO) and Percutaneous Transluminal
Coronary Angioplasty (PTCA) are procedures performed when patients suffer from a
chronic CHD.
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Table 2-8 - Elective and non-elective out~ut for Corona!): Heart Disease
Year Volume of output Volume of output
Elective and day
% change Emergencies %change
cases
1998-99 124,573 469,503
1999-00 127,683 2.50% 453,992 -3.30%
2000-01 135,901 6.44% 464,657 2.35%
2001-02 143,042 5.25% 459,704 -1.07%
2002-03 154,855 8.26% 509,938 10.93%
2003-04 166,600 7.58% 539,689 5.83%
Volumes of output for elective and day cases have continuously increased throughout
the period. Overall emergency output shows an increase over the period considered,
with some volatility in the early years (see Table 2-8). It is well known that emergency
output is subject to large year-on-year variations, the reasons for which are not fully
understood but are thought to relate to 1) particularly severe atmospheric conditions
(exceptional cold winters or hot summers) (Bagust et al., 1999) and 2) reporting
behaviour, particularly if providers increase coding of short stay emergencies to attract
more funding (Farrar et al., 2007).
not possible to pin down the exact nature of the volatility recorded in HES at is
routinely collected administrative data. Some variation in volumes of output However,
it is important to detect it and to correctly report it so that oddities in output growth
estimates can be easily identified and interpreted.
Unit costs for both electives and emergencies show a gradual increase up to 2002-03,
before decreasing in the last year (see Table 2-9).
Table 2-9 - Cost of hos~ital activity for Corona!): Heart Disease
Year Output weighted average unit costs
Eleaive and day
Emergencies
cases
1998-99 1,453 1,087
1999-00 1,463 1,161
2000-01 1,531 1,221
2001-02 1,655 1,323
2002-03 1,744 1,302
2003-04 1,681 1,286
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Average output weighted in-hospital and 30-day post discharge survival rates for
elective and day cases output have remained constant over the time period considered.
A slight improvement is registered for emergencies in both measures of survival.
Table 2-10 - In-hosl!ital and 30-daI I!ost discharge survival rates for CoronarI Heart Disease
Year Mean in-hospital survival rate Mean 30-day survival rate
Elective and day
Emergencies
Elective and
Emergencies
cases day cases
1998-99 0.9916 0.9335 0.9883 0.9220
1999-00 0.9935 0.9373 0.9906 0.9261
2000-01 0.9943 0.9444 0.9913 0.9345
2001-02 0.9954 0.9453 0.9929 0.9361
2002-03 0.9950 0.9517 0.9926 0.9438
2003-04 0.9960 0.9562 0.9941 0.9494
In the remainder of this section, we present trends in output, unit costs and survival rates
for CABO and PTCA procedures. These two procedures are in fact of particular interest
to us as patient-reported health outcomes are available for them and these will be used
in the construction of our output growth measures.
Figure 2-2 show respectively trends in elective and non-elective inpatient spells for
patients treated with CABG (E04) and PTCA (EIS). Rates of CABG have remained
stable throughout the period, whilst PTCA rates have increased rapidly, with more than
a doubling in output over the six year period. In the final year, there is some evidence of
what might be considered as treatment substitution, when a large increase in PTCA
procedures is accompanied by a quite sharp fall in CABO procedures. It is, however,
possible that some of the increased output might be due to treatment expansion, that is
the treatment with PTCA of less severe patients that might have previously treated with
medical management only.
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Figure 2-2 - Trends in Electives and Day cases (-e) and Non-electives (-ne) volumes of output for
CABG (E04) and PTCA (E1S)
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Figures 2-3 and 2-4 show output weighted average unit costs respectively for electives
and non-electives CABG and PTCA. Units cost have been deflated using both the GDP
deflator and the NHS Pay and Price Index. First, it should be noted how average unit
costs for non-elective procedures are consistently higher than their elective and day case
counterparts. This may in some part be due to the higher dependency of patients that are
admitted and operated as emergency cases. Second, PTCA is a consistently less costly
procedure than CABG (for both electives and day cases and non-electives).
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Figure 2-3 - Trends in output weighted unit cost for Electives and Day cases (-e) and Non-Electives
(-ne) CAGB (E04) - in 1998/99 prices using NHS Pay and Price Index (a) and GDP deflator (b)
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Figure 2-4 - Trends in output unit costs for Electives and Day cases (-e) and Non-electives (-ne)
PTCA (E1S) - in 1998/99 prices using NHS Pay and Price Index (a) and GDP deflator (b)
Survival rates for patients treated with CABG and PTCA (see Figure 2-5) are relatively
high throughout the period, and there is some evidence of improvement in non-elective
outcomes.
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Figure 2-S - Trends in Electives and Day cases (-e) and Non-elective (-ne) survival rates for CABG
(E04) and PTCA (EIS) - 30-day post discharge
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2.6 Output and productivity measures of circulatory diseases
This section presents the results of the growth in NHS hospital output for circulatory
diseases in the period from 1998/99 to 2003/04. First, we calculate the unadjusted cost
weighted output index. We then introduce the survival and cost adjusted version as set
out in Section 2.3. For illustrative purposes only, the effects on output growth of
introducing more general health outcomes into the equation are analysed. We
incorporate the broader definition of health outcome in our overall cost weighted output
growth measures. We conclude by analysing the productivity growth for the programme
of care 'circulatory diseases' in the NHS hospital sector.
A brief outline of some of the features of the data used is presented. Table 2-11 shows
volumes of output for both elective and day cases and non-electives.
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Table 2-11 - Elective and day cases and non-elective output for all circulatory diseases
Year Volume of output Volumeof output
Electives and
day cases
1998-99 189,805
1999-00 192,431
2000-01 202,121
2001-02 209,076
2002-03 229,169
2003-04 246,564
%change Non-electives %change
1.38%
5.04%
3.44%
9.61%
7.59%
754,125
717,097
727,002
723,410
810,200
862,735
-4.910%
1.381%
-0.494%
11.997%
6.484%
Elective and non-elective output has increased over time. Electives and day cases show
a steady increase throughout the period (with the exception of the years 2001-02 and
2003-04 where the rate fell); whilst non-electives show a more volatile picture in terms
of their growth up to 2001102with a high growth in the last two years of the time series.
Table 2-12 - In-hospital and 30-day post discharge survival rates
Year Average in-hospital survival rate Average 30 day post discharge
survival rate
Electives and
Non-electives
Electives and Non-e/ec lives
day cases day cases
1998-99 0.9864 0.9084 0.9818 0.8942
1999-00 0.9887 0.9097 0.9846 0.8953
2000-01 0.9899 0.9162 0.9858 0.9031
2001-02 0.9917 0.9168 0.9881 0.9045
2002-03 0.9911 0.9249 0.9880 0.9144
2003-04 0.9925 0.9318 0.9899 0.9227
In-hospital and 30-day post discharge survival rates have improved throughout the
period. Elective and days case procedures are usually associated with higher survival
rates than their non-elective counterparts (see Table 2-12).
In 2002/03, unit costs for elective procedures varied from £394 for deep vein
thrombosis to just under £27,000 for heart and lung transplant procedures; unit costs for
non-electives varied from £499 for chest pain to £34,000 for heart transplant.
Figure 2-6 shows the implied total expenditure on HRGs associated with circulatory
disease across the six-year period. The results are presented in 1998/99 prices, deflated
using both the GDP deflator and the NHS Pay and Prices Index. Both show a steady
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increase in real expenditure from £1.4 billion in the first year. The GDP deflator is
likely to be more appropriate for indicating the real increase in inputs used by the NHS
as it reflects the price of goods and services throughout the entire British economy,
rather than the cost of goods and service purchased by the NHS. It implies a growth of
5.3 per cent per annum in circulatory disease hospital inputs over the six-year period.
This is in line with ONS estimates of total NHS input growth over the same period
(between 4.8 per cent and 5.5 per cent depending on the methodology used)
(UKCeMGA, 2006).
Figure 2-6 - Total expenditure on circulatory diseases using GDP deflator (GDP) and NHS Pay and
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2.6.1 Simple CWO] and CWO] with survival adjustment
The first set of Figures produced is the simple cwor for our set of NHS hospital
activity for circulatory diseases. This index aggregates activity by weighting it by unit
costs, equivalent to multiplying the ratio of activities by their cost shares. The second
set also includes survival rates in the cost weighted output growth measure. Results
derived from using 'in-hospital' and 'thirty days' survival rates are shown separately.
The output growth estimates can be found in Table 2-13.
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NHS output for circulatory disease has increased over the time period from 1998/99 to
2003/04. The unadjusted output CWOI suggests an average annual growth in output of
3.9 per cent, although there is annual variation in the estimated amount of growth, with
growth particularly pronounced at the end of the period. This is due to exceptional
increases in output in a number of HRGs, for both electives and day cases, and non-
electives.
Table 2-13 - Cost Weighted Output Index simple and with survival adjustment
Years
CWOI _ CWOI with in-hospital CWOI with 30 day post
unadjusted survival adjustment discharge survival
adjustment
1998199 - 1999/00 2.23% 1.47% 1.36%
1999100 - 2000/01 2.86% 3.22% 3.33%
2000/01 - 2001102 3.24% 3.31% 3.42%
2001102 - 2002/03 6.28% 8.03% 8.37%
2002103 - 2003/04 4.88% 5.73% 5.93%
Average growth 3.90% 4.35% 4.48%
Introducing the quality adjustment produces higher growth rates in the indices, both on
average and for any given year, except for 1998/99 - 1999/00. The lower growth rate for
the survival adjusted output index for these years can be explained by the sharp decrease
registered for non-elective inpatient in 1999/00 (see Table 2-11). For all other years, the
higher growth rates are expected because of improvements in survival over time.
The use of '30-days post discharge' survival rates yields a higher adjustment than 'in-
hospital' survival rates for all years except for 1998/99-1999/00. This is due to the fact
that the rate of improvement in 30-days post discharge survival rate is greater than that
of the in-hospital survival, for any year and on average. The lower growth rate of the
output index in 1998/99 - 1999/00 using 30 days post discharge survival rate is due to
the multiplicative effect of a negative growth rate in non-elective inpatient activity in
1999/00 and a higher 30 day survival rate.
Overall, using 'in-hospital' survival rates leads to an average annual increase in the
estimates of output growth of 0.45 per cent compared with the unadjusted CWOI, while
the '30 days post discharge' measure of survival adds 0.58 per cent compared to the
unadjusted CWOI. The increase reflects the gradual improvement in survival rate
registered over the period under study.
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Our preferred measure for survival adjustment is the '30 days post discharge survival
rate' as used in many other studies (Lunn et al., 1987;, Kosecoff et al., 1990; Rogers et
al., 1990; Baker et al., 2002; Dawson et al., 2005, Castelli et al., 2007). We will use this
in the remainder of this chapter.
2.6.2 CWO] with survival and health outcome adjustments
We now consider the introduction of health effects in measuring NHS output growth for
circulatory diseases. In the first part of this section we explore the impact that the
introduction of health outcomes has on our cost weighted output growth measure for the
two procedures for which we have patient reported health outcomes. We then proceed in
Section 6.2.2 to calculate the cost weighted output growth index with both quality
adjustments for all HRGs for circulatory diseases. Assumptions will need to be made
about the value to be given to the ratio kj = hOlh *j and attributed to those HRGs (the
majority) for which no health outcome measures are currently available.
2.6.2.1 Introducing patient-reported outcome measures
The health outcome measures were made available by a private health insurance
provider. Table 2-14 shows before (hOj) and after (h) treatment measures of health
outcomes for CABG and PCTA, respectively. The private health insurance provider
reports data at procedural level, and not by HRG which is the 'unit of currency' used in
this paper. It is, therefore, necessary to map the provider's procedural codes to their
appropriate HRG. A presumption is made that experience of patients undergoing the
private health insurance provider's procedures are representative of all patient classified
within the specified HRG. This presumption is less likely to hold the more
heterogeneous the HRG. The before treatment health outcome measure was obtained
from a sample of 747 patients undergoing CABG and from a sample of 85 patients
undergoing PTCA. The sample sizes change slightly for the after treatment health
outcome measures, which are now equal to 725 and 75, respectively for patients treated
with CABG and PTCA. Average before and after treatment health outcomes data are
estimated from the full sample for whom data are available.
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Table 2-14 - Before and after health outcomes
HRG description
HRG
Health outcome
hO h'
J J
Coronary Artery Bypass Graft
Percutaneous Transluminal Coronary Angioplasty (PTCA)
E04
E15
0.50
0.54
0.73
0.79
These health outcomes measures are attributed to elective inpatient and day case
procedures. Health status before treatment for patients undergoing PTCA is slightly
better than that recorded for patients undergoing CABO. This is in line with evidence
from clinical practice, which shows that CABO has historically been used more
frequently in patients affected by more severe cases of chronic heart conditions (Cutler
et al. 2003). Studies on the efficaciousness of both CABO and PTCA procedures (e.g.
Henderson et al., 1998 and Cutler et al., 2003) maintain that both have comparable
outcomes in terms of survival rates. That said it is not implausible to assume and find
that patients' reported health outcomes after treatment are better for patients treated with
PTCA than those treated with grafting. After all, PTCA is a far less invasive procedure
than CABO.
As Mai (2004) points out, CABO and PTCA procedures administered to patients in an
elective setting should be considered as completely different procedures to those
administered in emergency cases. Hence, some assumptions need to be made about the
value to assign to patient's reported health outcomes before and after an emergency
procedure. It is not implausible to assume that in general the health status before
treatment as an emergency case is lower than that of an elective and day case.
A sensitivity analysis was undertaken to investigate the impact that different values of
before and after health status for non-elective procedures have on the output growth
index. In the first instance, we changed the values of both the before and the after health
treatment health statuses for non-elective procedures. Results show that the output
growth index is not particularly sensitive to these changes. See Appendix I-B. I for
further details.
Secondly, we made the more realistic assumption that only the before treatment health
status of patients that are treated as an emergency differs. In particular, we decided to
set these equal to half the value of their correspondent elective counterparts, as follows:
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(12) h~ABG.lloll-elective = 1/2 * h~ABG,elective
( 13) h ~CA .non=elective = 1/2 * h ~CA .elective
Further, we assume that the post-operative health outcome for CABO and PTCA is left
equal to their correspondent elective and day case counterparts. See identities (14) and
(15):
• •
(14) hCABG .non=elective = hCABG .elective
• •
(15) h PTCA.non=elective = h PTCA.elective
These assumptions will be used throughout the remainder of this section. Results for
cost weighted output growth for CABO and PTCA only are shown in Table 2-15.
Table 2-15 - Cost Weighted Output Index simple, with survival and health adjustments - time
series for CABG and PTCA -
1998199 - 1999/00
1999//00 - 2000/01
2000/01 - 2001/02
2001102- 2002103
2002103- 2003/04
CWOI with 30-day post CWOI with survival
CWOI discharge survival and health outcome
adjustment adjustment
-0.70% -0.67% -0.47%
5.37% 5.65% 5.86%
7.23% 7.20% 7.14%
15.43% 15.68% 15.81 %
4.66% 5.01% 5.58%
6.40% 6.58% 6.79%
Years
Average srowth
The unadjusted CWOI suggests an average output growth for CABO and PTCA of 6.4
per cent per annum. However, these results demonstrate the volatility inherent in using a
small sample, as it is shown by the large increase in the index of 15.43 per cent between
2001102 - 2002/03. This large increase is driven by an increase in activity for non-
electives CABO and PTCA procedures of 61 per cent and 42 per cent respectively
between 2001102 - 2002/03.
On average, the introduction of survival adjustment adds 0.18 per cent per annum to the
simple CWOI. Survival rates for these two HROs did not change much in the time
129
period considered, and they are quite high. Nevertheless, the incorporation of survival
rates in the index equation shows the extra value that is captured by this quality
adjustor. Failing to incorporate it would have resulted in an underestimate of the output
growth figure.
The last column shows the introduction in the measurement of the output growth index
of both survival and health outcomes. On average it adds 0.38 per cent to the unadjusted
CWOI and 0.21 per cent to the CWOI with survival adjustment.
2.6.2.2 Cost weighted output index with all quality adjustments
This section concludes the analysis of output growth for NHS hospital treatment of
circulatory diseases by incorporating all quality adjustments in our output growth index.
Some assumptions need to be made about 1) the value of the kj to be given to all the
HRGs for which we do not have health outcome measures and 2) whether to
differentiate this value for elective and day case treatments and non-elective treatments.
Regarding the first point, our preferred value for kj is equal to 0.8 for every j. This value
is equal to the average value for a sample of procedures where data on before and after
treatment outcomes are available (Castelli et al., 2007). We recognise that the average
above might not be representative of the effects of all NHS hospital treatments and that
it is a very strong assumption. We investigated whether different values for kj have an
impact on the output growth measures. We explored the two alternative values of 0.7
and 0.954•
We explore whether differentiating the value of kj for elective and non-elective activity
also has an impact on the output growth measures. Our preferred value for kj for non-
electives is equal to 0.4 when kj for electives is equal to 0.8. This is similar to making
the assumption that the before treatment health status of emergency cases is equal to
half the value of the before health status for elective cases. We believe that this is a
realistic assumption. We also explore two alternative values: 0.35 and 0.4555• These are
used alongside the preferred value k = 0.8 for elective HRGs.
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Cost weight output growth indices when Icj is equal to 0.8 and 0.4, respectively for
elective activity and non-elective activity except for CABG and PTCA are shown in
Table 2-16.
Table 2-16 - Cost Weighted Output Index, with survival and health outcome adjustments - time
series for all circulatory diseases
Average growth
CWOI- CWOI with survival
CWOI with survival
and health outcome
unadjusted adjustment adjustment
2.23% 1.36% 0.25%
2.86% 3.33% 3.86%
3.24% 3.42% 3.72%
6.28% 8.3?01o 11.16%
4.88% 5.93% 6.96%
3.90% 4.48% 5.19%
Years
1998199 - 1999100
1999100 - 2000101
2000101 - 2001102
2001102 - 2002103
2002103 - 2003104
Introducing the survival and health outcome quality adjustment produces higher in-year
growth rates in the indices, both compared to the unadjusted CWOI and the CWOI with
survival adjustment. The only exception is for the years 1998/99 - 1999/00, where the
quality adjusted output growth measure is much smaller. The same explanation given in
section 2.6.1 applies here. There is in fact a sharp decrease in non-elective inpatients
activity in 1999-00 compared to the previous year (see Table 2-11), which combined
with both survival and health outcome effect dampens the output growth between
1998/99 and 1999/00.
Overall, using the CWOI with survival and health outcome adjustment leads to an
average increase in output growth for all circulatory diseases of 5.19 per cent per
annum. Thus, adding 1.29 per cent and 0.71 per cent respectively to the unadjusted
CWOI and CWOI with survival adjustment only.
2.6.3 Productivity growth
Measuring productivity over time requires the calculation of a volume measure of
output change and compare it to an estimate of a volume measure of input change. As
indicated below.
Productivity change = Change in volume of outputs/Change in volume of inputs.
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As described in Section 2.4.4, we use average unit cost data from the Reference Cost
database to account for inputs used in the production process for the treatment of all
circulatory diseases. We produce two estimates of total expenditure using both the GDP
deflator and the NHS Pay and Price Index, to account for real changes in expenditure.
Total expenditure growth is expressed in terms of 1998/99 prices.
The total costs of hospital treatment of circulatory diseases have increased by 4.84 per
cent per annum in real terms. If this estimate is correct, it would imply that the cost-
effectiveness of this programme of care has been marginally falling over the period
under scrutiny if one considers the CWO I with survival adjustment only. Productivity
growth has fallen in this case by -0.325% on average. However, if one compares the
average growth in CWOI with survival and health outcome adjustment with the average
growth in expenditure a different picture emerges. Our results suggest that output has
grown marginally more relative to inputs measured at constant GDP prices, with annual
improvements in physical productivity of up to 0.318% per annum.
Figure 2-7 - Trends in output growth and total expenditure for aUcirculatory diseases
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Using the NHS price deflator implies an even larger growth in outputs relative to inputs
measured at constant NHS prices. A tentative conclusion is that the NHS has used its
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physical resources in this disease programme more efficiently to secure annual
improvements in physical productivity of up to 2.02 per cent per annum when compared
to the CWO I with survival adjustment only and up to 2.7 per cent per annum when
compared to the CWOI with survival and health outcome adjustment.
Figure 2-8 - Trends in output growth and total expenditure growth using the NHS Pay and Price
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2.7 Conclusions and implications for policy and future
research
This chapter has considered the feasibility and usefulness of developing measures of
growth in outputs, costs and productivity of a single programme of care within the
NHS: hospital treatment of circulatory diseases.
Productivity is the ratio of an aggregate measure of outputs to an aggregate measure of
inputs for the chosen programme of care. The key methodological challenges are:
• choosing the appropriate measures ofNHS output
• adjusting those measures for the quality of care
• aggregating the measures into a single measure of output
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• identifying the associated inputs and aggregating them into a single measure
• tracking these measures consistently over time.
We have demonstrated that it is feasible, using hospital spells as the unit of output, to
develop quite refined models of the output of a programme of care. The development of
HROs has assisted greatly in this endeavour, yielding meaningful counts of output. For
programmes of care outside hospitals future challenges will include developing
analogous measures of output in a community and primary care setting.
Output growth for hospital treatment of all circulatory diseases has increased over the
time period we considered. In actual cost-weighted volume terms, the increase is of the
order of 3.9 per cent per annum, but incorporation of quality data in the form of survival
rates implies an increased rate of 4.5 per cent per annum. This is clearly crude, but the
recent improvement in survival rates in many procedures for circulatory disease yields
quite a large improvement in estimates of annual rates of output growth. This is in line
with ONS estimates, which estimates annual increase in outputs over the same period
for the whole of the NHS (including primary care and prescribing) at about 5 per cent.
The lack of health outcome measurement in the NHS (other than survival data) means
that we are unable to say much about the quality of life after treatment. However, we
have demonstrated how this might be incorporated into an output index using health
status measures of before and after treatment from a private health insurer. Health
outcome data were available for CABO and PTCA elective procedures. For all other
procedures/diagnoses of circulatory disease we attributed an average value to the ratio
of before and after health outcome measures (kj = h/ Ihj) for electives and non-electives
activity (See Castelli et al., 2007a). Sensitivity analyses were carried out to determine
the effect of different values on the cost weighted output growth indices. In the first
instance, we calculated output growth measures for CABG and PTCA procedures only,
finding that consideration of the quality of health outcomes added about 0.2 per cent per
annum to the estimates of output growth. Incorporating health outcomes measures for
all circulatory diseases activity yields a higher increase in average output growth of
about 5.19 per cent per annum, adding about 1.3 per cent per annum to the unadjusted
CWOI and 0.71 per cent annum to the survival adjusted CWOI.
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Figure 2-9 - Changes in output growth index with different quality adjustment specification
baselined to unadjusted CWOI, by year
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Figure 2-9 shows how the baseline estimate of output changes as each subsequent
adjustment is made by year. It appears clearly that in the period 1998/99 - 1999100,
quality adjusting output in circulatory diseases lead to worse estimate in output growth
compared to the case with no adjustment. As discussed in Sections 2.6.1 and 2.6.2.2,
this is largely due to the multiplicative effect of a negative growth rate in non-elective
inpatient activity in 1999/00 which combined with both survival and health outcome
effect dampens the output growth between 1998/99 and 1999100. For all remaining
years, the introduction of different quality adjustors has a positive impact on the
baseline estimate, as these are always higher than the baseline output growth estimate.
CWOI CWOI with in-hospital CWOI with in-hospital and 30 CWO) with 30 days-post
survival rate day survival rate discharge survival and health
outcome
In our view, routine collection of measures of health outcomes by the NHS should be an
urgent priority for numerous reasons, such as improved patient care, informing patient
choice, surveillance of clinical performance and resource allocation. It would also
permit the development of more secure measures of output growth, based on the health
improvement experienced by patients as a result ofNHS treatment.
135
At this stage of development we also consider health outcomes to be the most important
element of quality to incorporate into the model ofNHS output growth. However, there
is also a case for exploring the feasibility and usefulness of incorporating non-health
aspects of NHS quality into the model, such as measures of the patient experience and
waiting time. Regarding patient experience, it is known that patients value other
attributes of the provision of health care that are strictly speaking not directly related to
the curative aspects of it. These are for example cleanliness, food quality and being
treated with dignity and respect. We have been made aware that the Picker Institute has
conducted surveys collecting patients' views on a number of these attributes for NHS
patients and service user in a number of settings (eg primary care and inpatient) and also
for specific disease groups such as stroke and chronic heart disease (Healthcare
Commission, 2004 and 2005). It will be considered a priority for future research in this
field to investigate these surveys and the data collected to find ways of incorporating
them into a measure of output growth. Other aspects of output that may be important in
some programmes of care include the benefits of treatment to the patient's carers, and
the implications ofNHS activities for labour productivity and social care expenditure.
A crucial methodological consideration concerns the weights to be applied to the
separate NHS output activities. The diverse hospital spells that make up this programme
of care do not necessarily confer equal patient benefits. We have followed the
conventional practice in weighting treatments according to their estimated costs,
acknowledging that these are imperfect measures of marginal social value.
It has also been shown that substantial improvements in survival rates for stroke and
coronary heart disease have occurred throughout the time period considered. These
improvements are spread across all circulatory diseases, thus meeting the health policy
targets set out in 1999 by the Department of Health of achieving substantial reduction in
mortality rates in this area of health care.
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36 Although the White Paper mentions specifically coronary heart disease and strokes as priority areas,
elsewhere in the document it states that "l...] all references to coronary heart disease and stroke should be
understood to cover all diseases of the circulatory system" (DR, 1999, chapter 6).
37 A 'service price index' can be constructed either at a disaggregated level, where the market basket is
given, for example, by the cost of operating time, or at an aggregated level, where the market basket
consists of different treatment procedures, such as for example a hip replacement.
38 The CPI and PPI try to incorporate quality changes.
39 Knowledge should be considered here as different from the knowledge included - embodied - in new
technologies that are included in new treatments. This type of knowledge refers to say medical knowledge
and know-how and is characterised to some extent by public good attributes.
40 Cutler et al. (2001) extend this case to one of multiple diseases with consumers having probabilities of
contracting various illnesses.
41 They also explore the use of quality adjusted life years (QALYs). A QALY is "a generic measure of
health-related quality of life that takes into account both the quantity and the quality generated by
interventions" (Culyer, 2005).
42 The assumption on the monetary value of health improvement is derived from existing US literature,
which places the value of a life year gained between $10,000 and $100,000. Cutler et al. (2001) use the
benchmark assumption of $25,000 for every year of additional life.
43 Sometimes in combination with therapy.
44 In particular, Berndt et al. defme incremental remission "as the difference between the expected
outcome and the outcome that would be expected if he patient received no treatment".
45 This is called in the paper the 'problem of durability' and is typical of many goods, not just healthcare.
46 Unfortunately, data limitations prevent the adoption of a unit value approach for cataract surgery
similar to that in Cutler et al. (2001).
47 Cutler at al. exclude from their time series both the years 1983 and 1984 as the number of reported
CABG procedures in these years is significantly higher than that in 1985.
48 A sensitivity analysis was carried out to look at the effects of different values for the cut-off point on
the output growth estimates. Using our preferred values for k = 0.8 for elective RRGs and k =0.4 for non-
elective HRGs, the estimates of the output growth indices are not very sensitive to values of the cut-off
E0int equal to 0.05 and 0.2.
9 The guidance spreadsheets can be obtained from
http://www.dh.gov.ukleniManagingyourorganisationiFinanceandplanning/Programmebudgeting/DH 411
7326 (last accessed 30/10/2008).
so Available at http://www.ic.nhs.uklour-services/classification-and-standards/casemix/hrgv35/hrgv35-
toolkit/grouper/on-line-hrg-v35-explorer. Last accessed 1110/2008.
51 See Appendix 2-A for the full list of HRGs complemented with volumes of activity and unit costs
(Table 2-A.l), and survival rates - both 'in-hospital' and 'in-hospital and 30 days' (Table 2-A.2) - for the
last year of the time series studied (2003/04).
52 These are both calculated from mortality rates, as 1 - mortality rate.
53 The WHO STEPwise approach to stroke surveillance - Manual (2006).
54 The full set of results of the sensitivity analysis can be found in Appendix 2-B.2.
55 The full set of results of the sensitivity analysis can be found in Appendix 2-B.2.
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3 Equity in the delivery of healthcare in Great
Britain: the impact of decentralisation
This chapter addresses the issues of income-related inequality in health and inequity in
healthcare utilisation for the constituent countries of Great Britain in an attempt to elicit
possible directions of changes in the above as a consequence of the devolution reform
introduced in 1998. After introducing the issues at hand, we briefly review the theory of
decentralisation in Section 3.2. In the same section, we summarise the process of the
British devolution of the healthcare sector. Section 3.3 contains a brief discussion of what
is usually meant by "equity" and how the concept is studied and measured in the economic
literature. InSection 3.4 we present the methodology used in this study. Data description and
descriptive statistics are presented respectively in Sections 3.5 and 3.6. Finally, results are
analysed and discussed in Sections 3.7 and 3.8, respectively for income-related inequality in
health and inequity in healthcare utilisation.
3.1 Introduction
Over the last decade or so decentralisation of the health care sector has received
substantial attention as a policy reform in many countries. Even so, the effects of this
reform are neither thoroughly investigated nor completely understood.
We believe that in public health systems, there is the risk that equity will be undermined
by a policy of decentralisation. In particular, decentralisation of the healthcare sector
can jeopardise equity if individuals who are "equal" in every respect but the
'jurisdiction'i" in which they happen to live are treated differently than they would be in
a more centralised structure.
In 1998 the Labour Government passed an important reform which transferred political
power and responsibilities from Westminster to Scotland, Wales and Northern Ireland.
Health is the most important responsibility that has been devolved to constituent
countries in the UK, representing about 70 per cent of the budget that the devolved
governments have control over. Prior to devolution'? , health services in the constituent
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countries of the United Kingdom were administered as part of the National Health
Service, which was designed to achieve common standards across the whole of the UK.
However, since devolution, each constituent country" has been granted freedom to
organise aspects of their NHS differently, subject to overarching criteria and constraints.
In this part we investigate how decentralisationof the healthcare sector affects equity in
the delivery of healthcare within a decentralised system, using the constituent countries
(England, Scotland, Wales) of Great Britain as a case study. Data are taken from the
GeneralHouseholdSurveys(GHS) administeredin 1995/96and 2001/02. In particular, we
test for income-related inequity in healthcare utilisation within and across the three
constituent countries of Great Britain, by means of a concentration curve index. The
level of health is captured through different measures of self-assessed health. The
utilisation of primary and secondary care is proxied by GP consultations, outpatient
visits and inpatient stays. Self-assessedhealth, however measured, and the utilisation of
health care resources is standardised by age and sex for individuals reporting morbidity,
following the direct standardisation methodologies outlined in O'Donnell and Propper
(1991).
3.2 Decentralisation: a review of the theory and the case of
the British devolution
3.2.1 A review of the economic literature on decentralisation
Decentralisationis a very broad conceptwhose definitionsvary according to the particular
discipline within which it is studied. In its broadest sense it refers to the transfer of
political, administrative and fiscal powers and responsibilities for public functions from
the central government to sub-national levels of government. Different types of
decentralisation can be envisaged according to the degree and type of powers and
responsibilities that are transferred. The fullest form of decentralisation is usually
referred to as "devolution" and is attained when the central government cedes not only
political and administrative responsibilities to local governments but also financial
responsibilities regarding the levying of taxes with which to finance the devolved
functions and responsibilities.
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For the purpose of this paper, we briefly surnmanse the economic literature on
Decentralisation (or Fiscal Federalism, as it is usually termed) by focussing on its
potential advantages and disadvantages'".
The economic literature on DecentralisationlFiscal Federalism studies the optimal
assignment of different governmental functions to different levels of government.
Further, it studies the appropriate fiscal instruments that need to be devolved to local
governments in order for them to carry out the assigned functions. Musgrave (1959)
identified three major governmental functions or responsibilities and analysed whether
and to what extent the transfer of any of the three functions to a sub-national level of
government would be appropriate. The functions identified are: (a) macroeconomic
stabilisation, (b) income redistribution and (c) resource allocation.
Jurisdictions at any sub-nationallevel shouldplay no role in macroeconomic stabilisation,
as it is believed, Musgrave stresses, that their relative openness may be detrimental for
the implementation of anti-cyclical fiscal policies at this level. Further, it is argued that
were sub-national levels of government allowed to fully control money supply, these
would be tempted to finance their current public expenditure by creating a new
monetary base rather than financing it through taxation. This policy definitely entails a
high political cost.
As regards income redistribution, Musgrave also assigns this function primarily to
central government. Income redistribution should be considered here not only in terms of
inter-jurisdictional redistribution but also in terms of personal income redistribution.
Redistributing income across jurisdictions is assumed to be better performed at a central
level because of the relatively high mobility of households and firms. The ultimate
negative effect of a highly redistributive programme carried out at local level would be
to attract poor income households from other jurisdictions, whilst driving away high
income households from the jurisdiction. However, a marginal role in income
redistribution can and should be also played by local governments as these have a better
knowledge oflocal needs and who constitute the poor. This role was particularly stressed
by Pauly (1973), who showed that the redistribution of incomewhen performed by local
governments(of any level)may result in a Pareto superior outcome (or at least not Pareto
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inferior) to a centrally performed re-distribution'", It is worth noting that, as envisaged
by Pauly, individuals are interested in income redistribution not solely for altruistic
reasons, noting particularly how poverty is usually associated with some negative
externalities (such as increased crime rates), which individuals may be keen to minimise.
Further, Pauly stresses the local dimension of income redistribution by emphasising how
the proximity to and the "frequency of contact" with poverty explains why individuals
are willing to engage in and promote poverty relieving programmes at a local level.
Musgrave concludes that a positive role for a sub-national level of government can be
envisaged only with regard to resource allocation and yet only in those cases where the
production and delivery of goods and services can be ascribed to a specific geographical
area. Oates (1972) reinforces the importance of local governments in resource allocation
with his decentralisation theorem. In particular, Oates shows that welfare gains may be
attained with fiscal decentralisation when the demand for public goods and services, that is
when citizens' preferences over these goods and services differs between jurisdictions, and
when production costs also differ at the local level.
Our focus being on health sector decentralisation, we will now proceed by addressing the
usual arguments brought forward by the supporters/advocates for decentralisation of the
healthcare sector. In particular, the World Bank plays an important role in this respect as
it has strongly supported the decentralisation of the healthcare sector (especially in the
developing world) and investigated some of its potential effects.
In particular, it is argued that the transfer of administrative, political, and/or fiscal
authority over healthcare production and delivery from the central government to sub-
national level of governments should improve overall healthcare performance (World
Bank, 1993). The benefits that can accrue from a policy of decentralisation can be
thought of in both efficiency and equity terms. In particular, decentralisation is thought
to improve (i) "allocative" efficiency by allowing local governments to adapt the
production and delivery of services, and also expenditures, to local preferences; and (ii)
'technical' efficiency through greater cost consciousness at the local level (Oates, 1972
and 1999).
Equity may be improved as well, if we think that local governments are closer to their
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citizens, and hence may be more aware of the specific local needs. Local governments
may be able, therefore, to respond to local needs in more appropriate ways than a central
government or agency (Pauly, 1973). Further, advocates of decentralisation argue that the
closeness of individuals to their local governments and hence, their increased participation
in the decision making process leads to greater and improved quality, transparency and
accountability (Bossert, 2002). It is also maintained that local autonomy may trigger
local innovations and specilisations in the production and/or delivery of a public
service.
The main disadvantage derives from the fact that individuals who are "equal" in every
respect but the jurisdiction in which they happen to live may end up being treated
differently. Decentralisation may give rise to ''unacceptable'' variations across the
country as a whole.
3.2.2 An introduction to devolution in the United Kingdom
In the UK the decentralisation reform is more commonly known as devolution. Political
devolution began in 1998 with the Scotland Act 1998, the Government of Wales Act 1998
and the Northern Ireland Act 1998. The administrative, executive and legislative
arrangements for England are untouched by the devolution process. The UK system is
often described as asymmetrical, in that each constituent country has different levels of
devolved responsibilities and has developed its own specific arrangements. The differences
relate to the extent to which administrative, executive and legislative powers have been
objects of the devolution process in each country.
The settlements for Scotland and Northern Ireland have similar characteristics; both
countries have been accorded legislative power to pass primary and secondary legislation
in areas not reserved to Westminster alongside their powers over the so called "devolved"
matters. These countries also have a separate executive accountable to that legislature,
whilst Wales has not. Differences between Scotland and Northern Ireland do exist and
are mainly restrictions imposed on Northern Ireland on issues such as criminal justice,
law and policing. These restrictions will be kept in place until the peace process in
Northern Ireland is fully completed.
142
In contrast, Wales' National Assembly is a single corporate body, in which both
legislative and executive functions are grouped together. Plans have been made to
separate these functions into two independent bodies. However, what really differentiates
the Welsh Assembly from its Scottish and the Northern Irish counterparts is that the
former can pass only delegated legislation, e.g. regulations, within the framework of Acts
of the UK Parliament. So, in effect, both Scotland and Northern Ireland (when the peace
process is completed) have been ceded more powers than Wales.
The peculiarity of the U.K. devolution system compared to other devolved systems can
also be seen in that the United Kingdom Parliament'" retains its superiority over the
Scottish Parliament, the National Assembly for Wales and the Northern Ireland
Assembly, which are all constitutionally subordinate to Westminster. In particular,
Westminster is able to amend or repeal the Acts devolving power to Scotland, Wales and
Northern Ireland. The legislative supremacy of the Westminster Parliament is expressively
stated in both the Scottish and Northern Irish devolution Acts, respectively in section 28
(7) and 5 (6).
Finally, the financial arrangements have not been touched by the devolution reform, as all
countries' public expenditure is still mainly funded by block grants from the UK
Government. Scotland, however, has been granted the power to vary the standard rate of
income tax levied, thus being able to either raise additional or less income.
Table 3-1 summarises the particulars of the devolution's arrangements made in Scotland,
Wales and Northern Ireland, separately for each country.
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Table 3-1: Devolution structure for Scotland, Wales and Northern Ireland
Scotland Wales Northern Ireland
Devolution arrangements
Negative list: identifies the
subjects that are reserved to
Westminster
Positive lists: details all
subjects devolved
Extended, excepted and transferred
subjects
Devolved matters
Local government
Housing
Transport
Planning
Sports and the art
Local government
Housing
Transport
Town and country planning
Culture
Enterprise, trade and investment
Culture, arts and leisure
Learning and employment
Police and fire services
Welsh Language
Agriculture and rural development
public safety
Tourism, economic development
and financial assistance to Economic development
industry
Regional and social development
Common to all three countries
Health, Education, Social services/work, Environment
In Scotland'r', the "Negative list" specifically identifies those items that are reserved to
Westminster, and automatically devolving all non-listed areas to the Scottish Parliament
that can pass legislation on them. Further, and in contrast to Scotland, the Government
of Wales Act contains a "Positive List" by detailing all the functions that are to be
transferred to the Assembly. Finally, the Northern Ireland Act 1998 differentiates three
categories of legislative powers: reserved, excepted and transferred. "Excepted" subjects
are all those subjects that are reserved to the UK Parliament. These are listed in Schedule 2
of the Northern Ireland Act 199863 and include roughly the same subjects for Scotland.
"Reserved" matters are those subjects which could be transferred if consent across
communities is reached. These subjects include criminal law, policing and prisons.
3.2.2.1 The devolved National Health Service
The devolution process for the National Health Service started long before the actual
political devolution was put into practice. Marked differences have in fact always
existed between the constituent countries of the United Kingdom in key health
indicators and also in total NHS per capita spending. Summary statistics presented in
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Alvarez-Rosete et al. (2005) are used as an overview of the existing differences across
the four countries of the UK in the years preceding the devolution reform, These are
reported in Table 3-2.
The first row shows total NHS expenditure per capita and by country for 1996/07.
England has the lowest per capita spending of all four countries, whilst Scotland has the
highest. A caveat needs to be drawn as the expenditure figures are not adjusted for
differences in need deriving from differential age, sex and morbidity structures of the
population. Hence, the reported figures could well be under-stated, as suggested in
Alvarez-Rosete et al. (2005).
Table 3-2: Total NHS expenditure per capita, key health indicators and provision of healthcare by
count!): - 1996/07 ~~re-devolution~
England Wales Scotland Northern Ireland
Expenditure per capita (£) 831 968 1047 944
Health Indicator
Standardised mortality ratio
Men 98 102 119 109
Women 98 102 116 108
Life expectancy (years)
Men 74.5 73.9 72.2 73.8
Women 79.6 79.1 77.9 79.2
Proportion reporting illness (%)
Longstanding iJlness 35 38 33 34
Limiting Longstanding iJlness 22 26 21 25
Provision of healtheare
Hospital beds/l 000 population (all specialties) 4.! 5.3 7.7 5.7
Hospital beds in acute specialties (% of tot. beds) 76.2 78.! 68.2 71.2
Staff/lOOO population
Medical and dental" 1.1 1.2 1.5 1.3
Nursing, midwifery, and health visiting " 5 5.9 6.9 6.9
General Practitioners "" 0.56 0.6 0.72 0.62
• Whole time equivalent.
•• Unrestricted principals.
Source: Own elaboration from summary statistics presented in Alvarez-Rosete et al. (2005)
In tenus of key health indicators, citizen living in England have higher life expectancy
(both for men and women) and lower mortality rates. Only in tenus of self-reported
morbidity, the proportions of people reporting a longstanding illness are higher in
England than they are in Scotland and Northern Ireland (only exception is posed by
Wales), whilst the proportion of people with a limiting longstanding illness in England
is higher only compared to Scotland.
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The last part of Table 3-2 shows some supply-side information for hospital and staffing.
In general, England is the country which ranks last in terms of total number of hospital
beds per 1000 population for all specialties and for the total number of staff per 1000
population (the only exception is given by the percentage of total beds in acute care).
Notwithstanding the existence of (in some cases marked) differences across England,
Wales, Scotland and Northern Ireland, it is only since the election of the Labour
Government in 1997 that differentiated white papers on the organisation of healthcare
services for the NHS were produced in each constituent country. These were the English
white paper The New NHS: Modern-Dependable, the Scottish white paper Designed to
Care, the Welsh white paper NHS Wales Putting Patients First, and the Northern Irish
consultation paper Fit for the Future64• Similar white papers tackling the issue of public
health were also produced in 1998 by England (Our Healthier Nation), Scotland
(Towards a Healthier Scotland) and by Wales (Better Health Better Wales). Northern
Ireland produced only two consultation papers (Investing in Health and Well into 2000),
which did not develop into a white paper.
In the remainder of this section, we report some key objectives of the new NHS, in
England, Wales and Scotland, to reiterate the understanding that health and the health
system, although now being a devolved matter, are nonetheless based on the same
founding principles of the NHS as it was at its first inception in 1948. We leave
Northern Ireland out of our analysis, as this paper addresses issues regarding the
equitable distribution in health and healthcare utilisation for England, Scotland and Wales
only. This is solely due to data unavailability for Northern Ireland.
In England, the Government's commitment is to ensure that 'if you are ill or injured
there will be a national health service there to help: and access to it will be based on
need (emphasis added) and need alone - not on your ability to pay, or on who your GP
happens to be or on where you live'. This reinforced commitment is a consequence of
what was believed to be a failure of the internal market in the NHS, which had brought
upon the patients the feeling that their access to NHS services was determined more by
the laws of competition than by the urgency of their conditions (Department of Health,
1997).
The Welsh white paper makes one of its key objectives to 'reduce health variations across
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Wales and tackle inequalities in health and in access to healthcare'. Further on, we read
that 'The NHS should be a service which embodies fairness (emphasis added), efficiency,
effectiveness, responsiveness, accountability, integration and flexibility. Patients should
receive the same level of service and quality of care for the same level of need. As health
needs vary across Wales, so services need to be tailored to local circumstances
(emphasis added) to deliver equity of access and treatment. Responsibility for decision-
taking should be devolved as close to patients as possible to encourage responsiveness and
innovation in service. Devolution of responsibility must be matched by mechanisms for
accountability and control'.
The Scottish white paper reads similarly, where it states that 'The Government will
ensure that the NHS remains true to its historic ideals, free at the point of use, funded
through general taxation and available on the basis of need'. Further, in the white paper it is
stated 'The Government believe the proposal in this Paper will result in an NHS in
Scotland designed to put patients first, better equipped to take advantage of new
technology to improve clinical effectiveness and the reliability of clinical care, and better
able to develop distinctive solutions to Scotland's health needs (emphasis added) and
to provide better value for money. It will keep faith to its founding ideals by delivering
comprehensive services to promote good health, rapid diagnosis and treatment for those
who are ill, and care for those with continuing needs, and it will be funded through
general taxation so that nobody need worry about the cost of being ill' .
Although it clearly appears that England, Wales and Scotland are all firmly committed to
the founding principle of the NHS when it was first created in the United Kingdom,
devolution allows each country to apply their own interpretation of local needs and
preferences within the overarching principle that ''need and not ability to pay" should
determine the access to healthcare resources.
3.3 Operationalising the concept of equity in the National
Health System
The concept of equity lends itself to various interpretations, Mooney points out (1987)
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equity in health is 'a value laden concept which has no uniquely correct definition'. He
identifies seven alternative ways of defining equity in healthcare: 1) equality of
healthcare expenditure per capita, 2) equality of inputs per capita, 3) equality of input
for equal need, 4) equality of access for equal need, 5) equality of utilisation for equal
need, 6) equality of marginal met need and 7) equality of health.
These different definitions of equity in healthcare have subsequently been studied and
debated in theoretical health economic literature, with a fundamental division between
some who argue that the intended aim of a national health system, as appears in many
policy statements, is to achieve equity of access to health care services; and others who
maintain that it is on utilisation of health care that studies on equity should be focussed
(Le Grand, 1982; Mooney, 1983; Mooney et al., 1991, 1992; Culyer et al., 1992a and
1992b)
The pursuit of either of these two concepts is firmly grounded in the Aristotelian principle
of 'horizontal equity', that requires the 'equal treatment of equals'. This principle is met
when individuals who are similar with respect to a given set of characteristics are treated
in exactly the same way. Translated to health and healthcare, the principle reads as the
'equal treatment of equal need'.
The concept of need, similarly to the concept of equity, can have several interpretations.
Culyer and Wagstaff (1993) offer four alternative formulations. The first defines 'need'
as an increasing function of the degree of ill-health of an individual; hence, individuals
who suffer from the highest degree of ill-health are regarded as those to have the greatest
need. The second formulation, defines 'need' as related to an individual's capacity to
benefit from a particular treatment; consequently, individuals with the greatest capacity
to benefit are identified as those with the greatest need. The third and fourth definitions
of 'need' presented by Culyer and Wagstaff (1993) focus on the amount of health
spending society reckons an individual 'ought' to have or the amount of healthcare
expenditure that is necessary to reduce an individual's capacity to benefit from further
healthcare spending to zero.
However, and leaving the theoretical debate on the preferred formulation of need aside, we
have to recognise that in much of the empirical research on equity in health and healthcare,
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need is often simply proxied by (a set of) health status variables.
In this part, we analyse the equal utilisation by individuals in equal need. In particular, we
will investigate whether income-related inequity in the delivery of healthcare occurs
within and across England, Wales and Scotland. The ultimate aim remains to establish
the impact of devolution on income-related equality in health and income-related equity
in health care utilisation.
3.4 Methodology
The concentration index (Cl) provides a measure of inequality for a specific variable, for
example health, with respect to a specified socio-economic status, such as income,
occupation, etc. (Wagstaff et al. (1991, 2000). The Cl is analogous to the Gini coefficient,
which is commonly used as a measure of income inequality. Similar to the Gini
Coefficient based on the Lorenz curve, the concentration index is based on the so called
concentration curve, L(s). Applied to healthcare, this graphs on the x-axis the cumulative
proportion (or percentage) of individuals (or groups) ranked by economic status, starting
from the least well-off. On the y-axis the cumulative proportion (or percentage) of the
population in health (population use of healthcare services) is plotted in correspondence
to each cumulative proportion of the distribution of the economic status variable. The
degree of inequality is captured by the vertical distance between the concentration curve
and the line of equality. The latter is represented by the 45 degree line, which runs from
the bottom-left corner to the top-right corner (see Figure 3-1).
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Figure 3-1: Concentration Curve for ill-health
The concentration index is equal to twice the area between the concentration curve and
the line of equality. Formally, the index is defined as:
C = 1- 2£ L" (p }ip
and is bounded between -1 and 1 (World Bank, 2008).
In the case of no income-related inequality the value of the concentration index is equal to
zero. There are a number of special cases leading to the following values of the Cl:
(1) the Cl is equal to zero. In this case, we may well have a situation where the
distribution of the health variable or the healthcare utilisation variable is equally
distributed among all individuals ranked by income or income groups (or any other socio-
economic variable against which we are measuring the inequality). It is worth noting,
however, that a value of zero for the concentration index does not necessarily imply that
the variable with regard to which the income-related inequality is measured is equally
distributed across the population. A zero value may arise because the inequalities
favouring the most advantaged individuals are exactly off-set by the inequalities favouring
the least advantaged individuals. This situation occurs when the concentration curve
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crosses the diagonal and the two areas between the concentration curve and the diagonal
before and after the point of intersection are exactly the same.
(2) the Cl is equal to 1 (-1). This corresponds to a situation where all the health65 is
concentrated in the hands of the least (most) disadvantaged individuals (or groups).
(3) the Cl takes values between -1 and 1. The concentration takes a negative value when the
curve lies above the line, this means that income-related inequality in the variable under
investigation is favouring the worst off, a positive value of the concentration index occurs
when the curve lies below the line of equality, meaning that income-related inequality is
favouring the better off. In the case that the variable under investigation is a "bad", that is
ill-health (as depicted in Figure 3-1), then negative values of the concentration index are
associated with pro-rich inequalities and positive values are associated with pro-poor
inequalities. The further away the concentration curve lies from the line of equality, the
larger the degree of inequality.
The concentration curve can be used as a means to compare income-related inequalities in
health and income-related inequities in healthcare utilisation (see van Doorslaer et al.,
1997) across several countries and within the same country but across time. In order to be
able to rank the distribution of health (or healthcare utilisation) of country A as strictly
more equitable than that of country B, it is important that the concentration curve of the
former lies everywhere closer to the line of equality than that of country B. When the
two curves cross it is not possible to state which country has less or more inequality in the
health variable in question, unless one makes further assumptions and/or value judgements
about the inequalities experienced by different sub-groups of the population. The same
holds when making comparisons through time for the same country.
In this paper, we are interested in assessing whether the distribution of health and healthcare
utilisation has been affected by the recent devolution of the NHS in Great Britain (Le.
excluding Northern Ireland). The distribution of health and healthcare utilisation will be
measured by means of the concentration index described above. In particular, because we
decided to carry out the analysis by grouping individuals into income quintiles, the
following formula'" is used to compute the concentration index.
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where Pi is the cumulative percent of the sample ranked by economic status and L(s) is the
corresponding concentration curve ordinate, and i is the number of income groups, with
i=5.
The Cl allows us to measure the extent of inequalities in health and inequities in health care
utilisation that are directly linked to income. However, as it is very likely that both age
and gender are related to income, the reporting of health and healthcare utilisation, it is
also necessary to age-sex standardise our data. This allows for the fact, for instance, that
elderly people are more likely to report both worse health and lower levels of income. To
address this, we follow the direct age-sex standardisation approach outlined in O'Donnell
and Propper (1991).
In the case of the "health" measures, the formula used is the following
(2) std_health; =LL bij/c . (n;Xnj/c)
j k nijk N
where bijk = number of individuals reporting morbidity in the ith income group, jth age
group and sex k;
nijk = number of individuals in the ith income group,jth age group and sex k;
n, = number of individuals in the ith income group;
njk = number of individuals in the jth age group and sex k;
and N = total number of individuals in the sample.
bij';nijk measures the actual proportion of individuals reporting morbidity in each income
group, by age group and sex. This is then weighted by the proportion of individuals in
the whole sample that belong to the same income group, age group and sex. Thus, the
standardisation formula allows the calculation of the number of individuals in each
income group who would report morbidity if that income group had the same age-sex
distribution as the whole sample.
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In the case of the healthcare utilisation measures, the age-sex standardisation procedure
extends formula (2) to incorporate adjustment for utilisation according to morbidity
status:
~~ a "k n"k(3) std _ health _ use mi = 4. 4. _!!!!!_ . _!!J!__
j k nijk Nm
where amijk = healthcare use by individuals in morbidity group m, income group i, age
group j , and sex k;
nmijk = number of individuals in morbidity group m, income group i, age group j , and
sex k;
nmjk = number of individuals in morbidity group m, age group j and sex k; and
Nm = total number of individuals in morbidity group m.
amijk!'nijk measures the actual proportion of healthcare use by individuals who are ill, for
each income group, age group and sex. This figure is then multiplied by the proportion of
all individuals who report morbidity in each age group and for each sex. In this way we are
able to calculate for each income group the average utilisation of healthcare resources that
would be made by each income group, if that group had the same age-sex distribution as the
whole morbidity group. We use as the reference for the age-sex standardisation not the
whole sample but the morbidity group, because the aim is to analyse "equal treatment for
equal need", and need is proxied here by a self-assessed measure of health.
We also compute a standard error for the concentration index with grouped data
following a formula given in Kakwani et al. (1997). We follow the steps set out in
'Quantitative Techniques for Health Equity Analysis - Technical Note #7' (World
Bank, 2004). We denote with n denote the sample size, Tthe number of groups, J;
the proportion of the sample size in the t-th group, 11, the mean value of the health
variable amongst the t-th group, and Cl the concentration index. R, is the
fractional of the t-th group, and is defined as
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This indicates the cumulative proportion of the population up to the midpoint of
each group interval.
The variance of the concentration index is given by eq (14) in Kakwani et al.
(1997):
(3) var(Cl)=.!.r~T_ !,a: -(I+CI)2 ]+_!_2 ~T_ !,a/(2R
I
-I-CI)2n ILl-I nJ1 £'1-1
Where 0"12 is the variance of the health variable in the z-th group and zz, is its mean,
a = J11 (2R -1-Cl)+2-q -q
I J1 I I-I I
1 ~I
q I = J1 £'y=1 J1yfy
Which is the ordinate of L(p), qo = 0 , and PI = L~=I fyRy .
As variances of the group means are unknown, the second term in equation (3) can
be assumed to be equal to zero and the n is replaced by T in the denominator.
Substituting the value of the Cl in equation (3), we compute its variance and
finally its t-statistics.
3.5 Data and variables
Weare interested in both cross-country comparisons for any given year, and cross year
comparisons for any given country.As the devolutionof the NHS was introduced in 1998,
we analyse two years' worth of data: selecting two years temporally equidistant from the
year that devolution took place (1995/96 and 2001/02).
The General Household Survey (GHS) is a large scale multipurpose survey of individuals
and households and it has been conducted in Great Britain annually since 197167• The
OHS contains several microdata on a range of core topics, such as household and family
information, consumer durables, employment, and education. It also includes microdata
on individuals' healthcare utilisation, self-assessed health (morbidity) and family
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Income.
Table 3-3 shows original and cleaned sample sizes of the General Household Surveys for
the years under consideration.
Table 3-3: General household Survey. sample size
GHS
Country 1995/96 2001/02
Original Cleaned Original Cleaned
England 19,928 12,779 18,341 15,732
Wales 1,195 671 1,063 873
Scotland 2,075 1,338 1,770 1,522
Great Britain 23.198 14,788 21,180 18,127
We deleted from our samples in each year individuals who did not answer any of the
questions about their own health, their healthcare utilisation and income. Also, we
dropped from our samples individuals whose reported income is equal to zero.
3.5.1 Health variables
Health variables are used as proxies for need. Different ways of measuring health have
been utilised by health researchers in their studies. Usually, they are either a measure of
mortality or a measure of morbidity. In this paper, we concentrate on morbidity
measures only, as is the case of many recent studies (Contoyannis and Jones, 2004; van
Doorslaer and KooIman, 2002).
The General Household Survey contains an Adult Health section", in which individuals
are invited to answer questions relating to their health. This section provides sufficient
information to construct various measures of health.
We concentrate on three different measures of health, which we call health state
(hstate), health status (hstatus) and self-assessed health (sah). All three measures of health
are self-assessed, in the sense that individuals surveyed answer personally to questions
relating to their general health. The GHS does not include objective measures of health,
such as body weight or body mass index. The assumption supporting the use of these
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measures of health is that individuals are, in general, believed to be able to assess and
evaluate their own health'".
The health state variable captures an individual's health relative to a period of time close
to the date of the interview. In the GHS, individuals were asked whether they had to
reduce their usual activity because of injury or illness in the two week period preceding
the interview. The health status variable captures the existence of a long-standing illness,
disability or infirmity of an individual. Both these measures of health are recorded with
yes/no answers and hence are straightforwardly employable in our analysis as binary
variables.
A more comprehensive measure of health is obtained by asking individuals to rate their
overall health over the last twelve months; we call this variable self-assessed health or
sah. Individuals are asked to rate their general health as either 'good', 'fairly good' or
'not good'. This measure of self-assessed health is the most frequently used in econometric
studies. In order to estimate inequalities in health, it is necessary to transform this
variable in either a dichotomous or continuous one. Following O'Donnell and Propper
« 1991), we created a dichotomous variable grouping together individuals that responded
that their overall health was either 'good' or 'fairly good'. We concentrate on those
individuals that report 'not good' health.
3.5.2 Healthcare utilisation variables
The General Household Survey allows one to construct three measures of healthcare
utilisation: inpatient stays, outpatient visits, and General Practitioner (GP) consultations.
The first two measures correspond to the use of NHS secondary care resources and the
last one refers to the use of NHS primary care resources. As our interest is in assessing
the utilisation of these resources by individuals who are in "need" of them, we consider
only the number of inpatient stays, outpatient visits and GP consultations received by
individuals who report some form of morbidity.
The measurement of inpatient stays, excluding maternity stays, is based on the questions:
"During the last year, that is, since (DATE 1 YEAR AGO), have you been in hospital as
an inpatient, overnight or longer?" and "(Apart from those maternity stays) how many
156
separate stays in hospital as an inpatient have you had since (DATE 1 YEAR AGO)?".
The first question allows one to determine whether the individual has had any inpatient
stay over the twelve month period in question. And if so, the second question allows one to
determine the number of inpatient stays an individual had, except those that one may have
had to have a baby.
Outpatient visits are measured based on the questions "During the months of (LAST 3
COMPLETE CALENDAR MONTHS) did you attend as a patient the casualty or
outpatient department of a hospital (apart from straightforward ante- or post-natal
visit)?" and "How many times do you attend in (EARLIEST/SECOND/THIRD
MONTH IN REFERENCE PERIOD)?". The GHS includes a variable created from the
questionnaire which scales answers up to cover a twelve month period prior to the
interview and we use this estimated measure of outpatient visits in our analysis.
The measurement of GP consultations is based primarily on the question "During the 2
weeks ending yesterday, apart from any visit to a hospital, did you talk to a doctor for
any reason at all, either in person or by telephone?". Further questions are then asked to
allow identifying the total number of consultations an individual had with an NHS GP.
3.5.3 Income
Income is measured using the gross family income variable recorded in the General
Household Survey. This variable measures income before taxes and deductions take place. In
the GHS, the family unit is defined as either of the following: (i) a married couple on their
own, or (ii) a married couple/lone parent and their never married children provided these
children have no children of their own.
In order to take account of differences in both the size and composition of families, we
transform gross family income into equivalent family income. The disposable income of
a family of four individuals cannot, otherwise, be compared with that of a single
individual. The equivalence scale used is the modified OECD scale:
(4) . I fi ./ . incomeequlva ent amI Y Income = ---,..---------- .....-----:-
1+O.5(household size -1- child )+O.3(child)
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This equivalence scale assigns a weight of 1 to the first adult member of the family, and
a weight of 0.5 to all subsequent adult members of the family. Children receive a weight
of 0.3 each. The reference family is composed of one adult with no children. A family
composed of two adults and two children will need, accordingly to the formula depicted
above, an income 2.1 times greater than that of a single person family to have an
equivalent family income.
Compared to the original OECD equivalence scale, which assigned a weight of 0.7 to each
subsequent adult member of the family and a weight of 0.5 to children, the modified scale
takes into account the economies of scale that larger families benefit from. The modified
OECD equivalence scale is the most widely used to equivalise income. Other scales do,
however, exist and are employed in the literature. Wagstaff et al. (2001) and van Doorslaer
and Jones (2003) use, for example, the square root of the household size; Gravelle and
Sutton (2003) use the square root of the sum of the number of adults with a weight of one
and the number of children, which are given a weight of 0.5. The superiority of one
particular income equivalising procedure/method has not yet been established.
3.6 Descriptive statistics
In this section, we present some summary statistics on the variables of interest to our
analysis by country.
Table 3-4 provides the percentages of adults that report acute sickness, long-standing
illness or 'not good health', for both 1995-96 and 2001-02.
Table 3-4: Distribudon of morbidity by country, in percentage terms
Percentage of adults reporting
Country acute sickness long-standing illness 'not good health'
1995196 2001102 1995/96 2001102 1995196 2001102
England 15.06 14.74 35.21 36.32 12.93 13.51
Wales 19.08 20.3 39.49 42.58 17.73 16.06
Scotland 16.07 15.85 36.55 35.65 14.13 13.88
Scotland is the only country for which the percentage of adults reporting any of the
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three morbidities has decreased over time, suggesting a move towards a healthier nation.
The situation in England and Wales is slightly different. England registers an
improvement only in the percentage of individuals reporting acute sickness, whereas in
Wales only the percentages of individuals reporting 'not good health' has decreased from
1995/96 to 2001/02.
Table 3-5 presents the summary of the distribution of health care utilisation by country. The
use of health care services, be it either in the form of a GP consultation, an inpatient stay or
an outpatient visit, has decreased in both Scotland and Wales in 2001102. In Scotland this
might be related to the improvement in health, but this explanation cannot be applied in
Wales. The English sampled population seems to have made less use of both GP
consultations and inpatient stays in 2001/02 compared to 1995/96. The opposite is true for
outpatient visits.
Table 3-5: Distribution of health care use by country, in percentage terms
Percentage of adults reporting to have had
Country GP consultations Inpatient stays Outpatient visits
1995/96 2001102 1995/96 2001102 1995/96 2001102
England 15.86 14.35 9.73 7.53 15.64 16.07
Wales 18.93 15.00 11.77 9.7 18.78 15.61
Scotland 18.16 16.91 12.33 8.87 14.78 14.37
If we compare across countries, no clear-cut pattern of utilisation appears. Wales
generally is the country with the highest percentage of individuals reporting to make use of
hea1thcare resources, in both 1995/96 and 2001/02, followed by Scotland and at last
England. However, this pattern does not hold across all measures of utilisation.
The basic statistics presented here provide us with an overall picture of the sampled
population in terms of their self-assessed health and in terms of the use of both primary
and secondary NHS healthcare resources. They do not tell us whether both (ill-) health
and healthcare resources are distributed in each population equitably, with respect to
income. This analysis is carried out in the following two sections.
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3.7 Inequalities in (ill-) health
We explore in this section the distribution of self-reported health in England, Wales and
Scotland. The analysis is carried out for all three measures of health presented in Section
3.5. This analysis will allow us to set the background on each country's level of ill-health
and its distribution with respect to income and over time.
The first two tables summarise the number of individuals in each income group reporting
morbidity as a percentage of all individuals reporting morbidity, respectively in 1995/96
and 2001102 for the whole of Great Britain. The picture that emerges does not show any
clear pattern in the distribution of any of the health measures in the population, once this
is ranked by income. As we are interested in the income-related distribution of (ill-)
health within each single country and across countries, we will not analyse the situation
for Great Britain in greater detail. However, two points are worth making. Firstly, it
appears that the percentage of individuals reporting 'not good' health is three times
higher in the bottom income quintile compared to the top one, in 1995/96; and this result
becomes even bigger in 2001102 (see Tables 3-6 and 3-7, respectively), where the
percentage of individuals reporting 'not good' health has not only increased in the lowest
income group, but compared to the highest income group it is almost four times higher in
the later period. Secondly, the number of individuals in the lowest income quintile
reporting any of the three measures of morbidity has increased in 2001102 compared to
1995/96. However, and interestingly, the opposite situation occurs for individuals
belonging to the upper income quintile.
Table 3-6: Actual and age-sex standardised percentages of aU adults reporting morbidity and
relative Concentration Inde!z Great Britain - GUS 1995/96
Acute sickness Long-standing 'Not good' health
Income group (hstate) illness (hstQtus) (sah)
Actual%
Age-sex
Actual%
Age-sex
Actual %
Age-sex
sland% stand % stand%
Poorest 1 21.9 22.3 22.6 22.3 29.5 30.1
2 26.2 24.3 27.1 24.2 32.S 29.3
3 17.5 17.6 IS.7 IS.9 17.0 16.S
4 16.S 17.3 16.0 17.3 11.4 12.5
Richest 5 17.5 18.5 15.6 17.3 9.3 11.2
Cl -0.094 -0.080 -0.121 -0.089 -0.268 -0.239
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Table 3-7: Actual and age-sex standardised percentages of all adults reporting morbidity and
relative Concentration Index! Great Britain - GHS 2001102
Acute sickness Long-standing 'Not good' health
Income group (hstate) nlness (hstatus) (sab)
Actual %
Age-sex
Actual %
Age-sex Actual %
Age-sex
stand% stand % stand %
Poorest 1 25.2 26.7 23.6 24.2 30.5 32.6
2 25.5 22.6 26.4 22.7 31.7 27.2
3 16.7 17.0 19.2 19.7 17.0 17.6
4 17.0 18.0 16.4 18.0 12.7 14.1
Richest 5 15.7 15.7 14.4 15.4 8.1 8.5
Cl -0.112 -0.109 -0.116 -0.092 -0.257 -0.247
Actual numbers of individual reporting any of the three measures of ill-health by
income group for the two years studied can be found in Appendix 3-A.
In the remainder of this section, we will analyse the results in income-related inequality in
each of the three morbidity measures separately. Our primary objective is to elicit whether
any changes in the distribution of morbidity have occurred after decentralisation was
implemented inGreat Britain for England, Wales and Scotland. There is an expectation
formed on the basis of the existing economic literature (see Section 3.2.1), that policy
makers may use information available at local level to tailor their public policies, both in
terms of public health and provision of healthcare services, to address local variations in
need. And that this may ultimately lead to improvements in the distribution of morbidity.
The distribution of morbidity across income groups is assessed by means of a
concentration index and concentration curves. However, it is possible to elicit interesting
results by looking at the percentage of individuals in each income group reporting an
illness, however defined, and comparing it with their share of income in the population.
We followed both approaches for completeness of analysis. We present here only the
results relating to the concentration indices. The percentages of individuals reporting
morbidity by income groups for England, Wales and Scotland can be found in Appendix
3-A.
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3.7.1 Income-related inequalities in the reporting of acute sickness
The variable 'acute sickness', as described earlier, measures the level of health of an
individual at a certain point in time. Hence, this measure reflects to a lesser extent the
working of the National Health Services locally.
Table 3-8 shows the concentration indices (Cl) for the distribution of acute sickness by
country and year. The results suggest the existence of income-related inequality in the
distribution of acute sickness favouring the better off. The inequality is, however, very
small. The age-sex standardisation has the effect, as expected, to reduce the degree of the
inequality in each constituent country of Great Britain.
Table 3-8: CIs for income-related inequality in the reporting of acute sickness
- England, Wales and Scotland, 1995/96 and 2001/02
1995/96 2001102
Actual %
Age-sex
Actual %
Age-sex
stand% stand%
England -0.089 -0.073 -0.108 -0.105
Wales -0.149 -0.135 -0.110 -0.059
Scotland -0.109 -0.099 -0.147 -0.166
In 1995/96, Wales is the country for which the income-related inequality in acute
sickness is most prominent, with an age-sex standardised Cl almost twice that for
England, whilst Scotland lies somewhere in between the other two countries. In 2001/02,
the Cl for Wales is more than halved. It is worth noting, however, that the reduction in
the degree of inequality in Wales is partly attributable to an increase in the reporting of
acute sickness by individuals belonging to the top two income quintiles, rather than by an
overall improvement in the distribution of sickness in the population (see Tables 3-A.2
and 3-A.3 in Appendix 3-A).
Figure 3-2 provides a graphical representation of how the CIs for the three countries
have changed over time, by means of concentration curves. It appears clearly that the
distribution of acute sickness in the three countries has been affected differently. England
and Scotland both experience an increase in the income-related inequality in acute sickness
as measured by their respective CIs, and as indicated by their concentration curves for
2001102 lying everywhere above those for 1995/96; hence, making the distribution of
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acute sickness in these two countries less equitable in 2001/02 compared to 1995/96.
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Figure 3-2: Concentration curves for the reporting of acute sickness in England, Wales and
Scotland, 1995/96 and 2001102
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Figure 3-3 shows the concentration curves for the three countries, for 1995-96 and 2001-02.
It is impossible to conclude which distribution of acute sickness is more equitable, as the
concentration curves cross, in some cases more than once. However, it is possible to draw
partial conclusions.
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Figure 3-3: Cross-country comparisons for CIs for the reporting of acute sickness
In 1995/96, the concentration curves show that adults belonging to the lowest income
group are better off in Scotland than they are in England and Wales. Adults belonging to
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the highest income group are better off in England than they are in any of the other two
countries. In2001102 the concentration curve for Scotland appears to lie everywhere above
the ones for England and Wales. This suggests that the income-related distribution of acute
sickness in more inequitable in Scotland than anywhere else.
3. 7.2 Income-related inequalities in the reporting of long-standing illness
Long-standing illness captures a different aspect of a population's health. It represents,
in effect, a measure of the existence and persistence of a continuous illness/disease in a
given population, whereas acute sickness captures a snapshot of an individual's health. As the
existence of a long-standing illness is very likely to be associated with a restricted ability to
carry out a job, we expect a high degree of income-related inequality with respect to this
measure ofill-health.
The concentration indices for long-standing illness for England, Wales and Scotland are
shown in Table 3-9.
Table 3-9: Cis for income-related inequality in the reporting of long-standing illness
- England, Wales and Scotland, 1995/96 and 2001/02
1995/96 2001/02
o Age-sex Actual %
Age-sex
Actual % d% stand%stan 0
England -0.118 -0.084 -0.112 -0.087
Wales -0.157 -0.123 -0.109 -0.056
Scotland -0.132 -0.108 -0.160 -0.165
As for the previous measure, the CIs for long-standing illness show the existence of
income-related inequality favouring the better off in each country and in both time
periods. The age-sex standardized figures are, as expected, smaller. Wales has the highest
income-related inequality in reported long-standing illness in 1995/96. The situation
changes dramatically in 2001/02, when the age-standardised Cl for Wales is more than
halved. Nevertheless, the huge decrease is partly attributable, as it was the case for acute
sickness, to a substantial increase in the numbers of individuals with long-standing
illnesses belonging to the highest and third-highest income quintiles (see Tables 3-A.4
and 3-A.5 in Appendix 3-A). An opposite pattern emerges for both England and
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Scotland, both experiencing a small increase in income-related inequality. The situation
for England changes so slightly, as to be almost unnoticeable (see Figure 3-4).
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Figure 3-4: Concentration curves for the reporting of long-standing illness in England, Wales and
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Figure 3-5 shows the concentration curves for long-standing illness for all countries,
separately for 1995/96 and 2001/02.
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Figure 3-5: Cross-country comparisons for CIs for the reporting of long-standing illness
As the concentration curve for England lies everywhere below that for Scotland and
Wales and closer to the line of equality in 1995/96, it is possible to state that the
income-related distribution of long-standing illness was more equitable in England
compared to Scotland and Wales in this particular year. The situation is not so clear cut
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when comparing the remaining two countries. In 2001102, the cross-country comparison
becomes much clearer. Scotland's concentration curve is the furthest away from the line of
equality and lies everywhere above the concentration curves for England and Wales,
making it the country with the least equitable income-related distribution in reported
long-standing illness. We can draw only partial conclusions when comparing England and
Wales. In particular, we can only state that the individuals belonging to the bottom two
income groups are better off in Wales than they are in England.
3.7.3 Income-related inequalities in the reporting of 'not good health
Table 3-10 shows the concentration indices for income-related inequality in the reporting
of 'not good' health. These are considerably higher than that for the other two health
measures. One reason behind this result may be that individuals when asked to assess
their own health take into account not only their physical health but their overall well-
being, which for example can stretch out as far as including more general aspects of
quality oflife.
Wales is the country where the distribution of 'not good' health in the adult population
is the most unequal in 1995/96. The situation is reversed in 2001/02 with the highest
improvement in inequality attained in Wales, whose Cl falls by almost 0.1. The
concentration indices for England and Scotland, in contrast, become larger in 2001/02.
The more unequal distribution is mainly due to increases in the number of individuals
reporting 'not good' health in the lowest income quintiles (see Tables 3-A.6 and 3-A.7 in
Appendix 3-A).
Table 3-10: CIs for income-related inequality in the reporting of 'not good' health
- England, Wales and Scotland, 1995/96 and 2001102
1995/96 2001/02
Actual% Age-sex Actual %
Age-sex
stand% stand%
England -0.265 -0.233 -0.256 -0.247
Wales -0.289 -0.286 -0.244 -0.198
Scotland -0.266 -0.247 -0.270 -0.271
These changes in the concentration indices are shown in Figure 3-6 for each country and
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for the two years under investigation by means of concentration curves.
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Figure 3-7 shows cross-country compansons of the concentration curves for the
reporting of 'not good' health. In 1995/96, the concentration curve for Wales is the
farthest away from the line of equality, thus suggesting that the distribution of
individuals reporting 'not good' health is the least equitable in this country as far as the
upper income groups are concerned. The concentration curves on the bottom end of the
income distribution is not so clear cut.
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Figure 3-7: Cross-country comparisons for CIs for the reporting of 'not good' health
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In 2001/02, Wales has the most equitable distribution of the three countries, although
the income-related inequality in this measure of morbidity is still favouring the better
off. That said, there appears to be considerable income-related inequity with this
measure.
3.7.4 Conclusions
Our results highlight the existence of a certain degree of income-related inequality in all
three measures of morbidity favouring the better off. This holds for every country.
However, the magnitude of this inequality varies across countries, with England, in the
pre-devolution year, scoring a smaller income-related inequality measure compared to
any of the two other countries.
Further, Wales is the country with the highest income-related inequality in the
distribution of ill-health, however measured, in 1995/96. After the devolution reform,
the situation changes completely, with income-related inequality in the distribution of
morbidity worsening in both England and Scotland, whilst improving in Wales.
Although it is not possible to attribute these changes directly to the devolution reform as
other concomitant reforms may have been introduced at the same time, it seems,
however, worth noting that the distribution of morbidity in each constituent country of
Great Britain has changed quite differently in each of them after the devolution of the
governmental function 'health' was introduced.
3.8 Income-related inequities in health care utilisation
Our aim in this section is to establish 1) whether income-related inequity in healthcare
utilisation exists in Great Britain as a whole and how it behaves in each constituent
country and 2) to track possible changes over time within each country and across
countries. The analysis will be carried out for General Practitioner (GP) consultations,
inpatient stays and outpatient visits. The first measure the existence of differentiated use
of the NHS primary care resources, and the last two capture the use of NHS secondary
care resources. As stated elsewhere we are interested in analysing the 'equal treatment
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of equal need', where need is proxied by a morbidity measure.
As appears from the results shown in the previous section, the distributions of morbidity
across income groups for each of the three measures used in this chapter are very
similar. Hence, we will focus in this section on one measure of morbidity only, that is
the one built on individuals reporting 'not good' health, and investigate whether
income-related inequity in healthcare utilisation by individuals who reported not good
health exists. The sensitivity analysis on income-related inequity in healthcare
utilisation using the two remaining measures of morbidity can be found in Appendix 3-
B.
Income-related inequity in healthcare utilisation is assessed by means of a concentration
index. We report also the percentages ofNHS healthcare utilisation by income groups.
3.8.1 General Practitioner (GP) consultations
First, we explore the distribution of GP consultation utilisation across income quintiles
in the whole of Great Britain. Table 3-11 shows the percentage of GP visits (actual and
age-sex standardised) reported by individuals whose health is not good, grouped by
income quintiles.
Table 3-11: Percentages ofGP consultations by individuals reporting 'not good health' by income
groups and relative concentration indices,
Great Britain - 1995/96 and 2001/02
1995/96 2001102
Income group
Age-sex Actual % Age-sexActual %
stand. % stand. %
Poorest 1 29.94 30.22 30.90 29.70
2 30.61 31.56 32.14 33.92
3 17.46 17.53 16.69 15.86
4 12.82 11.70 10.75 11.11
Richest 5 9.17 9.00 9.52 9.40
Concentration Index -0.237 -0.249 -0.259 -0.256
The results show that income-related inequity in healthcare utilisation exists, and that
this is favouring the poorest income groups (as indicated by the negative concentration
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indices). Looking at the percentages of GP visits across income quintiles, we can
conclude that the highest proportion (>60 per cent) of reported GP visits is concentrated
in the bottom two income groups, in both years. Overall, income-related inequity in GP
visits appears to be slightly increasing in 2001/02.
Tables 3-12 and 3-13 show the percentages of primary care consultations by income
groups in England, Wales and Scotland, respectively for 1995/96 and 2001102.
Concentration indices of income-related inequity in GP consultation are also reported.
Also at the country level, concentration indices are negative and favouring the lowest
income groups. The age-sex standardisation of GP consultations has the effect of
increasing the concentration indices for every country. In 1995/96, for example in
Scotland 37.96 per cent of individuals who reported to having had a GP consultation
belonged to the lowest income group.
Table 3-12: Percentages of GP consultations by individuals reporting 'not good' health by and
income group - GHS 1995/96
England Wales Scotland
Income group
Age sex Age sex Age-sex
Actual % - Actual % - Actual %
stand. % stand. % stand. %
Poorest 1 28.86 29.04 33.33 36.64 37.04 37.96
2 32.58 33.50 28.33 26.06 25.93 25.94
3 15.96 15.70 18.33 20.37 18.52 18.56
4 13.03 12.24 6.67 6.31 12.04 11.51
Richest 5 9.57 9.51 13.33 10.62 6.48 6.04
Concentration Index -0.232 -0.241 -0.247 -0.287 -0.300 -0.313
The majority of primary care consultations (>60 per cent) is concentrated amongst the
two lowest income groups. This is in line with evidence suggesting that lower income
groups make proportionally greater use of primary care, even though they are less likely
to engage in health promotion/preventive activities and enjoy lower access to secondary
care (Dixon et al., 2008).
Concentration indices are all negative suggesting pro-poor inequity in GP consultations.
The consistency of the results obtained across countries and years of data suggests the
results are robust. However, t-statistics for all countries are very small and indicate that
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some caution should be exercised when interpreting the inequality measures. See
Appendix 3-B, Table 3-B.l.
Similar conclusions can be drawn for 2001/02 (see Table 3-13).
Table 3-13: Percentages of GP consultations by individuals reporting 'not good' health by and
income Grou!! - GUS 2001/02
England Wales Scotland
Income group
Age-sex Age-sex Age-sex
Actual%
stand. %
Actual %
stand. %
Actual %
stand. %
Poorest 1 31.62 30.57 31.91 28.90 25.49 24.27
2 31.16 32.58 36.17 38.98 35.29 38.52
3 16.49 15.65 14.89 14.20 21.57 20.88
4 10.59 11.14 10.64 10.56 9.80 9.74
Richest 5 10.14 10.07 6.38 7.36 7.84 6.59
Concentration Index -0.256 -0.252 -0.308 -0.288 -0.245 -0.259
Comparing results across the two years by looking at the concentration indices for each
country and in each year, it emerges that inequity in GP consultations slightly increases
in 2001/02 for both England and Wales, whilst a slight reduction is registered for
Scotland. No clear patterns emerge in the way changes in utilisation of primary care
occur amongst income groups; in England, for example, the percentage of GP
consultations reported by individuals belonging to the bottom two income groups
increases in 2001102,and this despite the fact that overall healthcare utilisation is more
favourable to the worst off.
Further, no conclusions can be drawn on cross-country compansons as the
concentration curves for the three countries cross at least once (see Figure 3-B.l ,
Appendix 3-B).
After the decentralisation process, the utilisation of GP consultations is even more
inequitably distributed amongst income groups, with the poorer ones usually reporting
more consultations than the richer counterparts.
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3.8.2 Inpatient stays
Table 3-14 shows the concentration indices and the percentages of inpatients stays
across income groups, both actual and age-sex standardised, for Great Britain as a
whole, and for the two years under investigation.
Table 3-14: Percentages of Inpatient stays by individuals reporting 'not good' health by income
groups and relative concentration indices, Great Britain - 1995/96 and 2001102
1995/96 2001lQ2
Income group
Age-sex Age-sex
Actual % Actual %
stand. % stand. %
Poorest 1 23.76 23.77 24.28 23.09
2 33.44 34.13 36.35 36.46
3 20.68 20.82 16.86 16.58
4 11.44 9.67 13.08 14.41
Richest 5 10.67 11.60 9.43 9.47
Concentration Index -0.193 -0.195 -0.211 -0.197
Inpatient stays are still inequitably distributed across income groups, with poorer
income groups reporting a greater use of inpatient stays. The overall degree of income-
related inequity, as measured by the concentration index, is less prominent for this
healthcare service than it was for GP visits. A very marginal increase in income-related
inequity is registered in 2001/02. Also for the concentration indices for inpatient stays,
the t-statistics produced are very small, both for the ones for Great Britain as a whole
and the one for single countries (see Table 3-B.2). Thus, suggesting that caution should
be used in interpreting the results.
A quite different story appears when looking at the distribution of reported inpatient
stays by country (see Tables 3-15 and 3-16). The concentration indices for England, in
both years, are most similar to the one reported for the whole of Great Britain, whilst
the results for Wales and Scotland are somewhat diverse. The income-related
distribution for inpatient stays appears to be quite equitable in Scotland, after
standardising reported inpatient stays by age and sex. The percentages of total inpatients
stays reported by income groups 1, 2 and 4 are, in fact, very similar. However, the
percentage of reported inpatient stays of the richest income group is very small. The
situation in 2001102 does not appear to be changing very much when looking at the
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concentration index. It is, however, noticeable from the distribution of inpatients stays
by income groups that these are now more concentrated in the income groups 2 and 3.
The percentage of inpatient stays reported by the bottom income group is now smaller
than their income share. This becomes even more apparent when looking at the
concentration curve (see Figure 3-8.2, in Appendix 3-B).
The picture that emerges for Wales is very peculiar: 59.38 per cent of total reported
inpatient stays is concentrated in the penultimate income groUp.70This figures increases
to 62.35 per cent after taking into account the age and sex structure of the population.
Further, it is worth noting that the poorest income group reports a percentage of
inpatient stays smaller than their actual income share, an indication of the existence of
income-related inequity at the poorest end of the income distribution. In 2001/02,
however, the situation changes completely with income-related inequity in inpatient
stays decreasing (see Table 3-16).
Table 3-15: Percentages of Inpatient stays by individuals reporting 'not good' health by and income
group - GUS 1995/96
England Wales Scotland
Income group
Actual % Age-sex Actual % Age-sex Actual % Age-sex
stand. % stand. % stand. %
Poorest 1 23.85 23.17 17.71 19.07 27.03 27.24
2 33.75 35.20 59.38 62.35 30.63 27.34
3 21.20 20.78 10.42 9.67 13.51 13.47
4 10.04 8.46 4.17 2.78 21.62 25.86
Richest 5 11.16 12.40 8.33 6.13 7.21 6.09
Concentration Index -0.196 -0.193 -0.296 -0.342 -0.194 -0.175
Table 3-16: Percentages of Inpatient stays by individuals reporting 'not good' health by and income
group - GHS 2001/02
England Wales Scotland
Income group
Age-sex Age-sex Age-sex
Actual%
stand. %
Actual %
stand. %
Actual%
stand. %
Poorest 1 25.33 24.32 21.95 20.60 16.47 15.43
2 34.32 34.95 39.02 39.93 42.35 38.65
3 16.35 15.82 24.39 24.98 24.71 26.07
4 13.40 14.38 7.32 9.61 11.76 14.54
Richest 5 10.60 10.54 7.32 4.88 4.71 5.31
Concentration Index -0.201 -0.192 -0.244 -0.247 -0.216 -0.177
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It is not possible to draw any general conclusion on which country has the highest level
of inequity as the concentration curves underlying the concentration indices for the three
countries cross at least once (see Appendix 3-B).
3.8.3 Outpatient visits
The last measure of healthcare utilisation investigated is outpatient visits. Table 3-17
shows the concentration indices and percentages of reported outpatient visits by income
groups for the whole of Great Britain.
Table 3-17: Percentages of Outpatient visits by individuals reporting 'not good' health by ncome
groups and relative concentration indices, Great Britain - 1995/96 and 2001/02
1995/96 2001102
Income group
Actual % Age-sex Actual % Age-sex
stand. % stand. %
Poorest 1 25.99 25.38 28.07 27.65
2 3l.07 34.29 33.09 32.25
3 19.22 19.44 14.92 15.00
4 13.83 10.62 15.51 14.25
Richest 5 9.89 10.26 8.41 10.85
Concentration Index -0.198 -0.215 -0.228 -0.206
As indicated by the negative CIs, income-related inequity exists and this is favouring
the lowest income groups.
Tables 3-18 and 3-19 show the same results but disaggregated by country, respectively
for 1995/96 and 2001/02. The concentration indices are still negative in all three
countries. In 1995/96, the majority (>60 per cent) of total outpatient visits in England
and Wales are reported by individuals belonging to the bottom two income quintiles (in
Wales, 47 per cent of outpatient visits are made by the second income quintile alone).
Scotland is the only exception; the bottom two income groups partake to about 40 per
cent of total outpatient visit (non standardised percentage), these being concentrated in
the third and penultimate income group (about 50 per cent).
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Table 3-18: Percentages of Outpatient visits by individuals reporting 'not good' health by and
income grou(! - GHS 1995/96
England Wales Scotland
Income group
Age-sex Age-sex Age-sex
Actual %
stand. %
Actual %
stand. %
Actual %
stand. %
Poorest 1 26.93 25.14 18.24 19.91 25.50 29.82
2 33.54 38.25 49.32 47.02 12.75 14.42
3 16.35 16.02 16.89 18.96 28.29 28.95
4 12.28 9.48 9.46 9.07 26.29 19.73
Richest 5 10.90 11.11 6.08 5.04 7.17 7.09
Concentration Index -0.113 -0.227 -0.257 -0.271 -0.092 -0.160
The results for 2001/02 changes considerably. All countries show still negative
concentration indices, with England recording a very slight improvement. Wales and
Scotland both experience an increase in income-related inequity in outpatient visits (see
Table 3-19).
Table 3-19: Percentages of Outpatient visits by individuals reporting 'not good' health by and
income grou(! - GHS 2001/02
England Wales Scotland
Income group
Actual % Age-sex Actual % Age-sex Actual % Age-sex
stand. % stand. % stand. %
Poorest 1 25.90 25.71 38.57 37.48 27.13 29.02
2 36.39 34.98 34.29 31.63 31.78 29.70
3 15.02 15.01 17.14 18.08 19.38 21.63
4 14.43 13.10 6.43 10.32 9.30 9.81
Richest 5 8.27 11.19 3.57 2.48 12.40 9.84
Concentration Index -0.229 -0.204 -0.391 -0.365 -0.208 -0.233
Similarly to the results obtained for the concentration indices for GP consultations and
inpatient stays, results across countries and years of data are consistent suggesting that
they are robust. However, as before t-statistics for the concentration indices for
outpatient visits are all very small, and therefore need to be interpreted with caution (as
reported in Table 3-B.3 in Appendix 3-B).
Further, it is not possible to compare more meaningfully the results obtained for
outpatient visits across countries as the concentration curves for outpatient visits of each
country cross at least once (see Appendix 3-B).
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3.8.4 Conclusions
The utilisation of healthcare services - GP consultations, inpatient stays and outpatient
visits - is inequitably distributed in all three countries and favouring the lowest income
groups. Further, the degree of these inequities varies with type of NHS care, with GP
consultations having the largest negative concentration index in each country. My
results are in line with evidence suggesting that lower income groups make
proportionally greater use of primary care, even though they are less likely to engage in
health promotion/preventive activities and enjoy lower access to secondary care (Dixon
et al., 2006).
England, Wales and Scotland follow very different pattern of healthcare utilisation, both
in 1995/96 and 2001102.This is an indication that NHS services were already allocated
to individuals in each country following different priority criteria. One of the
advantages that may accrue The economic theory on decentralisation suggests that
income-related inequity in healthcare utilisation should be positively affected by a
policy of decentralisation of the healthcare sector; however, our findings do not allow to
draw any definite conclusions supporting the above expectation. On the other hand, it
may be also plausible for differences observed to be much more accentuated had the
devolution process not taken place. It is simply not possible at this early stage of the
analysis to draw definitive conclusions.
3.9 Conclusions
The aim of this part was to explore the issue relating income-related inequality in health
and inequity in healthcare utilisation in England, Wales and Scotland and how these
have changed after the introduction of the devolved health system in Great Britain.
The advantages of decentralised health system lie in the fact that resources can be
allocated more efficiently to meet local preferences and used with greater cost
consciousness at the local level (Oates, 1972; 1999). Further, it is believed that
improvements in equity can be attained as local governments may be able to respond to
specific local needs in more appropriate ways than a central government or agency can
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(Pauly, 1973). The main disadvantage derives from the fact that individuals who are
"equal" in every respect but the jurisdiction in which they happen to live may end up
being treated differently and that this may give rise to "unacceptable" variations across
the country as a whole.
We used a well-known and widely used measure of inequality in health and inequity in
healthcare utilisation: the concentration index. The concentration index is analogous to
the Gini coefficient, which is commonly used as a measure of income inequality.
Further, we analysed the distribution ofNHS care within morbidity groups by looking at
the percentages of total utilisation made by each income group.
We find that income-related inequality in (ill-) health in all three countries exists and
that it is favouring the highest income groups. A summary of the direction of change is
shown in Table 19.
Country
in healthTable 3-20: Summar
England Wales Scotland
Pro-rich, increase in Pro-rich, reduction Pro-rich, increase in
Acute sickness (hstate) inequality in inequality inequality
Pro-rich, no change Pro-rich, reduction Pro-rich, increase in
Long-standing illness (hstatus) in inequality in inequality inequality
Pro-rich, increase in Pro-rich, reduction Pro-rich, increase in
Not good health (sah) inequality in inequality inequality
Further, we find that income-related inequity in healthcare utilisation exists and that it is
favouring the lowest income groups. Table 20 shows a summary of our findings.
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Table 3-21: Summar of income-related ine ui in healthcare utilisation
Country
England Wales Scotland
GP consultations
Pro-poor, increase
in inequity
Pro-poor, increase
in inequity
Pro-poor, reduction
in inequity
Inpatient stays
Pro-poor, no change Pro-poor, reduction Pro-poor, no change
in inequity in inequity in inequity
Outpatients visits
Pro-poor, reduction
in inequity
Pro-poor, increase
in inequity
Pro-poor, increase
in inequity
We realise that the results for Wales should be taken cum grano salis as they might be
contaminated by measurement error given the small sample size.
It is not possible to attribute any changes directly to the implementation of devolution,
as other policy reforms may have been introduced in any country at the same time.
However, it is a first attempt to investigate whether pre-existing inequalities in health
and inequities in healthcare utilisation have evolved differently in the three countries.
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S6 In this paper we use the term "jurisdiction" as a synonym for either of the following: local government,
sub-national level of government, region, state, country. That is for the sub-national level of government
to which the governmental function "health" has been decentralised. In the case of the United Kingdom,
"Jurisdiction" hence refer to either England, Wales, Scotland and Northern Ireland.
S The decentralisation reform in the United Kingdom is usually referred to as devolution. We will adopt
throughout this chapter the above convenience, whenever and wherever we refer to the British reform.
This despite the fact that the term has been erroneously adopted in this country as will appear clearly from
the section on Decentralisation.
S8 With the exclusion of Northern Ireland, which has been administered centrally by Westminster because
of the political instabilities that have since interested this area.
S9 An excellent review of the literature can be found in 'An Essay on Fiscal Federalism", by Oates (1999).
60 The hypothesis of income redistribution as a local or spatial public good was tested by Brown and
Oates for the American Provinces.
61 Also referred to as "Westminster Parliament" or simply "Westminster".
62 Further details on the specific arrangements made for Scotland and Wales can be found in the
Devolution Guidance Note 11, Ministerial Accountability after Devolution, available at
http://dca.gov.uk!constitution!devolution!guidance.htm.
63 Further details are available in the Devolution Guidance Note 5.
64 The Northern Irish consultation paper did not terminate in an equivalent white paper or legislation. The
Erocess was stopped because of the turmoil of the Northern Irish political scene.
S In case one is studying the distribution of a specific health care utilisation measure in a given
population, then a value of the Cl equal to 1 corresponds to a situation where the use of that particular
healthcare service is concentrated in the hands of the most advantaged individuals (or groups). The
of,posite is true when Cl is equal to -I.
6 This formula is taken from the World Bank (2004) "Quantitative Technique for Health Equity Analysis
- Technical Paper # 7"
67 With the exception of 1997/98.
68 For the purpose of this study, an adult is an individual who is 16 years of age or older.
69 Caution should, however, be used in employing the measure of health that we call in this paper "self-
assessed (sah)" in cross-country comparisons. Several studies (Mathers and Douglas, 1998; Murray,
1996; Wagstaff 2002; Lindeboom and van Doorslaer, 2004; van Doorslaer and Gerdtham, 2003; Milcent
and Etile, 2006; Salomon et al., 2004; Tandon et al., 2006; Bago d'Uva et al. 2007) show that these are
highly affected by factors such as culture and tradition, as well as the individuals' socio-economic status.
70 The actual and age-sex standardised percentages of inpatient stays by income group are computed
from statistics reported in the following Table.
Income Actual nr. of Age-sex stand. nr. of
group Inpatient stays Inpatient stays
1 17 18.78
2 57 61.39
3 10 9.52
4 4 2.74
5 8 6.03
Total 96 98
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Conclusions
This thesis has investigated the issues relating to the measurement of health system
performance. Two different dimensions of health system performance were addressed:
efficiency and equity. Part I and II consider the first dimension, respectively for the
health system as a whole and for a specific programme of care. The third part of the
thesis considers the second dimension, assessing the impact of the devolution reform on
equity in health and healthcare utilisation in Great Britain.
In Part I we addressed the issues relating to the measurement of government output for
the healthcare sector. Three key challenges usually arise when measuring output
growth. First, it is necessary to identify and quantify healthcare output correctly. We
distinguish between activity, output and outcome. We define output as courses of
treatment that may require a bundle of activities (tests, surgery, drugs, etc.) and outcome
as the quality characteristics of healthcare output that individuals value (health
improvement, waiting time, being treated with dignity, etc.). We identified as the unit of
output the patient treated. The IT system in the NHS does not currently allow tracking
patients across all of the settings in which they receive care (primary and secondary
sectors, for example). However, and limited to hospital activity, the HES database
includes information that enables us to at least track patients across consultants within
providers and also across providers. All remaining NHS services are included in the
output growth in the units of activity that they are collected and reported in the various
sources. These vary from number of tests performed to bed days, to attendances, etc.
Second, even if it is possible to count these outputs, it is difficult to measure their
quality. Quality of healthcare goods and services is likely to be an important source of
output growth. Two challenges are involved: 1) identifying and defining what
constitutes the quality of healthcare and 2) develop a way of incorporating these quality
characteristics into an output growth index. We have identified the following quality
adjustors: survival rates, pre- and post-treatment health status for a limited number of
hospital outputs, life expectancy and waiting times. These data are currently available
only for patients admitted to hospitals as inpatients. Third, some means of weighting
different goods and services is required in order to aggregate them into a single index.
In principle, marginal social values of different NHS outputs should be used. The
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standard assumption in the national accounting literature is that marginal social values
are measured by the unit costs of production. Although an imperfect measure, and in the
absence of marginal social values, we decided to follow the National Accounts and use
unit costs derived from the National Schedule of Reference Costs. We have
demonstrated how quality change can be accounted for in an output growth index, given
current data availability. Quality-adjusting output adds on average about 0.2 per cent per
annum to the simple cost weight output growth measure. In 2001/02 - 2002/03 and
2002/03 - 2003/04 alone, it adds between 0.50 and 0.73 percentage points.
Part II has considered the feasibility and usefulness of developing measures of growth
in outputs, costs and productivity of a single programme of care within the NHS:
hospital treatment of circulatory diseases. Determining output indices that consider the
complete treatment of individual illnesses has been recognised as early as the 1960s.
The US literature has studied widely and developed disease-specific and patient-based
healthcare output and price indices that focus on the direct measurement of medical
costs of treating an episode of illness. We have demonstrated that it is feasible, using
hospital spells as the unit of output, to develop quite refined models of the output of a
programme of care. The development of HRGs has assisted greatly in this endeavour,
yielding meaningful counts of output. Output growth for hospital treatment of all
circulatory diseases has increased over the time period we considered. In actual cost-
weighted volume terms, the increase is of the order of 3.9 per cent per annum, but
incorporation of quality data in the form of survival rates implies an increased rate of
4.5 per cent per annum. This is clearly crude, but the recent improvement in survival
rates in many procedures for circulatory disease yields quite a large improvement in
estimates of annual rates of output growth. This is in line with ONS estimates, which
estimates annual increase in outputs over the same period for the whole of the NHS
(including primary care and prescribing) at about 5 per cent. The lack of health outcome
measurement in the NHS (other than survival data) means that we are unable to say
much about the quality of life after treatment. However, we have demonstrated how this
might be incorporated into an output index using health status measures of before and
after treatment from a private health insurer. Health outcome data were available for
CABG and PTCA elective procedures. For all other procedures/diagnoses of circulatory
disease we attributed an average value to the ratio of before and after health outcome
measures (19 = h/lh/) for electives and non-electives activity (See Castelli et al.,
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2007a). Sensitivity analyses were carried out to determine the effect of different values
on the cost weighted output growth indices. In the first instance, we calculated output
growth measures for CABG and PTCA procedures only, finding that consideration of
the quality of health outcomes added about 0.2 per cent per annum to the estimates of
output growth. Incorporating health outcomes measures for all circulatory diseases
activity yields a higher increase in average output growth of about 5.19 per cent per
annum, adding about 1.3 per cent per annum to the unadjusted CWO I and 0.71 per cent
annum to the survival adjusted CWO I.
Common conclusions can be drawn for part I and II.The measurement of output growth
and productivity for any public sector relies on the existence of routinely collected
administrative data. The benefits of this type of data are well known and are for
example 100 coverage of target population, minimised attrition problems, and accuracy
(Jones and Elias, 2006). Nonetheless, some drawbacks may arise with the introduction
of new collection exercises which are very often phased into a system. One of the
problems that this may cause is that of introducing volatility in the output growth
measure. This problem is usually avoided and/or minimised in the National Accounts by
using the so-called 'mapping technique' by which activity in any two consecutive years
is matched, where possible, and all the activity that cannot be compared and/or mapped
is discarded from the estimates. Further and although, we recognise that the mapping
approach used for the inclusion of new activity categories reported in the Reference
Costs constitutes a step forward compared to the traditional approach, which required
output categories to be consistent through time, it has the limitation that it relies heavily
on judgements about the nature of the relationship between existing categories and new
categories, and that it is not always possible to map all activity, especially activity that
was previously not recorded. In the presence of technological progress, which
constantly introduces both new treatments/procedures and drugs, as well as new ways of
recording and tracking patients' care, it becomes more and more important to be able to
account for this new activity categories as soon as they are reported. We believe that the
issue of changing output categories needs to be addressed. Elsewhere, (Castelli et al.
(2008», we have developed a new method, and our research should be updated in order
to incorporate this improved approach.
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We strongly recommend that the NHS makes it their priority to start the routine
collection of health outcomes data. These are important not only to be used in improved
measure of health care output growth, but could also successfully be used in surveillance
of clinical performance, resource allocation, and informing patient choice and improved
patient care.
Health outcomes constitute undoubtedly the most important element of quality to
incorporate into the model of NHS output growth. However, there is also a case for
exploring the feasibility and usefulness of incorporating non-health aspects of NHS
quality into the model, such as measures of patient experience. Other aspects of output
that may be important in some programmes of care include the benefits of treatment to
the patient's carers, and the implications of NHS activities for labour productivity and
social care expenditure. Further, we recommend to extend the quality adjustments to
other areas of health care; in particular, the primary care sector.
A crucial methodological consideration concerns the weights to be applied to the
separate NHS output activities. The diverse hospital spells that make up this programme
of care do not necessarily confer equal patient benefits. We have followed the
conventional practice in weighting treatments according to their estimated costs,
acknowledging that these are imperfect measures of marginal social value. We
recognise that is desirable to do further research on determining 'value weights'.
The analysis carried out in Part I and II focus on the English NHS only, this does not
preclude, however, for the same methods to be applied to any of the devolved
administrations. An analysis of NHS output growth and productivity for Wales,
Northern Ireland and Scotland is not only to be encouraged but necessary, especially for
the purposes of the National Accounts. We consider extending this analysis to the
remaining three countries of the UK a priority to be addressed in the near future. It is to
our knowledge that ONS has already started calculating output and productivity growth
for the Northern Ireland NHS (ONS, 2008).
Limitedly to part II, we believe that it is important to extend the analysis to programmes
of care performed outside the hospital sector, such as community and primary care
settings.
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In part III "Equity in the delivery of healthcare in Great Britain: the impact of
decentralisation", we investigated the impact of devolution on equity in the delivery of
healthcare in the constituent countries of Great Britain: England, Wales and Scotland.
Decentralisation of the health care sector has received substantial attention as a policy
reform in the last decade or so in many countries. In 1998 the Labour Government passed
an important reform which transferred political power and responsibilities from
Westminster to Scotland, Wales and Northern Ireland, .with Health being the most
important responsibility that has been devolved. Prior to devolution, health services in
the constituent countries of the United Kingdom were administered as part of the
National Health Service, which was designed to achieve common standards across the
whole of the UK. However, since devolution, each constituent country has been granted
freedom to organise aspects of their NHS differently, subject to overarching criteria and
constraints. We investigated whether any significant changes had occurred in the
distribution of health and healthcare utilisation across different income groups, by means
of the concentration index. We found that income-related inequality in (ill-) health exists
in all three countries, and that it is favouring the highest income groups. In the case of
healthcare utilisation, income-related inequity also exists and it is favouring the lowest
income groups. Although important changes occur in the way health and healthcare
utilisation are distributed across income groups from 1995/96 to 2001/02, no clear
pattern of change emerges. Although we realise that it is not possible to attribute these
changes directly to the introduction of the devolution reform as other policy reforms
may have been implemented in any country at the same time; we consider, however,
this study as a very first attempt to investigate these issues. We recommend
investigating this issue further by adding more years to the time period considered both
before and after the policy reform was introduced. Further, we recommend to harmonise
data specification across the 3 countries under investigation to enable more accurate
comparisons of income-related inequality in health and inequity in healthcare
utilisation.
This PhD thesis has investigated important aspects of the measurement of health system
performance and the uses to which such measures might be put. Performance is a multi-
dimensional concept which can be addressed from a variety of points of views and with
a variety of instruments. We presented in this thesis one way of assessing NHS
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performance as a whole and for one programme of care by means of a quality-adjusted
output index, respectively in part I and II.
The way in which healthcare output is measured constitutes a novelty on its own. The
output index formulation developed allows for the comprehensive measurement of all
output produced by the NHS, and for quality aspects to be taken into account.. Further,
and following suggestions set out both in the Eurostat Handbook (2001) and in the
Atkinson Review (2005), building on Lakhani et al. (2005) we develop a measure of
healthcare output which considers the treatment pathway that a patient follows whilst
under the care of the NHS. Limitations in current IT technology, allow us only to track
patients in acute care and we develop a new unit of output measure: Continuous
Inpatient Spell of NHS hospital care. Output growth measurements in the National
Accounts use still an elementary measure of healthcare (hospital) activity, based of
finished consultant episodes.
The increased interest in the measurement of output and productivity growth in the
NHS, extends also to gaining a better understanding of the output growth and
productivity of individual programmes of care, so as to ensure that resources are
allocated efficiently within the NHS. Hitherto, such information has not been available.
In the second part of the thesis using the method developed in the first chapter, we
undertake and exploratory study of the feasibility and usefulness of developing
measures of growth in outputs and productivity of a single programme of care within
the NHS hospital setting.
Further, the fundamental objective of any public health system is still that to improve
patients' health and to that end to provide healthcare services to people according to
their needs and not their ability to pay. It is, therefore, important to be able to
investigate whether this objective is met in the presence of any policy reform that could
potentially jeopardise it. We have focused on this issue in the third part of this PhD
thesis.
In the last chapter an attempt is made to evaluate the devolution of the NHS in the UK
by looking at the effects it has on income-related equity in health and healthcare
utilisation. No previous attempt has been made to evaluate this reform and within the
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specific methodological framework used in this chapter. We are aware of only one
paper (Alvarez-Rosete et al., 2005) that attempts to evaluate the effects of the diverging
policies introduced since the devolution of the NHS. In this paper, however, only
routine data on performance of the NHS are used to compare the four constituent
countries of the UK on a number of aspects such as health indicators, expenditure,
waiting times before and after the devolution took place. Our paper constitutes an
improvement compared to this paper, in that we apply a more sophisticated framework
in order to establish whether the devolution of the NHS has allowed each constituent
country to improve the realisation of the fundamental aim of the NHS which is that of
delivering healthcare to people who are in need of them, based on need and need alone.
The research undertaken for this PhD has been affected by severe data difficulties;
however, we have shown power of data sources. There is a clear case for improving
data specification and collection, which will allow for the improved measurement of
health system performance for both policy making purposes and accountability to the
public.
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Appendix I-A
Atkinson's principles for the direct measurement of government output, inputs
and productivity (Atkinson, 2005)
Principle A: The measurement of government non-market output should, as far as
possible, follow a procedure parallel to that adopted in the National Accounts for market
output.
Principle B: The output of the government sector should in principle be measured in a
way that is adjusted for quality, taking account of the attributable incremental
contribution of the service to the outcome.
Principle C: Account should be taken of the complementarity between public and
private output, allowing for the increased real value of public services in an economy
with rising real GDP.
Principle D: Formal criteria should be set in place for the extension of direct output
measurement to new functions of government, Specifically, the conditions for
introducing a new directly measured output indicator should be that (i) it covers
adequately the full range of services for that functional area, (ii) it makes appropriate
allowance for quality change, (iii) the effects of its introduction have been tested service
by service, (iv) the context in which it will be published has been fully assessed, in
particular the implied productivity estimate, and (v) there should be provision for
regular statistical review.
Principle E: Measures should cover the whole of the United Kingdom; where systems
for public service delivery and/or data collection differ across the different countries of
the United Kingdom, it is necessary to reflect this variation in the choice of indicators.
Principle F: The measurement of inputs should be as comprehensive as possible, and in
particular should include capital services; labour inputs should be compiled using both
direct and indirect methods, compared and reconciled.
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Principle G: Criteria should be established for the quality of pay and price deflators to
be applied to the input spending series; they should be sufficiently disaggregated to take
account of changes in the mix of inputs and should reflect full and actual costs.
Principle H: Independent corroborative evidence should be sought on government
productivity, as part of a process of 'triangulation', recognising the limitations in
reducing productivity to a single number.
Principle I: Explicit reference should be made to the margins of error surrounding
national accounts estimates
* * *
Health - recommendation 8.5 (Atkinson, 2005)
We regard the measurement of quality change in health care as a difficult area, but have
a number of suggestions for work which should be taken forward. The results of
research commissioned by the DH from the University of York and National Institute
for Economic and Social Research will be important. We recommend that:
a) a number of dimensions of quality should be measured, with results weighted
together by marginal social valuation: more work would be required to underpin
these weights;
b) a range of expertise should be used to develop quality measures, including
public health medicine, epidemiology, health service management, health
informatics and health economics;
c) ONS and the health departments should assess options for collecting new
information on health outcomes resulting from NHS treatment, with particular
consideration to the needs ONS has for measurement of change over time, rather
than cross-sectional data sets which are useful to health departments for other
purposes;
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d) ONS and the health departments should consider studies of changing treatment
patterns for particular major disease groups to assess whether these could
provide useful estimates of improved health outcomes resulting from changes in
clinical practice;
e) ONS and the health departments should explore the data set on quality standards
in general practice, resulting from the new GP contract, to see whether this could
be the basis for a measure of quality change;
f) ONS and the health departments should consider whether, with advice from the
National Institute for Clinical Excellence, it might be possible to identify
treatments where marginal valuation and cost weights are very different, and
explore the difference in output growth resulting from use of estimated marginal
valuation instead of cost weights;
g) ONS and the health departments should develop a measure of quality change
based on speed of access to elective treatment, using the Hospital Episode
Statistics data set and taking account of non-linearity, with further developments
if new measures of total waiting time are introduced;
h) ONS and the health departments should explore whether measures of quality
change could be developed from information sources for time taken for
admission to hospital from accident and emergency departments, time before
seeing a general practitioner and ambulance emergency response times;
i) ONS and the health departments should explore whether measures of quality
change over time could be based on the national patient survey programme
which measures aspects of patient experience.
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Appendix I-B
Literature search strategy
HMIC
Initial strategy
#1 quantity index
#2 growth accounting
#3 tomqvist index
#4 fisher index
#5 labour productivity
#6 residual productivity
#7 solow residual
#8 index number theory
#9 translog production
#10 hedonic
#11 medical productivity
#12 health productivity
#13 health care productivity
#14 healthcare productivity
#15 frontier analysis
#16 frontier analyses
#17 data envelopment analysis
#18 data envelopment analyses
#19 total factor productivity
#20 multifactor productivity
#21 multi factor productivity
#22 multi-factor productivity
#23 (multi-factor productivity) or (multi factor productivity) or (hedonic) or (translog
production) or (index number theory) or (solow residual) or (residual productivity) or
(labour productivity) or (fisher index) or (tomqvist index) or (growth accounting) or
(quantity index) or (multifactor productivity) or (total factor productivity) or (data
envelopment analyses) or (data envelopment analysis) or (frontier analyses) or (frontier
analysis) or (healthcare productivity) or (health care productivity) or (health
productivity) or (medical productivity)
#24 (medical service") in ti,de
#25 (medical system*) in ti,de
#26 (public service") in ti,de
#27 (public sector*) in ti,de
#28 «health adj care) or healthcare) in ti,de
#29 (health service") in ti,de
#30 (health system") in ti,de
#31 (health insurance system") in ti,de
#32 (primary care) in ti,de
#33 (family health service*) in ti,de
#34 (family practice*) in ti,de
#35 (general practice") in ti,de
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#36 nhs in ti,de
#37 (national health service*) in ti,de
#38 hospitals in ti,de
#39 «medical service*) in ti,de) or (hospitals in ti,de) or «national health service*) in
ti,de) or (nhs in ti,de) or «general practice*) in ti,de) or «family practice*) in ti,de) or
«family health service*) in ti,de) or «primary care) in ti,de) or «health insurance
system*) in ti,de) or «health system*) in ti,de) or «health service*) in ti,de) or «(health
adj care) or healthcare) in ti,de) or «public sector*) in ti,de) or «public service*) in
ti,de) or «medical system*) in ti,de)
#40 (productivity or output or outputs of efficient or efficiency) in ti,de
#41 «productivity or output or outputs of efficient or efficiency) in ti,de) and «(medical
service*) in ti,de) or (hospitals in ti,de) or «national health service*) in ti,de) or (nhs in
ti,de) or «general practice*) in ti,de) or «family practice*) in ti,de) or «family health
service*) in ti,de) or «primary care) in ti,de) or «health insurance system*) in ti,de) or
«health system*) in ti,de) or «health service*) in ti,de) or «(health adj care) or
healthcare) in ti,de) or «public sector*) in ti,de) or «public service*) in ti,de) or
«medical system*) in ti.de)
#42 «medical service*) in ti,de,ab) or (hospitals in ti,de,ab) or «national health
service*) in ti,de,ab) or (nbs in ti,de,ab) or «general practice*) in ti,de,ab) or «family
practice*) in ti,de,ab) or «family health service*) in ti,de,ab) or «primary care) in
ti,de,ab) or «health insurance system*) in ti,de,ab) or «health
system*) in ti,de,ab) or «health service*) in ti,de,ab) or «(health adj care) or healthcare)
in ti,de,ab) or «public sector*) in ti,de,ab) or «public service*) in ti,de,ab) or «medical
system*) in ti,de,ab)
#43 (productivity or output or outputs of efficient or efficiency) in ti,de,ab
#44 (measur* or estimat* or index or indexes or indices or indicator* or instrument* or
calculat* or monitor* or gain* or chang* or increas* or improv* or grow*)in ti,de,ab
#45 «productivity or output or outputs of efficient or efficiency) in ti,de,ab) and
«(medical service*) in ti,de,ab) or (hospitals in ti,de,ab) or «national health service*) in
ti,de,ab) or (nbs in ti,de,ab) or «general practice*) in ti,de,ab) or «family practice*) in
ti,de,ab) or «family health service*) in ti,de,ab) or «primary care) in ti,de,ab) or
«health insurance system*) in ti,de,ab) or «health system*) in ti,de,ab) or «health
service*) in ti,de,ab) or «(health adj care) or healthcare) in ti,de,ab) or «public sector*)
in ti,de,ab) or «public service*) in ti,de,ab) or «medical system*) in ti.de.ab) and
(uneasur= or estimat* or index or indexes or indices or indicator+ or instrument" or
calculat* or monitor* or gain* or chang* or increas* or improv* or grow*)in ti,de,ab)
#46 outcome* in ti
#47 «medical service*) in ti) or (hospitals in ti) or «national health service*) in ti) or
(nbs in ti) or «general practice*) in ti) or «family practice*) in ti) or «family health
service*) in ti) or «primary care) in ti) or «health insurance system*) in ti) or «health
system*) in ti) or «health service") in ti) or «(health
adj care) or healthcare) in ti) or «public sector*) in ti) or «public service") in ti) or
«medical system*) in ti)
#48 «(medical service*) in ti) or (hospitals in ti) or «national health service") in ti) or
(nbs in ti) or «general practice") in ti) or «family practice") in ti) or «family health
service*) in ti) or «primary care) in ti) or «health insurance system*) in ti) or «health
system*) in ti) or «health service") in ti) or «(health
adj care) or healthcare) in ti) or «public sector*) in ti) or «public service") in ti) or
«medical system*) in ti) and (outcome* in ti)
#49 (technical change*) or (technological change*)
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#50 (technical innovation*) or (technological innovation")
#51 technology adj2 (chang*)
#52 technology adj (change or changes or changing or changed)
#53 «technical innovation*) or (technological innovation") or (technology adj (change
or changes or changing or changed» or «technical change") or (technological
change") or (technology adj2
(chang")
#54 health sector account*
#55 (health or medical) near (price index)
#56 (health or medical) near (price indexes)
#57 (health or medical) near (price indices)
#58 (Imeasur" or estimate* or index or indexes or indices or indicator* or instrument*
or calculat* or monitor* or gain* or chang* or increas* or improv* or grow*) in ti,de)
near2 quality
#59 «productivity or efficient or efficiency or output or outputs) in ti,de) near2 quality
#60 «(productivity or efficient or efficiency or output or outputs) in ti,de) near2 quality)
or «(measur* or estimate* or index or indexes or indices or indicator* or instrument* or
calculat* or monitor* or gain* or chang* or increas* or improv* or grow*) in ti.de)
near2 quality)
#61 (inspection in ti) and «services or council or borough or city) in ti)
#62 #60 not #61
#63 burden near2 disease
#64 cost* near2 disease*
#65 economic burden*
#66 (economic burden*) or (cost* near2 disease*) or (burden near2 disease)
#67 (survival rate*) near2 (measur* or estimate* or index or indexes or indices or
indicator* or instrument* or calculat* on monitor* or gain* or chang* or increas* or
improv* or grow*)
#68 physical capital
#69 capital near2 (hospital* or building* or equipment or infrastructure)
#70 (general practice* or family practice or family health service* or primary care) in
ti,ab,de
#71 (input or inputs) and #70
#72 #23 or #41 or #45 or #48 or #53 or #54 or #55 or #56 or #62 or
#57 or #66 or #67 or #68 or #69 or #71
#73 (#23 or #41 or #45 or #48 or #53 or #54 or #55 or #56 or #62 or
#57 or #66 or #67 or #68 or #69 or #71) and «PY :HMIC >= 1989) or
(PY:HQ >= 1989)
Refined strategy
#1 quantity index
#2 growth accounting
#3 tomqvist index
#4 fisher index
#5labour productivity
#6 residual productivity
#7 solow residual
#8 index number theory
#9 translog production
#10 hedonic
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#11 medical productivity
#12 health productivity
#13 health care productivity
#14 healthcare productivity
#15 frontier analysis
#16 frontier analyses
#17 data envelopment analysis
#18 data envelopment analyses
#19 total factor productivity
#20 multi factor productivity
#21 multi factor productivity
#22 multi-factor productivity
#23 (multi-factor productivity) or (multi factor productivity) or
(hedonic) or (translog production) or (index number theory) or (solow residual) or
(residual productivity) or (labour productivity) or (fisher index) or (tomqvist index) or
(growth accounting) or (quantity index) or (multifactor productivity) or (total factor
productivity) or (data envelopment analyses) or (data envelopment analysis) or (frontier
analyses) or (frontier analysis) or (healthcare productivity) or (health care productivity)
or (health productivity) or (medical productivity)
#24«productivity OR output*) in ti,de) AND «medical service*) in ti,de) or (hospitals
in ti,de) or «national health service") in ti,de) or (nbs in ti,de) or «general practice*) in
ti,de) or «family practice") in ti,de) or «family health service*) in ti,de) or «primary
care) in ti,de) or «health insurance system *) in ti,de) or «health system *) in ti,de) or
«health service*) in ti,de) or «(health adj care) or healthcare) in ti,de) or «public
sector*) in ti,de) or «public service") in ti,de) or «medical system*) in ti,de)
#25 health sector account*
#26 (health or medical) near (price index)
#27 (health or medical) near (price indexes)
#28 (health or medical) near (price indices)
#29 #23 or #24 or #25 or #26 or #27 or #28 and «PY :HMIC >= 1989) or
(PY:HQ >= 1989)
EconLit
Initial strategy
#1 quantity index
#2 growth accounting
#3 tomqvist index
#4 fisher index
#5 labour productivity
#6 residual productivity
#7 solow residual
#8 index number theory
#9 translog production
#10 hedonic
#11 frontier analysis
#12 frontier analyses
#13 data envelopment analysis
#14 data envelopment analyses
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#15 total factor productivity
#16 multifactor productivity
#17 multi-factor productivity
#18 multi factor productivity
#19 (hedonic) or (translog production) or (index number theory) or (solow residual) or
(residual productivity) or (labour productivity) or (fisher index) or (tomqvist index) or
(growth accounting) or
(quantity index) or (multi factor productivity) or (multi-factor productivity) or
(multifactor productivity) or (total factor productivity) or (data envelopment analyses)
or (data envelopment analysis) or (frontier analyses) or (frontier analysis)
#20 medical service*
#21 medical system*
#22 public service*
#23 public sector*
#24 (health adj care) or healthcare
#25 health service*
#26 health system*
#27 health insurance system*
#28 primary care
#29 family health service*
#30 family practice*
#31 general practice*
#32 nhs
#33 national health service*
#34 hospitals
#35 «health adj care) or healthcare) or (public sector*) or (public service*) or (medical
system*) or (hospitals) or (national health service*) or (nhs) or (general practice*) or
(medical service*) or (family practice*) or (family health service*) or (primary care) or
(health insurance system*) or (health system*) or «health service*) in ti,ab,de)
#36 «(health adj care) or healthcare) or (public sector*) or (public service*) or (medical
system*) or (hospitals) or (national health service*) or (nhs) or (general practice*) or
(medical service") or (family practice*) or (family health service") or (primary care) or
(health insurance system*) or (health system*) or «health service") in ti.ab.de) and
«hedonic) or (translog production) or (index number theory) or (solow residual) or
(residual productivity) or (labour productivity) or (fisher index) or (tomqvist index) or
(growth accounting) or (quantity index) or (multi factor productivity) or (multi-factor
productivity) or (multifactor productivity) or (total factor productivity) or (data
envelopment analyses) or (data envelopment analysis) or (frontier analyses) or (frontier
analysis»
#37 «health or medical) in til and #19
#38 «(health or medical) in til and #19) or ««health adj care) or healthcare) or (public
sector*) or (public service") or (medical system") or (hospitals) or (national health
service") or (nhs) or (general practice=) or (medical service*) or (family practice*) or
(family health service*) or (primary care) or (health insurance system*) or (health
system") or «health service") in ti.ab.de) and «hedonic) or (translog production) or
(index number theory) or (solow residual) or (residual productivity) or (labour
productivity) or (fisher index) or (tomqvist index) or (growth accounting) or (quantity
index) or (multi factor productivity) or (multi-factor productivity) or (multifactor
productivity) or (total factor productivity) or (data envelopment analyses) or (data
envelopment analysis) or (frontier analyses) or (frontier analysisjj)
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#39 (productivity or output or outputs or efficient or efficiency) near2 #35
#40 (productivity or output or outputs or efficient or efficiency) near2 (health or
medical)
#41 «productivity or output or outputs or efficient or efficiency) near2 #35) or
«productivity or output or outputs or efficient or efficiency) near2 (health or medical»
#42 outcome* and #35
#43 (technical innovation*) or (technological innovation*) or «technology near2
(change or changes or changing or changedjjin ti,ab,de)
#44 #43 and (health or medical)
#45 #43 and #35
#46 (#43 and #35) or (#43 and (health or medical»
#47 health sector account*
#48 (health or medical) near (price index or price indexes or price indices)
#49 (measur* or estimat* or index or indices or indexes or indicator* or instrument* or
calculat* or monitor* or gain* or chang* or increas* or improv* or grow*) near2
quality
#50 #49 and (health or medical or #35)
#51 burden near2 disease
#52 cost near2 disease*
#53 illness near2 burden
#54 (illness near2 burden) or (cost near2 disease*) or (burden near2 disease)
#55 survival rate*
#56 capital near2 hospital*
#57 (input or inputs) in ti,ab,de
#58 #57 near2 (health or medical or #35)
#59 (#38 or #41 or #42 or #46 or #47 or #48 or #50 or #54 or #55 or
#56 or#58) and (PY:ECON >= 1989)
Refined strategy
#1 «health or medical) in ti) and «hedonic) or (translog production) or (index number
theory) or (solow residual) or (residual productivity) or (labour productivity) or (fisher
index) or (tomqvist index) or (growth accounting) or (quantity index) or (multi factor
productivity) or (multi-factor productivity) or (multifactor productivity) or (total factor
productivity) or (data envelopment analyses) or (data envelopment analysis) or (frontier
analyses) or (frontier analysis»
#2 «(health adj care) or healthcare) or (public sector*) or (public service*) or (medical
system*) or (hospitals) or (national health service*) or (nhs) or (general practice*) or
(medical service*) or (family practice*) or (family health service*) or (primary care) or
(health insurance system*) or (health system*) or «health service*) in ti.ab.de) and
«hedonic) or (translog production) or (index number theory) or (solow residual) or
(residual productivity) or (labour productivity) or (fisher index) or (tomqvist index) or
(growth accounting) or (quantity index) or (multi factor productivity) or (multi-factor
productivity) or (multi factor productivity) or (total factor productivity) or (data
envelopment analyses) or (data envelopment analysis) or (frontier analyses) or (frontier
analysis»
#3 (productivity or output or outputs or efficient or efficiency) near2 (health or medical)
#4 (productivity or output or outputs or efficient or efficiency) near2 «health adj care)
or healthcare) or (public sector*) or (public service*) or (medical system*) or
(hospitals) or (national health service*) or (nhs) or (general practice*) or (medical
service*) or (family practice*) or (family health service*) or
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(primary care) or (health insurance system*) or (health system*) ortjhealth service*) in
ti,ab,de)
#5 (productivity or output or outputs or efficient or efficiency) near2 (health or medical)
#6 (#1 or #2 or #3 or #4 or 5) and (PY:ECON >= 1989)
These search strategies were carried out by members of staff at CRD - University of
York.
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Appendix l-C
Table I-C.I: Pre- and post-treatment health status
Health outcome
HRG description HRG Source hO h OJ
Intermediate pain procedures A07 PHI 0.41 0.57
Phakoemulsification cataract extraction with lens implant B02 PHI 0.73 0.76
Other cataract extraction with lens implant B03 PHI 0.7 0.72
Mouth or throat procedures - category 2 C14 PHI 0.87 0.95
Nose procedures - category 3 C22 PHI 0.83 0.91
Mouth or throat procedures - category 3 C24 PHI 0.77 0.93
Coronary bypass E04 PHI 0.5 0.73
Acute myocardial infarction w/o cc E12 CT 0.68 0.72
Percutaneous trans luminal coronary angioplasty (PTCA) E15 PHI 0.54 0.79
Chest pain >69 or w cc E35 CT 0.63 0.69
Inguinal umbilical or femoral hernia repairs >69 or w cc F73 PHI 0.64 0.69
Inguinal umbilical or femoral hernia repairs <70 w/o cc F74 PHI 0.74 0.81
Liver transplant GOI CT 0.53 0.59
Biliary tract - major procedures >69 or w cc G13 PHI 0.63 0.66
Biliary tract - major procedures <70 w/o cc G14 PHI 0.68 0.81
Primary hip replacement H02 PHI 0.37 0.62
Primary knee replacement H04 HT 0.35 0.54
Soft tissue disorders >69 or w cc H23 PHI 0.77 0.84
Soft tissue disorders <70 w/o cc H24 PHI 0.72 0.74
w/o cc H26 CT 0.41 0.53
Complex breast reconstruction using flaps JOI PHI 0.93 0.96
Non-malignant prostate disorders L32 CT 0.81 0.85
Upper genital tract major procedures M07 PHI 0.7 0.8
Threatened or spontaneous abortion M09 PHI 0.72 0.83
Psychiatric disorders P18 CT 0.36 0.41
Varicose vein procedures Qll CT 0.77
Surgery for degenerative spinal disorders R02 PHI 0.37 0.67
Spinal fusion or decompression excluding trauma R03 PHI 0.36 0.62
Revisional spinal procedures R09 PHI 0.32 0.6
where PHI: Private Health Insurer; CT: Clinical Trials; HT: Hospital Trust
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Appendix I-D
Table 1-D.1 - Calculation of Quality-adjusted Life Expectancy base on the 2000-2002 Life Tables
MALES FEMALES
Life QA Life Life Quality QA Life
Age Expectancy Quality Adjustment Expectancy Expectancy Adjustment Expectancy
i ii iii i ii iii
0 75.70 11.66 64.04 80.40 11.95 68.45
1 74.84 11.38 63.47 79.57 11.99 67.57
2 73.96 ILl I 62.85 78.70 12.03 66.67
3 73.06 10.86 62.21 77.79 12.05 65.75
4 72.14 10.61 61.53 76.86 12.05 64.81
5 71.20 10.39 60.81 75.90 12.05 63.85
6 70.24 10.17 60.07 74.92 12.03 62.89
7 69.27 9.97 59.30 73.93 12.01 61.92
8 68.29 9.78 58.51 72.92 11.97 60.95
9 67.30 9.61 57.69 71.91 11.93 59.98
10 66.30 9.44 56.86 70.90 11.87 59.03
11 65.30 9.28 56.01 69.89 11.81 58.08
12 64.29 9.13 55.16 68.89 11.74 57.14
13 63.29 8.99 54.29 67.89 11.67 56.22
14 62.29 8.86 53.43 66.89 11.59 55.30
15 61.30 8.74 52.56 65.90 11.50 54.40
16 60.33 8.62 51.70 64.91 11.41 53.50
17 59.36 8.51 50.85 63.93 11.32 52.62
18 58.41 8.41 50.00 62.95 11.22 51.73
19 57.45 8.31 49.14 61.98 11.12 50.86
20 56.50 8.22 48.28 61.00 11.02 49.98
21 55.55 8.13 47.42 60.02 10.91 49.11
22 54.59 8.04 46.55 59.04 10.81 48.23
23 53.63 7.96 45.67 58.06 10.71 47.36
24 52.66 7.88 44.79 57.08 10.60 46.48
25 51.70 7.80 43.90 56.10 10.50 45.60
26 50.73 7.72 43.02 55.12 10.40 44.72
27 49.77 7.64 42.13 54.14 10.30 43.84
28 48.81 7.56 41.24 53.16 10.20 42.96
29 47.85 7.48 40.37 52.18 10.11 42.07
30 46.90 7.41 39.49 51.20 10.02 4Ll8
31 45.96 7.33 38.63 50.22 9.93 40.29
32 45.02 7.25 37.77 49.23 9.83 39.40
33 44.09 7.17 36.91 48.25 9.73 38.52
34 43.15 7.09 36.06 47.27 9.63 37.64
35 42.20 7.01 35.19 46.30 9.53 36.77
36 41.24 6.93 34.32 45.34 9.42 35.92
37 40.28 6.84 33.44 44.38 9.31 35.07
38 39.31 6.75 32.56 43.42 9.20 34.22
39 38.35 6.66 31.70 42.46 9.08 33.38
40 37.40 6.56 30.84 4l.50 8.96 32.54
41 36.46 6.47 30.00 40.53 8.84 31.69
42 35.53 6.37 29.16 39.57 8.72 30.85
43 34.62 6.27 28.34 38.60 8.60 30.01
44 33.71 6.18 27.53 37.65 8.47 29.18
45 32.80 6.08 26.72 36.70 8.34 28.36
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Table l-D.l - continued
MALES FEMALES
Life QALife Life Quality
Age Expectancy Quality Adjustment Expectancy Expectancy Adjustment QA Life Expectancy
i 11 iii i ii iii
46 31.90 5.97 25.92 35.77 8.21 27.56
47 31.00 5.86 25.l4 34.85 8.08 26.77
48 30.10 5.74 24.36 33.93 7.94 25.99
49 29.20 5.61 23.59 33.02 7.81 25.21
50 28.30 5.48 22.82 32.10 7.67 24.43
51 27.40 5.34 22.06 31.17 7.53 23.65
52 26.51 5.21 21.30 30.25 7.39 22.86
53 25.63 5.08 20.55 29.32 7.25 22.07
54 24.76 4.95 19.81 28.40 7.l1 21.29
55 23.90 4.82 19.08 27.50 6.97 20.53
56 23.06 4.69 18.36 26.62 6.81 19.80
57 22.23 4.56 17.67 25.75 6.65 19.10
58 21.41 4.42 16.99 24.89 6.48 18.42
59 20.61 4.28 16.33 24.05 6.29 17.75
60 19.80 4.13 15.67 23.20 6.10 17.10
61 19.00 3.98 15.02 22.35 5.91 16.44
62 18.20 3.82 14.38 21.51 5.72 15.79
63 17.42 3.66 13.75 20.66 5.53 15.13
64 16.65 3.50 13.14 19.83 5.35 14.48
65 15.90 3.35 12.55 19.00 5.18 13.82
66 15.18 3.20 11.98 18.19 5.00 13.18
67 14.48 3.05 11.43 17.39 4.84 12.55
68 13.81 2.91 10.89 16.60 4.68 11.92
69 13.15 2.78 10.36 15.84 4.53 11.31
70 12.50 2.66 9.84 15.10 4.37 10.73
71 11.86 2.54 9.32 14.38 4.22 10.16
72 11.24 2.43 8.81 13.68 4.06 9.62
73 10.64 2.32 8.32 13.01 3.90 9.11
74 10.06 2.21 7.84 12.35 3.73 8.62
75 9.50 2.11 7.39 11.70 3.56 8.14
76 8.97 2.01 6.97 11.07 3.39 7.68
77 8.48 1.90 6.58 10.45 3.22 7.23
78 8.00 1.79 6.21 9.85 3.06 6.79
79 7.54 1.69 5.86 9.26 2.90 6.37
80 7.10 1.58 5.52 8.70 2.74 5.96
81 6.67 1.48 5.l9 8.16 2.59 5.56
82 6.25 1.38 4.87 7.63 2.45 5.18
83 5.85 1.29 4.56 7.13 2.31 4.82
84 5.46 1.20 4.27 6.65 2.18 4.48
85 5.10 1.11 3.99 6.20 2.05 4.15
86 4.76 1.03 3.73 5.77 1.93 3.84
87 4.45 0.96 3.49 5.36 1.81 3.55
88 4.17 0.89 3.28 4.98 1.70 3.28
89 3.92 0.82 3.09 4.63 1.59 3.04
90 3.70 0.76 2.94 4.30 1.49 2.81
91 3.52 0.71 2.82 4.00 1.39 2.60
92 3.39 0.65 2.73 3.73 1.30 2.42
93 3.29 0.61 2.69 3.48 1.22 2.26
94 3.24 0.56 2.68 3.27 1.14 2.13
95 3.24 0.52 2.73 3.08 1.07 2.01
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Appendix 2-A
Table 2-A.l: List ofHRGs attributable to Circulatory Diseases, activity and unit costs for
2003/04
203
Table 2-A.l: List of HRGs attributable to Circulatory Diseases, activity and unit costs for
2003/04 - continued
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Table 2-A.2: List of HRGs attributed to Circulatory diseases, Survival rate
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Table 2-A.2: List ofHRGs attributed to Circulatory diseases, Survival rate - continued
e- 008&&
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Appendix 2-D
2-B.l Sensitivity analysis for CABG and PTCA only.
We present the four different cases considered in our sensitivity analysis, including the
one shown in Section 6.2. The differences across the various estimates rest in different
values attributed to both the before and after treatment health outcomes of non-elective
patients, as shown in the Table below.
Case 1 (seen in Section 6.2) assumes that the value of before treatment health outcome
measures for no-elective patients is equal to half the value of the corresponding elective
counterparts. The post-operative health outcomes for non-electives are set equal to the
respective electives ones.
In Case 2, we make the same assumption as in Case 1 for non-elective pre-treatment
health outcomes, but assume that the post-operative health outcomes for CABO and
PTCA are the same and are equal to half the average value of their elective counterparts.
Case 3 assumes that both the before and after treatment health outcomes for non-
elective procedures are equal to half their elective counterparts as follows.
In Case 4, we assume that the before treatment health outcomes for non-elective CABO
and PTCA procedures are equal to half the average value of the elective before
treatment health outcomes; whilst the post-operative health outcomes are equal to half
the value of their elective counterparts.
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Results of the CWOls are shown in the Table below.
Table 2-B.2: Results for CWOIs using different values for before and after treatment health outcome
Year
CWOl with survival CWOl with survival CWOI with survival CWOI with survival
and health effect - and hea Ith effect - and health effect - and health effect -
Case 1 Case 2 Case 3 Case 4
1998/99 - 1999/00 -0.47% -0.62% -0.63% -0.65%
1999/11)0-
2000/01 5.86% 6.39% 6.38% 6.40%
2000/01 - 2001/02 7.14% 7.17% 7.14% 7.10%
2001102 - 2002/03 15.81% 1629% 16.33% 16.38%
2002/03 - 2003/04 5.58% 5.84% 5.85% 5.87%
Averase srowth 6.79% 7.01% 7.01% 7.02%
2-B.2 Sensitivity analysis for all HRGs of circulatory diseases.
The first set of sensitivity analyses assumed a common value of k for both electives and
non-electives HRGs of circulatory diseases. The value for CABG and PTCA procedures for
elective activity is equal to the values of the before and after health outcome, whereas those
for non-elective activity for these two procedures are the same as set out in Case 1 in
Appendix 2-B.I. The results (see Table 2-B.2) show that on average, cost weighted output
growth for hospital treatment of all circulatory diseases has increased by 4.49 per cent per
annum when kelective = knon-elective = 0.9 (Case C), by 4.94 per cent per annum when kelective =
knon-elective k = 0.8 (Case A), and 5.24 per cent per annum when kelective = knon-elective = 0.7
(Case B). The results show some sensitivity of the output growth measures to the value of
k.
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Table 2-B.3: Results for CWOIs using different values for before and after treatment health outcome
Year CWOI with 30 day post CWOI with 30 day post CWOI with 30 day post
discharge and health effect discharge and health effect discharge and health effect
- Case A - Case B -Case C
1998199 - 19991110 0.83% 0.84% 1.38%
19991110 - 2000.111 3.56% 3.71% 3.33%
2000.111- 2001.112 3.65% 3.79% 3.42%
2001.112 - 2002.113 9.63% 10.32% 8.38%
2002.113 - 2003.114 7.06% 7.53% 5.93%
Averale l2;0wth 4.94% 5.24% 4.49%
Estimates of the cost weighted output growth indices using different values for the before
and after health outcomes measures are shown in Table 2-B.3. The first column (Case A)
presents results for the combination kelective = 0.8 and knon-elective = 0.4. InCase B and Case C
3, we have changed the value of knon-elective only, setting it equal to 0.35 and 0.45
respectively. Results show that output growth indices are slightly sensitive to the choice of
the value of the health outcome for non-elective HRGs.
Table 2-B.4: Results for CWOls using different values for before and after treatment health outcome
Year CWOI with 30 day post CWOI with 30 day post CWOI with 30 day post
discharge and health effect discharge and health effect discharge and health effect
- Case A 1 - Case A 2 - Case A 3
1998199 - 1999.110 0.25% 0.58% -0.12%
1999.110 - 2000.111 3.86% 3.74% 3.99%
2000.111 - 2001.112 3.72% 3.85% 3.89%
2001.112 - 2002.113 11.16% 10.50% 12.23%
2002.113 - 2003.114 6.96% 6.TI% 7.19%
Averale Eowth 5.19% 5.09% 5.44%
The sensitivity analysis carried out show that cost weighted output growth measures are
sensitive to different values of the health outcomes. The routinely collection of data on
patient reported outcomes has just started to take off in some NHS hospital Trusts. Until
these data become publicly available, we will continue using average measures of health
effect (k) derived from Castelli et al. (2007a).
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Appendix 3-A
3-A.l Inequalities in health: distribution of morbidity by income groups and country
Table 3-A.l: Actual number of individuals reporting ill-health by income group - 1995/96 and 2001/02
Great Britain - 1995/96
Number of individuals
Income group Acute Long-standing 'Not good'
sickness illness ~hstatus~ health
Poorest 1 497 1,186 578
2 594 1,424 643
3 397 983 334
4 382 838 223
Richest 5 398 822 182
Total 2,268 5,253 1,960
Great Britain - 2001/02
Number of individuals
Income group Acute Long-standing 'Not good'
sickness illness ~hstatusl health
Poorest 1 531 1,203 582
2 537 1,345 604
3 351 976 324
4 359 836 242
Richest 5 330 732 155
Total 2,108 5,092 1,907
211
Acute sickness (hstate)
Table 3-A.2: Actual and age-sex standardised percentages of all adults reporting acute
sickness {hstate} and relative Cis bl countrl - GHS 1995/96
England Wales Scotland
Income group
Age-sex Age-sex Age-sex
Actual%
stand%
Actual%
stand%
Actual %
stand%
Poorest 1 21.9 22.3 22.7 24.9 21.9 21.5
2 26.0 24.2 28.9 22.9 27.4 26.8
3 17.0 16.9 21.9 23.7 17.7 17.6
4 17.1 17.5 10.9 12.6 16.7 17.6
Richest 5 18.0 19.2 15.6 15.8 16.3 16.5
Concentration Index -0.089 -0.073 -0.149 -0.135 -0.109 -0.099
Table 3-A.3: Actual and age-sex standardised percentages of all adults reporting acute
sickness {hstate} and relative CIs bl count!,;r- GHS 2001102
England Wales Scotland
Income group
Age-sex Age-sex Age-sexActual%
stand%
Actual%
stand%
Actual %
stand%
Poorest 1 25.4 27.0 20.9 20.2 27.5 29.7
2 25.3 22.3 27.6 23.4 23.8 21.9
3 15.9 16.2 23.1 23.3 18.7 19.3
4 17.3 18.3 14.2 16.8 17.6 17.8
Richest 5 16.1 16.2 14.2 16.3 12.4 11.2
Concentration Index -0.108 -0.105 -0.110 -0.059 -0.147 -0.166
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Long-standing illness (hstatus)
Table 3-A.4: Actual and age-sex standardised percentages of aU adults reporting long-
standing illness ~hstatusland relative CIs bl: countrl: - GHS 1995/96
England Wales Scotland
Income group
Age-sex Age-sex Age-sex
Actual%
stand %
Actual%
stand%
Actual %
stand%
Poorest 1 22.S 22.2 23.8 24.5 22.9 22.7
2 27.1 24.1 28.7 23.4 27.6 2S.4
3 18.4 18.S 18.S 19.0 18.6 18.S
4 IS.9 17.2 15.8 18.8 16.0 17.6
Richest 5 16.0 17.9 13.2 14.2 14.9 IS.9
Concentration Index -0.118 -0.084 -0.157 -0.123 -0.132 -0.108
Table 3-A.5: Actual and age-sex standardised percentages of aU adults reporting long-
standing illness ~hstatusland relative CIs bl: countrI - GHS 2001102
England Wales Scotland
Income group
Age-sex Age-sex Age-sex
Actual %
stand%
Actual% stand%
Actual%
stand%
Poorest 1 23.7 24.2 21.4 20.8 26.3 27.9
2 26.2 22.5 26.7 22.2 26.8 24.1
3 19.0 19.5 22.8 22.9 18.5 19.2
4 16.4 17.9 IS.7 17.7 17.1 18.4
Richest 5 14.8 IS.9 13.S 16.4 11.4 10.4
Concentration Index -0.112 -0.087 -0.109 -0.056 -0.160 -0.165
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'Not good health' (sah)
Table 3-A.6: Actual and age-sex standardised percentages of all adults reporting 'not good'
health ~sahland relative Cis b~ countr~ - GUS 1995/96
England Wales Scotland
Income group
Age-sex Age-sex Age-sexActual%
stand%
Actual%
stand%
Actual %
stand%
Poorest 1 29.6 30.3 28.6 31.0 29.6 2904
2 32.7 28.9 35.3 3004 31.2 30.0
3 16.5 16.2 19.3 20.5 19.6 18.8
4 11.8 12.9 804 lOA 10.1 11.5
Richest 5 904 11.7 804 7.7 9.5 lOA
Concentration Index -0.265 -0.233 -0.289 -0.286 -0.266 -0.247
Table 3-A.7: Actual and age-sex standardised percentages of all adults reporting 'not good'
health ~sahland relative Cis b~ count!l- GUS 2001/02
England Wales Scotland
Income group
Age-sex Age-sex Age-sexActual %
stand%
Actual %
stand%
Actual %
stand%
Poorest 1 30.6 32.9 28.3 2804 30.2 31.6
2 31.3 26.6 33.0 27.9 33.1 30.9
3 17.5 18.1 19.8 19.8 17.2 17.5
4 12.4 13.6 8.5 12.3 12.4 13.0
Richest 5 8.3 8.7 10.4 11.6 7.1 7.0
Concentration Index -0.256 -0.247 -0.244 -0.198 -0.270 -0.271
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Table 3-A.8: Actual number of individuals reporting ill-health by income group and country - 1995/96
England
Total
Number of individuals
Acute Long-standing 'Not good'
sickness illness (hstatus) health
1 422 1,014 489
2 501 1,221 540
3 327 827 272
4 329 716 195
5 346 721 156
1,925 4,499 1,652
Wales
Number of individuals
Acute Long-standing 'Not good'
sickness illness (hstatus) health
1 29 63 34
2 37 76 42
3 28 49 23
4 14 42 10
5 20 35 10
128 265 119
Scotland
Number of individuals
Acute Long-standing 'Not good'
sickness illness (hstatus) health
1 47 112 56
2 59 135 59
3 38 91 37
4 36 78 19
5 35 73 18
215 489 189
Income group
Poorest
Richest
Total
Income group
Poorest
Richest
Total
Income group
Poorest
Richest
215
Table 3-A.9: Actual number of individuals reporting ill-health by income group and country - 2001102
England
Total
Number of individuals
Acute Long-standing 'Not good'
sickness illness (hstatus) health
1 452 1,038 499
2 450 1,149 511
3 283 833 285
4 309 720 202
5 287 649 135
1,781 4,389 1,632
Wales
Number of individuals
Acute Long-standing 'Not good'
sickness illness (hstatus) health
1 28 60 30
2 37 75 35
3 31 64 21
4 19 44 9
5 19 38 11
134 281 106
Scotland
Number of individuals
Acute Long-standing 'Not good'
sickness illness (hstatus) health
1 53 111 51
2 46 113 56
3 36 78 29
4 34 72 21
5 24 48 12
193 422 169
Income group
Poorest
Richest
Total
Income group
Poorest
Richest
Total
Income group
Poorest
Richest
216
Appendix 3-B
3-B.1 Concentration Indices and respective t-statistics for healthcare utilisation by
individuals reporting 'not good' health
Table 3-B.l: GP consultations: Cl and t-statistics - b~ countr~ and year
Concentration Index - 1995/96
Actual t-statistics
Age-sex
t-statistics
stand.
England -0.232 -0.31 -0.241 -0.34
Wales -0.247 -0.34 -0.287 -0.49
Scotland -0.300 -0.45 -0.313 -0.50
Great Britain -0.237 -0.32 -0.249 -0.36
Concentration Index - 2001102
Actual t-statistics
Age-sex t-statistics
stand.
England -0.256 -0.41 -0.252 -0.38
Wales -0.308 -0.37 -0.288 -0.31
Scotland -0.245 -0.33 -0.259 -0.38
Great Britain -0.259 -0.33 -0.256 -0.33
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Table 3-B.2: Inl!atient sta~s: Cl and t-statistics - b~ count!): and ~ear
Concentration Index -1995/96
Actual t-statistics
Age-sex
t-statisticsstand.
England -0.196 -0.24 -0.193 -0.23
Wales -0.296 -0.47 -0.342 -0.63
Scotland -0.194 -0.22 -0.175 -0.17
Great Britain -0.193 -0.23 -0.195 -0.23
Concentration Index - 2001/02
Actual t-statistics
Age-sex
t-statistics
stand.
England -0.201 -0.28 -0.192 -0.22
Wales -0.244 -0.37 -0.247 -0.43
Scotland -0.216 -0.37 -0.177 -0.28
Great Britain -0.212 -0.26 -0.197 -0.24
Table 3-B.3: Outl!atient visits: Cl and t-statistics - b~countr~ and year
Concentration Index - 1995/96
Actual t-statistics
Age-sex t-statistics
stand.
England -0.213 -0.26 -0.227 -0.29
Wales -0.257 -0.48 -0.271 -0.55
Scotland -0.092 -0.10 -0.160 -0.20
Great Britain -0.198 -0.25 -0.215 -0.29
Concentration Index - 2001/02
Actual t-statistics
Age-sex t-statistics
stand.
England -0.229 -0.31 -0.204 -0.23
Wales -0.391 -0.83 -0.365 -0.73
Scotland -0.208 -0.23 -0.233 -0.30
Great Britain -0.228 -0.29 -0.206 -0.23
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3-B.2 Concentration Curves for healthcare utilisation by individuals reporting 'not
good'health
GP consultations
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Figure 3-B.l: Concentration curves for England, Wales and Scotland, GP consultations, 1995/96 and
2001102
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Figure 3-B.2: Concentration curves for England, Wales and Scotland, Inpatient stays,
1995/96 and 2001102
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Outpatient visits
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Figure 3-B.3: Concentration curves for England, Wales and Scotland, Outpatient visits,
1995/96 and 2001/02
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Appendix 3-C
3-C.l Distribution of healthcare utilisation by income groups made by individuals
reporting acute sickness
GP consultations
Table 3-C.l: Percentages of GP consultations by individuals reporting acute sickness
and b~ income Grou~- GHS 1995/96
England Wales Scotland
Income group
Age-sex Age-sex Age-sex
Actual %
stand. %
Actual %
stand. %
Actual %
stand. %
Poorest 1 20.2 19.7 23.4 25.5 33.6 32.3
2 25.8 25.4 31.2 24.2 26.0 24.5
3 19.0 18.8 18.2 19.7 18.5 18.5
4 17.7 17.7 7.8 9.8 14.4 17.1
Richest 5 17.3 18.3 19.5 20.8 7.5 7.6
Concentration Index -0.055 -0.041 -0.125 -0.095 -0.255 -0.227
Table 3-C.2: Percentages ofGP consultations by individuals reporting acute sickness
and b~ income Grou~- GHS 2001/02
England Wales Scotland
Income group
Age-sex Age-sex Age-sex
Actual% stand. %
Actual%
stand. %
Actual %
stand. %
Poorest 1 26.2 27.2 28.3 28.2 26.8 28.0
2 29.5 26.8 28.3 29.5 29.5 23.5
3 16.2 16.4 24.5 24.4 17.0 18.0
4 15.7 16.9 11.3 10.1 17.9 18.3
Richest 5 12.4 12.7 7.5 7.8 8.9 12.3
Concentration Index -0.168 -0.157 -0.236 -0.244 -0.191 -0.149
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Inpatient stays
Table 3.C.3: Percentages of Inpatient stays by individuals reporting acute sickness
and by income group - GHS 1995/96
England Wales Scotland
Income group
Age-sex Age-sex Age-sex
Actual %
stand. %
Actual %
stand. %
Actual %
stand. %
Poorest 1 23.4 21.2 26.8 34.4 27.7 23.6
2 32.9 31.6 44.6 38.7 31.7 21.2
3 18.9 17.3 10.7 11.9 12.9 11.2
4 12.5 14.1 1.8 1.2 23.8 38.8
Richest 5 12.3 15.8 16.1 13.7 4.0 5.2
Concentration Index -0.171 -0.112 -0.257 -0.315 -0.222 -0.076
Table 3.C.4: Percentages ofinpatient stays by individuals reporting acute sickness
and b~ income group - GHS 12001/02
England Wales Scotland
Income group
Age-sex Age-sex Age-sex
Actual %
stand. %
Actual %
stand. %
Actual%
stand. %
Poorest 1 24.l 26.3 18.5 17.9 13.8 15.l
2 38.5 31.0 37.0 33.7 45.0 34.3
3 12.8 14.1 20.4 20.8 21.3 26.0
4 13.9 17.2 13.0 15.7 13.8 18.7
Richest 5 10.7 11.4 11.1 12.0 6.3 5.9
Concentration Index -0.205 -0.175 -0.156 -0.119 -0.185 -0.136
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Outpatient visits
Table 3.C.5: Percentages of Outpatient visits by individuals reporting acute sickness
and b~ income Grou2 - GHS 1995/96
England Wales Scotland
Income group
Age-sex Age-sex Age-sexActual %
stand. % Actual % stand. %
Actual %
stand. %
Poorest 1 19.5 17.7 28.2 35.7 26.1 27.2
2 34.1 37.4 41.1 32.7 9.2 8.7
3 15.8 14.1 14.7 16.8 32.4 29.0
4 14.4 13.1 8.0 8.0 27.1 28.5
Richest 5 16.2 17.7 8.0 6.8 5.3 6.5
Concentration Index -0.106 -0.096 -0.294 -0.329 -0.095 -0.087
Table 3.C.6: Percentages of Outpatient visits by individuals reporting acute sickness
and b~ income Grou!! - GHS 2001/02
England Wales Scotland
Income group
Age-sex Age-sex Age-sexActual %
stand. %
Actual %
stand. % Actual % stand. %
Poorest 1 21.7 25.7 19.9 17.9 21.0 26.0
2 42.1 30.9 47.7 47.1 37.3 29.3
3 12.6 14.3 25.2 24.1 16.5 20.6
4 12.5 15.0 6.0 9.1 6.5 7.2
Richest 5 ILl 14.2 1.3 1.8 18.7 16.9
Concentration Index -0.203 -0.155 -0.315 -0.286 -0.142 -0.161
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3-C.2 Distribution of healthcare utilisation by income groups made by individuals
reporting longstanding illness
GP consultations
Table 3-C.7: Percentages of GP consultations by individuals reporting along-standing illness
and b~ income Grou~ - GHS 1995/96
England Wales Scotland
Income group
Age-sex Age-sex Age-sexActual %
stand. %
Actual %
stand. %
Actual%
stand. %
Poorest 1 24.8 24.9 27.7 29.9 30.2 29.7
2 28.2 26.4 25.7 22.0 29.6 29.6
3 18.0 18.3 16.8 17.3 17.3 16.7
4 15.3 16.3 13.9 16.0 15.6 18.3
Richest 5 13.7 14.1 15.8 14.8 7.3 5.7
Concentration Index -0.140 -0.127 -0.142 -0.144 -0.239 -0.237
Table 3-C.S: Percentages of GP consultations by individuals reporting long-standing ilInesss
and b~ income Grou~ - GHS 2001102
England Wales Scotland
Income group
Age-sex Age-sex Age-sexActual %
stand. %
Actual %
stand. % Actual % stand. %
Poorest 1 28.3 28.2 23.8 22.5 30.3 28.2
2 27.5 27.0 25.0 26.1 32.4 35.8
3 18.1 17.6 26.3 25.1 16.9 16.9
4 13.6 14.0 12.5 12.5 12.0 11.2
Richest 5 12.4 13.1 12.5 13.8 8.5 7.8
Concentration Index -0.184 -0.175 -0.142 -0.126 -0.258 -0.264
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Inpatient stays
Table 3-C.9: Percentages ofInpatient stays by individuals reporting along-standing illness
and b~ income Grou!! - GHS 1995/96
England Wales Scotland
Income group
Age-sex Age-sex Age-sex
Actual %
stand. %
Actual%
stand. % Actual% stand. %
Poorest 1 24.6 23.5 27.8 36.1 26.5 24.8
2 32.0 31.2 43.0 38.8 33.8 28.1
3 20.7 20.3 11.4 11.5 11.8 10.5
4 12.2 12.6 7.6 6.3 21.3 30.5
Richest 5 10.5 12.5 10.1 7.3 6.6 6.1
Concentration Index -0.192 -0.163 -0.283 -0.360 -0.209 -0.140
Table 3-C.I0: Percentages of Inpatient stays by individuals reporting long-standing iIInesss
and b~ income Grou!! - GHS 2001/02
England Wales Scotland
Income group
Age-sex Age-sex Age-sexActual % Actual% Actual%stand. % stand. % stand. %
Poorest J 25.3 24.3 17.5 17.7 15.5 14.2
2 32.7 32.9 38.6 39.3 37.9 35.8
3 15.7 15.6 22.8 23.0 23.3 23.8
4 14.5 16.0 14.0 12.4 14.7 16.0
Richest 5 11.8 11.3 7.0 7.5 8.6 10.2
Concentration Index -0.180 -0.172 -0.182 -0.189 -0.148 -0.111
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Outpatient visits
Table 3-C.11: Percentages of Outpatient visits by individuals reporting along-standing illness
and b~ income grou~ - GHS 1995/96
England Wales Scotland
Income group
Age-sex Age-sex Age-sexActual %
stand. %
Actual %
stand. %
Actual %
stand. %
Poorest 1 23.0 21.8 17.8 19.8 21.4 25.5
2 34.5 36.5 36.4 30.6 16.5 18.0
3 16.7 15.7 18.2 19.2 27.2 24.6
4 13.1 12.2 20.5 25.0 22.9 21.3
Richest 5 12.7 13.8 7.1 5.5 11.9 10.6
Concentration Index -0.168 -0.162 -0.149 -0.136 -0.051 -0.106
Table 3-C.12: Percentages of Outpatient visits by individuals reporting along-standing illness
and b~ income Grou~- GHS 1995/96
England Wales Scotland
Income group
Age-sex Age-sex Age-sexActual %
stand. %
Actual %
stand. %
Actual%
stand. %
Poorest 1 24.1 24.3 29.0 26.8 22.1 23.4
2 31.5 31.2 37.0 37.7 30.3 30.0
3 16.3 16.4 23.5 22.0 17.3 17.6
4 16.2 16.2 7.0 9.7 16.8 17.3
Richest 5 11.8 11.9 3.5 3.7 13.5 11.7
Concentration Index -0.160 -0.159 -0.324 -0.297 -0.123 -0.144
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3-C.3 Concentration Curves for healthcare utilisation by individuals reporting acute
sickness
GP consultations
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3-C.4 Concentration Curves for healthcare utilisation by individuals reporting long-
standing illness
GP consultations
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